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Abstract 
Degeneration of the intervertebral disc (IVD) is thought to account for 40% of all 
cases of chronic low back pain.  Alterations in the behaviour of the IVDs’ native cell 
population mediate the processes that lead to structural failure, as seen in IVD 
degeneration.   
Cytokines are implicated in this process, several studies have identified that 
Interleukin-1 (IL-1) and Tumour Necrosis Factor-α (TNF-α) expression is increased 
in degenerate IVDs compared to their normal counterparts.  Furthermore, it has 
been shown in vitro that these cytokines stimulate alterations in the behaviour of 
the IVDs’ native cells in a similar manner to those observed in IVD degeneration.  
However, IL-1 and TNF-α are only two of a large group of intercellular signalling 
molecules known as cytokines, and studies investigating the expression of other 
cytokines in the human IVD are limited.   
This thesis demonstrates the production of numerous cytokines and chemokines 
(chemoattractant cytokines) by the human IVDs’ native cell population.  Detailed 
gene and protein expression studies identified several novel cytokines and 
chemokines that are differentially expressed in cells isolated from degenerate or 
prolapsed IVDs compared to those isolated from the normal counterpart.  Co-
expression of receptors for these molecules was also identified, indicating a 
capacity of these cells to respond to cytokine intercellular signalling.  
The response of IVD cells to cytokine and chemokine stimulation in vitro was 
investigated.  The data presented indicates that inter-regulatory relationships exist 
between the cytokines and chemokines of the intervertebral disc.  Particularly, IL-1 
exerts modulatory potential over the expression of other cytokines and chemokines 
by IVD cells.  Effects of stimulation were also observed in relation to reduced 
anabolic metabolism and increased catabolic metabolism, both of which are 
characteristic features of IVD degeneration.         
Together, the findings presented in this thesis indicate that cytokines and 
chemokines are integral to the pathogenesis of IVD degeneration and prolapse that 
may lead to low back pain.    
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1.1 The Spine 
The human spine, or vertebral column, is comprised of 26 bones: 24 vertebrae, the 
sacrum and the coccyx.  It functions to provide a column of support to the body and 
to transfer weight through to the appendicular skeleton of the lower limbs (Martini & 
Ober, 2005).   
The vertebral column can be divided into 5 anatomical regions; cervical, thoracic, 
lumbar, sacral and coccygeal (superior to inferior).  Each vertebra comprises of a 
vertebral body, vertebral arch and articular processes.  It is the vertebral body that 
is responsible for the transfer of weight along the axis of the vertebral column 
(Martini & Ober, 2005).  The bodies of adjacent vertebra are separated by an 
intervertebral disc (IVD) (Figure 1-1).   
1.1.1 The Lumbar Spine 
The lumbar spine comprises 5 vertebra (L1 – L5) and 5 IVDs separating the 
vertebral bodies and between vertebra L5 and the sacrum, S1 (Figure 1-1).  The 
structure of the lumbar spine is stabilised by encasing longitudinal ligaments 
(anterior, posterior and posterio-lateral) and the musculature of the lower back. 
1.2 The Intervertebral Disc 
The IVD is a fibro-cartilaginous structure that separates adjacent vertebra of the 
spine (Peacock, 1952) (Figure 1-1).  Each IVD is an amphiarthrosis (Taylor et al., 
1992), or cartilaginous joint, and as such permits a small degree of flexion, 
extension and lateral bending between adjacent vertebrae.  Summated the small 
movement at each IVD constitutes the mobility of the spine.   
IVDs function to maintain the correct biomechanical separation of adjacent vertebra 
(Adams, 2002).  They are resistant to compressive load and maintain separation 
even throughout weight bearing (Lu et al., 1996).  IVDs are comprised of three 
distinct tissue regions; the end plates, the annulus fibrosus (AF) and the nucleus 
pulposus (NP) (Peacock, 1952).     
1.2.1 The End Plates 
In the adult vertebral column, opposing vertebral bodies are covered by the end 
plates (Peacock, 1952).  These are a layer of hyaline cartilage (cartilaginous end 
plate, CEP) and the central parts of the superior and inferior cortical bone surfaces 
(bony end plate) of the vertebral bodies that they cover (Moore, 2006).   
The structure of the CEP is seen to vary across the IVD, with tissue resembling that 
of which it is most closely associated (Roberts et al., 1989a).  The central region is 
thinnest, approximately 0.1mm and being NP associated, is more gelatinous than 
the peripheral fibrous AF associated regions, that increase to approximately 1.6mm 
in thickness (Roberts et al., 1989b).  The CEP confers the structural resilience that  
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prevents loads transferred through the IVD from fracturing the bone of vertebral 
bodies (Moore, 2006). 
1.2.2 The Annulus Fibrosus  
The AF constrains the NP around the periphery and binds together the outer rims 
of adjacent vertebrae (Peacock, 1952).  It can be subdivided into morphologically 
distinct outer and inner regions; 
1.2.2.1 The Outer Annulus Fibrosus 
The outer AF consists primarily of type I collagen fibres arranged into a series of 
concentric lamellae (Eyre & Muir, 1976).  The collagen fibres are inserted into the 
cortical bone at the vertebral body rim (Hilton & Ball, 1984) and pass obliquely 
between vertebral bodies (Eyre & Muir, 1976) (Figure 1-2).  The orientation of fibres 
is reversed in successive lamellae and this arrangement confers concentric tissue 
elasticity (Walmsley, 1953; Adams, 2002).           
1.2.2.2 The Inner Annulus Fibrosus 
The inner AF is the transition zone between the organised fibrous structure of the 
outer AF and the irregular gelatinous structure of the NP (Walmsley, 1953; Baer et 
al., 2001).  A smooth transition is seen from type I to type II collagen fibres from 
outer to inner regions with increasing interspersion of hydrating proteoglycan 
molecules towards the inner (Eyre & Muir, 1976).  
The AF confers the structural resilience to prevent excessive separation of the 
vertebra during flexion and withstands internal pressure as a response to loading, 
to resist deformity and prolapse of the IVD (Prescher, 1998).  
1.2.3 The Nucleus Pulposus 
The NP is the central component of the IVD, it is constrained above and below by 
the end plates and around the periphery by the AF (Peacock, 1952).  NP is a highly 
hydrated gelatinous tissue containing large amounts of aggregating proteoglycans 
(Stevens et al., 1979; Taylor et al., 1992) held together loosely by a network of type 
II collagen fibres (Stevens et al., 1979).    
The proteoglycan content renders the structure hydrophilic and so it imbibes water 
(Urban & McMullin, 1988).  This generates a swelling pressure within the IVD 
sufficient to force apart, and maintain separation of, adjacent vertebral bodies 
(Urban & McMullin, 1988; Mwale et al., 2004).   
1.2.4 Vasculature 
With the exception of the outermost AF the adult human IVD is avascular (Peacock, 
1952; Hassler, 1969; Rudert & Tillmann, 1993).  Blood supply to the adjacent 
vertebral bodies is by exterior vertebral arteries that encircle the ‘waist’ of each 
vertebra (Crock, 1993).  From these, centrum branches penetrate to form a grid  
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within the vertebral body, off which vertically oriented tributaries pass up- and 
down-wards toward the end plates (Hassler, 1969; Crock, 1993).  These give rise 
to capillary circuits in the region of the CEP (Crock, 1993; Rudert & Tillmann, 
1993).   
1.2.5 Nutrition 
Nutritional support to the IVD is provided by diffusion across the CEP from the 
capillary networks of the superior and inferior vertebral bodies (Urban et al., 2004) 
and from the capillary networks of the outer AF (Urban et al., 2004)  (Figure 1-3).  
Similarly, metabolic waste is excreted by this route (Holm et al., 1981).    
1.2.6 Innervation 
The posterior longitudinal ligament is innervated by the lumbar sinuvertebral nerves 
(Bogduk et al., 1981), fibres from these are seen to form free nerve endings in the 
adjacent posterior AF (Bogduk et al., 1981).  The anterior and lateral aspects of the 
IVD are supplied by branches from the rami communicantes (Bogduk et al., 1981).  
In either case, nerve fibres are not seen to penetrate further than the outermost one 
third of the AF (Bogduk et al., 1981).     
1.2.7 Development 
During embryonic organogenesis, the NP is formed from the notochord (Walmsley, 
1953) whereby notochordal cells secrete a ‘mucoid substance’ that will later 
become the NP extracellular matrix (ECM) (Walmsley, 1953).  This is surrounded 
by the inner AF, formed from the embryonic pre-cartilage structure – the 
perinotochordal mesenchyme (Walmsley, 1953; Rufai et al., 1995), and the outer 
AF that is derived from surrounding fibrous mesenchymal tissue (Walmsley, 1953; 
Rufai et al., 1995; Aulisa et al., 1998).   
After 6 month’s gestation a decline in the notochordal cell population is seen and 
‘chondrocyte like’ cells begin to appear in the NP (Walmsley, 1953).  These are 
thought have migrated from the pre-cartilage structure of the inner AF and 
contribute collagen fibres to the mucoid NP (Walmsley, 1953).   
Organisation of IVD tissue structures at full-term is as of that of an adult, however 
increased vasculature is observed at birth compared to that in mature IVDs 
(Walmsley, 1953; Crock, 1993).  Immediately post-natally, a sharp decrease in IVD 
cell numbers occurs (Liebscher et al., 2011) which corresponds with decreasing 
vasculature supply into the IVD (Crock, 1993).  Cell numbers decline as a result of 
notochordal cell death, leaving only ‘chondrocyte like’ cells within the NP 
(Walmsley, 1953).                  
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1.2.8 The Cells of the Intervertebral Disc 
The adult human IVD contains three native cell populations, one in each tissue 
region and each exhibiting morphological distinction from the others;   
1.2.8.1 Cartilaginous End Plate Cells 
The CEP is home to a population of chondrocytes (Moore, 2006).  This region 
exhibits the highest cell density of any IVD tissue with the central region of the 
young adult human lumbar CEP containing ~18,000 cells/mm
3
 (Liebscher et al., 
2011).   
1.2.8.2 Annulus Fibrosus Cells 
Native AF cells are flattened, elongated, bipolar and aligned parallel to tissue 
collagen fibres (Walmsley, 1953; Chelberg et al., 1995).  This morphology has 
resulted in them being termed ‘fibroblast like’.  Throughout the AF there is a 
transition from the flattened morphology observed in the outermost region where 
cells are characterised by type I collagen expression (Chelberg et al., 1995), to a 
more rounded morphology in the innermost where cells are characterised by both 
type I and II collagen expression (Chelberg et al., 1995).  The young adult human 
lumbar AF cell population is sparse, ~2,600 cells/mm
3
 (Liebscher et al., 2011).  
Individual cells are isolated, residing in distinct lacuna within the ECM, and 
separated from any direct cell-cell contact with neighbours.   
1.2.8.3 Nucleus Pulposus Cells 
Native NP cells have a rounded morphology and appear microscopically very 
similar to the chondrocytes of the CEP (Walmsley, 1953).  This morphology has 
resulted in them being termed ‘chondrocyte like’ and cells from this region are 
characterised by expression of type II collagen (Chelberg et al., 1995).  As in the 
AF the cell population is sparse, ~2,600 cells/mm
3
 in the young adult human lumbar 
NP (Liebscher et al., 2011), with individual cells isolated within distinct ECM lacuna 
and separated from any direct cell-cell contact.   
1.2.9  Metabolism 
The energy demands of IVD cells are met by anaerobic metabolism.  Glucose 
diffuses into the IVD from neighbouring capillary networks and lactic acid diffuses 
out (Holm et al., 1981; Holm et al., 1982; Ishihara & Urban, 1999).   
1.2.10 The Extracellular Matrix of the Intervertebral Disc 
The cellular component of IVD tissue accounts for only 0.05% total volume (Urban 
et al., 2000), the remainder is made up of water and ECM.  The ECM in all three 
IVD regions is composed almost entirely of collagens and proteoglycans.  The 
major proteoglycan of the IVD is aggrecan (Taylor et al., 1992) which, because of 
its high anionic glycosaminoglycan side chain content (chondroitin and keratin 
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sulphates) (Roughley et al., 2006), provides the osmotic properties needed for the 
tissue to resist compression.  Variations in the ratio of composition, and so osmotic 
potential, confer the structural differences between the tissue regions.   
Hydroxyproline is a collagen constituent that makes up 10% weight of collagen-α 
chains (Nimni, 1983).  Hydroxyproline content in hydrolysed tissue digests can be 
quantified using dimethylaminobenzaldehyde (Burleigh et al., 1974), providing a 
means to determine tissue content of collagens.  Sulphated glycosaminoglycans 
(GAGs) represent the bulk component of IVD proteoglycan molecules (Taylor et al., 
1992).  GAG content in tissue digests can be determined using 1,9-
dimethylmethylene blue (DMMB) dye-binding assay (Farndale et al., 1986), 
providing a means to determine proteoglycan content.  The GAG to hydroxyproline 
ratio can be used to distinguish differences in ECM constituents and structural 
properties across IVD tissue regions.             
1.2.10.1 Cartilaginous End Plate Extracellular Matrix   
The CEP ECM is comprised of type II collagen interspersed with proteoglycans 
(Antoniou et al., 1996b).  The GAG to hydroxyproline ratio of the young adult 
human lumbar CEP is 2:1 (Mwale et al., 2004).  This finding is similar to the 
GAG/hydroxyproline ratio measured for other hyaline cartilages, including that of 
the human nasal septum (Homicz et al., 2003) and human talar ankle, distal femur 
knee and tibial plateau knee cartilages (Treppo et al., 2000).  The GAG to 
hydroxyproline ratio is always below 5 in human hyaline cartilages (Mwale et al., 
2004).   
Since hydroxyproline represents only 10% weight of collagen, the total collagen 
content is likely to be around 83% in the young adult human lumbar CEP, with 
proteoglycans accounting for the remaining 17%.  The proteoglycan content is 
responsible for the weight bearing capacity of the CEP.  The osmotic potential it 
confers is what renders the structure resistant to compressive loads.        
1.2.10.2 Annulus Fibrosus Extracellular Matrix  
The outer AF ECM is comprised of highly organised type I collagen fibre bundles 
(Eyre & Muir, 1976) and the inner AF a combination of organised type I and II 
collagen fibres interspersed with proteoglycans (Eyre & Muir, 1976; Stevens et al., 
1979).  The GAG to hydroxyproline ratio in the young adult human lumbar AF is 
1.6:1 (Mwale et al., 2004).  This structural difference with the CEP indicates AF 
tissue is less capable of resistance to compressive loading, however the concentric 
ECM organisation renders the tissue resistant to torsion and tension forces 
(Walmsley, 1953; Adams, 2002).           
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1.2.10.3 Nucleus Pulposus Extracellular Matrix 
The NP ECM consists of an irregular network of type II collagen fibres interspersed 
with proteoglycans (Stevens et al., 1979).  The GAG to hydroxyproline ratio in 
young adult human lumbar NP is 27:1 (Mwale et al., 2004).  Total collagen content 
is likely to be around 27% with the remaining 73% made up of hydrophilic 
proteoglycans.  The high proteoglycan to collagen ratio explains the gelatinous 
consistency of the NP compared to the rigid structures observed for CEPs and 
other hyaline cartilages.  This gelatinous consistency allows the temporary 
deformation required to permit flexion throughout the spine.  And further, it confers 
the ability to generate hydrostatic pressure sufficient to maintain separation of 
vertebra, even under compressive loading (Figure 1-4).   
High proteoglycan content (greater than 50%) is the structural difference that marks 
NP as a unique tissue type, distinct from hyaline cartilages found elsewhere in the 
body. 
1.2.11 Biomechanics 
Compressive loading of the IVD generates hydrostatic pressure in the NP and 
subsequently, tensile stresses in the AF (Adams, 2002) (Figure 1-5).  The balance 
between swelling pressure in the NP and tension in the AF maintains IVD height 
and separation of adjacent vertebra (Nachemson & Elfstrom, 1970; Boos et al., 
1993).   
1.2.12 Tissue Remodelling 
ECM in all three tissue regions is synthesised and maintained by local cells, where 
a continuous process of re-modelling maintains functional integrity of the structures.  
Collagen and proteoglycan ECM components are synthesised continually (Antoniou 
et al., 1996a; Antoniou et al., 1996b), this synthesis of new ECM components is 
balanced by the degradation of old.  IVD cells are seen to produce matrix 
degrading enzymes that facilitate this process and two families have been identified 
within the IVD; the matrix metalloproteinases (MMPs) and the ‘a disintegrin and 
metalloproteinase with thrombospondin motif’s’ (ADAMTS’s) (Table 1-1). 
Native IVD cells mediate ECM remodelling as an adaptive response to changes in 
the tissue microenvironment.  As such, biochemical and mechanical stimuli 
modulate the process.  Biochemical factors include diffusible gaseous signals such 
as oxygen (Holm et al., 1981; Ishihara & Urban, 1999; Horner & Urban, 2001; Bibby 
et al., 2005) and the substrates and products of anaerobic metabolism (Holm et al., 
1981; Urban et al., 2001; Razaq et al., 2003; Bibby & Urban, 2004; Bibby et al., 
2005), mechanical stimuli include the hydrostatic pressures and tensile stresses 
 Figure 1-4
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experienced during loading and flexion (Ishihara et al., 1996; Handa et al., 1997; 
MacLean et al., 2005; Wuertz et al., 2009; Barbir et al., 2011; Neidlinger-Wilke et 
al., 2012).  
1.2.13 Aging 
The rate of ECM turnover declines in the aging IVD (Antoniou et al., 1996a; 
Antoniou et al., 1996b; Gruber et al., 2005; Bachmeier et al., 2007; Gruber et al., 
2007).  This compromises structural integrity (Gruber & Hanley, 2002) and is 
associated with reduced flexibility and loading capacity and increased susceptibility 
to injury during normal activity (Prescher, 1998). 
1.3 Intervertebral Disc Injury & Disease 
1.3.1 Injury 
The IVD is susceptible to traumatic and repetitive strain injuries (Figure 1-6).  Adult 
IVDs vary in compressive strength related to individual fitness and lifestyle choices; 
factors such as obesity and smoking are associated with reduced capacity, whilst 
regular physical activity is associated with enhanced capacity (Adams et al., 1986).  
In healthy adults the IVD may resist force applications of up to 13,000 N (Adams & 
Hutton, 1982).   
Outer IVD injury is seen to induce local inflammation, with increased tissue 
expression of cytokines, up-regulated activity of MMPs (Antoniou et al., 1996a; 
Kang et al., 1996) and the promotion of scar tissue formation (Nerlich et al., 1997).  
Post-injury, increased rates of ECM turnover occur (Antoniou et al., 1996a; Duance 
et al., 1998), although sites of gross injury are never completely remodelled.  The 
original matrix structure is replaced by granulation tissue bridged only in the 
outermost few millimetres with scar tissue (Melrose et al., 1992; Kaigle et al., 
1997).  For this reason the IVD is considered to have a limited repair capacity.  This 
may result from an inability to replicate the complex native fibre arrangement laid 
down during embryonic development, or from low cell density and limited vascular 
supply that hamper the ability to replace damaged structures.         
1.3.2 Prolapse 
IVD prolapse is a hyper flexion injury that results from exceeding the physiological 
limit of flexion or compressive force through a motion segment (Adams & Hutton, 
1982; Adams et al., 2000).  The IVD is considered to be prolapsed when NP is 
displaced to an extent that the periphery of the AF is affected.  Depending on the 
extent of displacement, the prolapse can be considered either; an annular bulge or 
protrusion, where the AF remains intact constraining the NP but has undergone 
elastic deformation that is not reversed under normal physiological conditions, or 
extruded, where the CEP or AF has ruptured and NP material is no longer
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constrained within the IVD space.  Sequestration refers to NP material that has 
been extruded from the IVD and has become detached from it.   
1.3.2.1 Spontaneous Resorption 
Prolapsed NP may be cleared by spontaneous resorption (Key, 1945).  This is 
more common in lumbar IVD prolapse than in other anatomical regions (Key, 1945; 
Teplick & Haskin, 1985; Keskil et al., 2004), and even large sequestered NP 
fragments are seen to disappear in as little as 4 months post displacement (Orief et 
al., 2012).  Exposure of NP tissue to the systemic circulation and inflammatory 
responses are thought to mediate this process.   
1.3.2.2 Inflammatory Response   
Inflammation is mediated by the innate immune system in response to tissue 
infection or injury.  Following injury the inflammatory response functions to remove 
damaged tissue components so that healing can occur.  Inflammation is 
characterised by increased permeability in local vasculature and the influx of fluid, 
proteins and leukocytes from the circulation to the site of tissue injury (Watkins et 
al., 1995; Trinchieri, 1999; Letts et al., 2000; Weiss, 2008).        
Immune cell infiltrates are found in prolapsed IVD tissue.  Studies have 
characterised these infiltrates in extruded NP as a combination of macrophages 
(Kanerva et al., 1997; Habtemariam et al., 1998; Kawaguchi et al., 2002; Kobayashi 
et al., 2009) monocytes (Kawaguchi et al., 2002), T lymphocytes (Kanerva et al., 
1997; Habtemariam et al., 1998), B-lymphocytes (Habtemariam et al., 1998) and 
fibroblasts (Kobayashi et al., 2009).  In the case of extruded and sequestered NP, 
ultrastructural analysis reveals neovascularisation of prolapsed tissue by capillary 
invasion from the posterior longitudinal ligament (Kobayashi et al., 2009).  
Neovascularisation enhances immune cell infiltration and migrating monocytes and 
activated macrophages are often localised to the immediate vicinity of capillary 
invasion (Kobayashi et al., 2009).   
The exact mechanism by which inflammation promotes spontaneous resorption is 
unclear however, tissue destruction by macrophage mediated enzymatic digestion 
is implicated.  Phagosome presence within the infiltrating macrophages (Kobayashi 
et al., 2009) indicates phagocytic activity and intracellular digestion, and lysosomal 
degranulation (exocytosis) indicates secretion of degrading enzymes directly into 
the ECM to break down intercellular macromolecules (Kobayashi et al., 2009).  
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1.3.2.3 Autoimmunity 
The adaptive immune system may also play a role in spontaneous resorption.  It 
has been shown that exposure of autologus NP to the systemic circulation can 
activate T and B lymphocytes.   
Following embryological development, NP makes no further contact with the blood 
circulation.  This is thought to limit establishment of immunological tolerance to NP 
derived antigens.  It is postulated that subsequent NP exposure to the systemic 
circulation would induce an autoimmune response (Naylor, 1962).  Evidence in 
support of this theory was first presented by Bobechko & Hirsch, in 1965 who 
observed that exposure of autologus NP to the systemic circulation stimulates the 
production of auto-immune antibodies in the primary lymph nodes of laboratory 
animals.  Since then immunoreactivity to prolapsed NP has been indicated by the 
presence of antigen-antibody complexes (Marshall et al., 1977; Habtemariam et al., 
1998; Satoh et al., 1999).  And further animal studies have shown that autologus 
NP attracts activated lymphocytes (T and B cells) (Geiss et al., 2007) and 
stimulates differentiation of the T-helper subset towards a TH2 effector phenotype 
(Geiss et al., 2009).    
This adaptive immune system response to exposed NP tissue is little studied and 
the contribution it may make to spontaneous resorption is unclear.  Presumably, T 
cell mediated tissue destruction would enhance spontaneous resorption and further 
promote the inflammatory response of the innate immune system.   
Other proposed mechanisms by which spontaneous resorption may occur are 
tissue shrinkage by dehydration (Hirabayashi et al., 1990; Slavin et al., 2001) and 
protrusion regression by retraction of the AF (Guinto et al., 1984; Teplick & Haskin, 
1985).  Native cells within prolapsed NP tissue may also mediate the breakdown of 
displaced tissue, increased expression of matrix degrading enzymes is observed 
(Kang et al., 1996; Kang et al., 1997) alongside increased rates of cellular 
apoptosis (Wang et al., 2011).    
1.3.3 Intervertebral Disc Degeneration  
IVD degeneration is a non-inflammatory arthropathy that affects the fibro-
cartilaginous joints of the spine.  A characteristic pattern of morphological and 
histological changes occur that lead to disorganisation of ECM and structural 
failure.  It is thought that these changes are mediated by disturbances in the 
biology of IVD cells (Freemont et al., 2002).     
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1.3.3.1 Cell Phenotype and Viability 
Decreased cell viability is observed within degenerate IVDs (Horner & Urban, 2001; 
Bibby et al., 2002; Johnson & Roberts, 2003; Bibby & Urban, 2004; Gruber et al., 
2005; Roberts et al., 2006; Le Maitre et al., 2007c).  This has been assessed by 
expression of the transcription factor, SOX9, that is down-regulated in degeneration 
(Gruber et al., 2005).  SOX9 modulates chondrogenesis in development (Healy et 
al., 1999; Huang et al., 2001; Lefebvre et al., 2001; Kronenberg, 2003) and 
modulates type II collagen and aggrecan expression (Lefebvre et al., 1997; Huang 
et al., 2002; Han & Lefebvre, 2008), which is both essential for IVD health and 
characterises the native cell population (Chelberg et al., 1995).  Down-regulation of 
SOX9 indicates that cells present within degenerate IVDs may no longer be of a 
native cell phenotype.   
An increased percentage of senescent and apoptotic cells are also observed within 
the degenerate cell population (Park et al., 2001a; Roberts et al., 2006; Gruber et 
al., 2007; Le Maitre et al., 2007c; Tschoeke et al., 2008; Wang et al., 2011).  Whilst 
senescent cells may persist within tissues, they are often observed to exhibit a 
catabolic phenotype (Coppe et al., 2008) and increased rates of cellular apoptosis 
would indicate a declining cell population.  However, tissue cellularity is maintained 
in the degenerate IVD (Liebscher et al., 2011) by replication of surviving non-
senescent cells within lacuna that give rise to cell clusters (Johnson & Roberts, 
2003).  
1.3.3.2 Anabolic Metabolism   
Anabolic metabolism of the cells present within the degenerate IVD is altered from 
that in the normal.  Synthesis of aggrecan and type II collagen is decreased and 
synthesis of type I collagen is increased (Antoniou et al., 1996a).  This alters the 
ECM structure in all 3 IVD tissue regions (Antoniou et al., 1996a; Antoniou et al., 
1996b), hydration is reduced and gelatinous structures become increasingly 
fibrous. The stimulus for this altered metabolism is not known however, presumably 
senescent cells and cells that exhibit an altered phenotype no longer contribute to 
correct ECM synthesis.     
1.3.3.3 Catabolic Metabolism 
Catabolic metabolism of the cells present within the degenerate IVD is altered from 
that seen in the normal.  Expression of matrix degrading enzymes is increased  
(Weiler et al., 2002; Le Maitre et al., 2004; Gruber et al., 2005; Le Maitre et al., 
2007a; Hoyland et al., 2008; Rutges et al., 2008; Bachmeier et al., 2009; 
Richardson et al., 2009; Zhao et al., 2011) and localised to areas of altered tissue 
morphology (Weiler et al., 2002).  Matrix degrading enzyme activity correlates 
 47 
 
positively with increasing severity of degenerative tissue changes (Weiler et al., 
2002; Le Maitre et al., 2004; Le Maitre et al., 2007a; Pockert et al., 2009).   
1.3.3.4 Aetiology 
The order in which cellular changes occur in IVD degeneration is poorly 
understood.  There is considerable evidence to link decreased cell viability and 
dysregulated metabolism with impaired diffusion through the IVD, although whether 
this is a cause of alterations in native cell biology or a consequence of it, is yet to 
be established.  Decreased permeability of the bony and cartilaginous endplates is 
observed alongside IVD degeneration (Nachemson et al., 1970) and limits the 
diffusion of nutrients to cells within the IVD and the diffusion of metabolic waste 
away from them.  Nutrient supply is critical to IVD cell survival and whilst transient 
episodes of decreased glucose may be tolerated, low concentrations maintained for 
several days result in cell death (Horner & Urban, 2001; Bibby & Urban, 2004; 
Bibby et al., 2005).  The accumulation of waste from anaerobic metabolism (lactic 
acid) results in an increasingly acidic cellular micro-environment (Diamant et al., 
1968; Kitano et al., 1993) and low pH (<6.4) has a further adverse effect on cell 
viability (Horner & Urban, 2001; Bibby et al., 2005) and reduces rates of ECM 
synthesis (Razaq et al., 2003).  Reduced oxygen tension is also seen to impair 
rates of ECM synthesis (Ishihara & Urban, 1999; Horner & Urban, 2001).  However, 
whilst impaired diffusion may reduce cell viability and rates of ECM synthesis, the 
altered anabolic activities of native cells, especially the increased production of type 
I collagen results in an increasingly fibrous ECM.  This in itself impairs rates of 
diffusion, particularly through the CEP and NP.  It’s therefore unclear whether 
impaired diffusion contributes to altered cell biology or altered cell biology results in 
impaired diffusion.   
Similarly, the effects of low oxygen tension are not understood, since little energy is 
derived from oxidative phosphorylation and the IVD cells energy requirements are 
met by glycolysis even in the presence of oxygen (Ishihara & Urban, 1999; Horner 
& Urban, 2001).  However, the loss of effective transport routes across the CEPs 
does correlate with decreased cell viability within the IVD (Urban et al., 2001; Bibby 
et al., 2002).   
Increased rates of catabolic metabolism are attributed in part to the increased 
percentage of senescent cells that produce MMPs and ADAMTSs (Le Maitre et al., 
2007c).  However, remaining non-senescent cells also contribute to increased 
catabolism within the IVD, and whilst nutrient deprivation reduces anabolic 
metabolism in these cells, it has no effect on the rate at which active matrix 
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degrading enzymes are produced (Razaq et al., 2003).  This may represent a 
mechanism by which catabolism overtakes anabolism and results in the 
characteristic ECM depletion.   
There is also considerable evidence to suggest a genetic predisposition to IVD 
degeneration.  Genetic polymorphisms associated with structural components of 
the IVD, ECM degrading enzymes and biochemical regulators of IVD cell biology 
such as cytokines and growth factors, are implicated in the onset and progression 
of IVD degeneration (Table 1-2). 
1.3.3.5 Structural Failure of the Degenerate Intervertebral Disc  
Over time, the imbalance between anabolic and catabolic activity compromises the 
structural integrity of the IVD (Figure 1-7).  Decreased aggrecan concentration 
reduces osmotic potential and dehydration occurs (Antoniou et al., 1996a; Antoniou 
et al., 1996b).  This is first evident in the NP where the ability to generate 
hydrostatic pressure is compromised (Wenger et al., 2005).  Progressively, the NP 
condenses to form a more fibrous structure and IVD height is reduced.  This 
process is exacerbated by the incorporation of type I collagen fibres  (Antoniou et 
al., 1996a; Nerlich et al., 1997) and demarcation between NP and AF is lost 
(Nerlich et al., 1997; Prescher, 1998; Gruber & Hanley, 2002).  Dehydration and 
type I collagen fibre incorporation is also evident in the CEP (Antoniou et al., 
1996b).  These changes reduce diffusion rates (Nachemson et al., 1970), 
particularly of water soluble nutrients.   
1.3.3.6 Biomechanics of the Degenerate Intervertebral Disc 
Reduced IVD height alters the biomechanics of the motion segment (Adams, 1996; 
Adams, 2002).  Of the IVD tissues, the AF is least resistant to compressive loading.  
Dehydration of the inner AF (Antoniou et al., 1996a; Adams, 2002) further reduces 
this capacity.  Hydrostatic pressure in the NP is required to generate tension in the 
concentric lamella of the AF and to maintain their correct alignment (Peacock, 
1952; Walmsley, 1953).  In the absence of this hydrostatic pressure the lamella 
‘sag’, bulging outward, and the AF is subjected to compressive forces during 
normal movement (Adams et al., 1996a).  The degenerate IVD functions 
increasingly as a fibrous ‘pad’ to withstand loading forces and the biomechanical 
properties are greatly reduced compared to those of the normal IVD (Adams et al., 
1996a; Ebara et al., 1996).     
Permeative slits, or fissures appear in the condensed NP (Nerlich et al., 1997; 
Prescher, 1998).  Fissure formation correlates with increased rates of catabolism 
(Le Maitre et al., 2004; Le Maitre et al., 2007a; Pockert et al., 2009) and cells 
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Figure 1-7  
Disc Degeneration
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(red arrow).  (D) Severe IVD degeneration; demarcation 
IVD height is reduced.  (E) Posterior extrusion IVD prolapse; NP has extruded through the 
ruptured posterior AF and is constrained between the vertebral body and the posterior 
longitudinal ligament (red arrow).  
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producing matrix degrading enzymes are localised to the vicinity of tissue damage 
(Weiler et al., 2002).  Progressively, the fissures radiate outward and into the AF 
where inner lamella may collapse into the NP space (Adams & Hutton, 1985; Osti 
et al., 1992; Osti et al., 1992).  The mechanisms of fissure formation are poorly 
understood, whether the compressive loading of dehydrated, weaker IVD tissue 
results in fissure formation and the increased cellular catabolic activity is an attempt 
to remodel damaged ECM, or whether regions of excessive cellular catabolic 
activity destroy ECM sufficiently for fissures to appear remains unclear. 
1.3.3.7 Vasculature and Innervation 
In severely degenerate IVDs, proliferation of blood vessels and accompanying 
sensory nerve fibres occurs in the CEP region (Brown et al., 1997).  Vascularisation 
in the AF is also increased with the appearance of vertically oriented arteries 
(Kauppila, 1995).  This neovascularisation has been traced to the CEP through 
which new vessels penetrate the IVD from adjacent vertebral bodies (Freemont et 
al., 2002).  Sensory nerve fibre in-growth is seen to follow the same route and 
vascular endothelial expression of nerve growth factors is associated with this 
process (Freemont et al., 1997; Freemont et al., 2002).  
1.3.4 The Relationship between Injury and Degeneration 
The relationship between IVD injury and degeneration is not well understood.  Each 
can be observed independently however, frequently evidence of both is apparent in 
pathological tissues.  Injury occurs to the IVD through trauma that exceeds the 
physiological limit of the tissues strength (Adams & Hutton, 1982).  Annular tear 
and delaminating injuries are seen in IVDs from young individuals that show no 
signs of degeneration (Hirsch & Schajowicz, 1953; Jensen et al., 1994).  However, 
degenerative changes weaken the IVD and are associated with increased 
susceptibility to certain injuries, particularly radial fissures (Adams & Hutton, 1985; 
McNally et al., 1993).  Prolapse is linked to mild and moderate levels of 
degeneration, through radial fissures that provide the route down which NP is 
displaced (Adams & Hutton, 1985).   
Similarly, degeneration occurs in IVDs that show no signs of previous injury 
(Jensen et al., 1994).  Although certain injuries are associated with the instigation 
of degenerative changes, particularly injuries to the end plates (Adams et al., 
2000).  Typically, these result in NP decompression and are followed by rapid 
degenerative changes (Kaigle et al., 1997).  IVD degeneration increases 
susceptibility to delaminating injuries that result from compressive loading of the AF 
(Adams et al., 1996b; Ebara et al., 1996), however, prolapse is inhibited once 
hydration of the NP is lost (Adams & Hutton, 1982). 
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1.3.5 Loading and Intervertebral Disc Degeneration 
Historical loading patterns appear to be an environmental risk factor associated 
with IVD degeneration (Adams et al., 2000).  Obesity and manual occupations 
increase loading through the IVDs and are associated with an enhanced risk of IVD 
degeneration development (Solovieva et al., 2002).  Since native IVD cells mediate 
ECM remodelling as an adaptive response to mechanical stimuli (Ishihara et al., 
1996; Handa et al., 1997; MacLean et al., 2005; Wuertz et al., 2009; Barbir et al., 
2011; Neidlinger-Wilke et al., 2012), which is considered beneficial to IVD structural 
integrity, efforts to understand the detrimental effects of excessive loading have 
examined the biologic responses of the IVD to force applications (Wang et al., 
2007; Walter et al., 2011).  Key findings from these investigations are that 
excessive or complex loading patterns detrimentally modulate expression of 
biochemical regulators of native IVD cell biology, such as growth factors and 
cytokines.  Growth factors, particularly transforming growth factor-β (TGF-β), are 
suggested to promote anabolic metabolism by native IVD cells (Nishida et al., 
1999) while cytokines such as Interleukin-1 (IL-1) and tumour necrosis factor-α 
(TNF-α), are suggested to promote catabolic metabolism (Bachmeier et al., 2007; 
Le Maitre et al., 2007a; Le Maitre et al., 2007d;  Hoyland et al., 2008).  It is 
postulated that IVD degeneration is induced by abnormal loading and mediated by 
cytokines (Freemont et al., 2001).             
1.4 Cytokines  
Cytokines are a large and diverse group of peptide molecules that act as messages 
in the bodies’ intercellular communications network.  They convey signals between 
local cells to modulate physiological responses to altered or adverse micro-
environmental conditions (Hancock, 2005).  They are produced by many cell types 
in response to a wide variety of stimuli.   
Cellular perception of stimuli that requires a cytokine mediated response results in 
the secretion or extracellular membrane presentation of a particular cytokine.  This 
signal can then be perceived by another ‘target’ cell that possesses the specific 
receptor molecule (Dinarello & Moldawer, 2000).  Signal transduction, which is 
transfer of the signal through several intracellular components, is then often 
required to convey the message to its terminal destination within the cell (Hancock, 
2005).  A response is elicited so that the outcome is appropriate to the original 
stimuli or stress.   
Cytokine extracellular signals are generally confined to the locality in which they are 
produced.  Extracellular membrane presentation limits their range to adjacent cells 
and secretion (or in some cases ‘shedding’ of membrane bound cytokines) permits 
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only short range signal diffusion.  This is because cytokines released into the 
extracellular medium are rapidly degraded by extracellular proteases, sequestered 
within the ECM or taken up by neighbouring cells (Hancock, 2005).  As such, 
cytokines generally modulate only local cellular responses.   
Autocrine, paracrine and cell-cell contact form the basis of cytokine intercellular 
signalling mechanisms (Hancock, 2005).  Diffusible signals produced and 
perceived by the same cell are autocrine, and a means of the cell signalling to 
itself.  Paracrine and cell-cell contact facilitate communication between different 
cells; diffusible signals released by one cell and perceived by another are 
paracrine, and receptor mediated perception of membrane bound cytokines or 
diffusion through plasma membrane gap junctions are cell-cell contact 
mechanisms.   
Cytokines are produced within the IVD by native cells.  Among those identified 
some, particularly those associated with the pathogenesis of IVD degeneration, 
have been characterised.  These include IL-1 and TNF-α.   
1.4.1 Interleukin-1  
Seven members make up the IL-1 family.  Two related but distinct genes encode 
the agonists, IL-1α and IL-1β.  Both cytokines are synthesised as 31kDa precursor 
molecules that remain in the cytosol after translation (Andersson et al., 1992).  
Post-translational cleavage results in the mature 17kDa peptides (Black et al., 
1988; Stevenson et al., 1992).  
The IL-1α precursor molecule, proIL-1α, has full biological activity (Mosley et al., 
1987) and can be targeted for secretion or membrane presentation (Kurt-Jones et 
al., 1985).  ProIL-1α is constitutively expressed by cells in several organs including 
skin, liver, lungs and kidneys and accumulates in the cytosol (Andersson et al., 
1992).  In healthy tissues, proIL-1α functions to promote homeostasis and in skin 
this is an autocrine effect (Hauser et al., 1986; Maier et al., 1990).  In disease or 
inflammation, cell necrosis releases cytosolic proIL-1α to act as a paracrine signal 
on neighbouring cells (Chen et al., 2007; Cohen et al., 2010).       
In contrast, the IL-1β precursor molecule, proIL-1β, is not biologically active 
(Mosley et al., 1987).  Intracellular post-translational modification by another IL-1 
family member, IL-1 converting enzyme (ICE), is required to generate the mature 
peptide (Black et al., 1988).  ProIL-1β accumulates in the cytosol (Andersson et al., 
1992), cleavage and activation occurs at the inner surface of the cell membrane 
and triggers secretion from the cell (Dinarello & Moldawer, 2000).  IL-1β is not 
presented on the extracellular plasma membrane and is not constitutively 
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expressed in healthy tissues.  Both IL-1 agonists are powerful inducers of the 
innate immune systems inflammatory response, and regulators of other cytokines 
involved in this process (Dinarello & Moldawer, 2000). 
Perception of IL-1 signalling is by the functional IL-1 family receptor, IL-1RI, that 
forms a heterodimeric complex with the IL-1 receptor accessory protein, IL-1RAcP, 
to facilitate signal transduction (Greenfeder et al., 1995).  A second IL-1 receptor 
exists, IL-1RII, that sequesters ligands without transducing a signal, and is often 
referred to as a ‘decoy’ receptor (Colotta et al., 1993; Sims et al., 1993) (Figure 
1-8). 
The final member of the IL-1 family is IL-1 receptor antagonist, IL-1Ra.  IL-1Ra is a 
22kDa glycosylated peptide molecule (Seckinger et al., 1989; Hannum et al., 1990; 
Mazzei et al., 1990) that is secreted into the extracellular medium (Arend et al., 
1998).  IL-1Ra binds receptor IL-1RI without triggering signal transduction (Dripps 
et al., 1991).  Receptor occupancy by IL-1Ra effectively blocks signalling by both 
IL-1α and IL-1β.     
1.4.1.1 Interleukin-1 Intracellular Signalling 
Almost all biological effects of IL-1 are mediated by inducing the expression of 
target genes.  As such, IL-1 signalling results in the production of transcription 
factors that drive expression of inducible genes.  The IL-1 signalling receptor, IL1-
RI, is a trans-membrane protein expressed by a wide variety cells (Saklatvala & 
Guesdon, 1991; Kracht & Saklatvala, 2002).  Agonist induced association of IL-1RI 
with IL-1RAcP initiates the formation of an intracellular protein complex, whose 
main component is the adaptor protein, TRAF6, a member of the TNF-Receptor-
Associated Factor family (Jiang et al., 2002).  The TRAF6 complex contains active 
forms of IκB kinases (IKKs) and certain members of the mitogen activated protein 
kinases (MAP3K) family, such as TGF-β-activated kinase (TAK1) and MEKK3 
(Jiang et al., 2002).  The IKKs phosphorylate IκB, the inhibitor of Nuclear Factor 
(NF)-κB, triggering degradation of IκB and release of the p50/p65 heterodimeric 
transcription factor NF-κB.  The MAP3Ks activate three subtypes of mitogen 
activated protein kinases (MAPKs), Erk, JNK and p38, which in turn activate 
transcription factors such as ELK-1, AP1 or ATF2 (Kracht & Saklatvala, 2002).   
IL-1RI may also activate the phosphatidyl-inositol-3 kinase (PI3K) pathway by two 
mechanisms (Davis et al., 2006; Wang et al., 2006; Liu et al., 2007; Parhar et al., 
2007); the first via TRAF complex activation of the tyrosine kinase, c-src (Gelman 
et al., 2006; Wang et al., 2006), and the second via direct activation of the P13K 
subunit, p85, by IL-1RI (Davis et al., 2006).  PI3K activates 3-phosphoinositide-
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dependent protein kinase 1 (PDK1) which may then trigger either or both; IκB 
degradation and release of NF-κB and/or activation of protein kinase B and 
subsequent Akt transcription factor activity (Liu et al., 2007; Parhar et al., 2007). 
1.4.2 Tumour Necrosis Factor-α 
TNF-α is synthesised as a 26kDa protein that is biologically active and displayed on 
the extracellular plasma membrane (Kriegler et al., 1988).  Membrane bound TNF-
α may signal to adjacent cells displaying receptors through cell-cell contact but also 
functions as a paracrine signal when ‘shed’ from the plasma membrane.  TNF-α 
converting enzyme (TACE/ADAM-17) is a membrane bound ‘a disintegrin and 
metalloproteinase’ (ADAM) that cleaves the extracellular domain of membrane 
bound TNF-α to release a biologically active 17kDa soluble TNF-α molecule (Black 
et al., 1997; Moss et al., 1997).   
TNF-α is produced by many cell types and in response to a broad range of stimuli.  
Biologically, it modulates cellular proliferation, differentiation, metabolism, and can 
induce apoptosis (Zhang & Tracey, 1998).  TNF-α is also a powerful inducer of the 
innate immune systems inflammatory response, and a regulator of other cytokines 
involved in this process (Dinarello & Moldawer, 2000).   
Responses to TNF-α are mediated by ligand binding to two types of 
transmembrane glycoprotein receptors, TNF receptor I (TNF-RI/TNF-R55) and TNF 
receptor II (TNF-RII/TNF-R75) (Figure 1-9).  Both receptors are constitutively 
expressed in all cells but are susceptible to cleavage by MMPs.  Inflammatory 
signals can induce this cleavage and ‘shedding’ of the receptors’ extracellular 
domain (Higuchi & Aggarwal, 1994; Solorzano et al., 1997), shed receptors retain 
binding affinity and may then function as inhibitors of TNF-α activity.    
1.4.3 Interleukin-1 and Tumour Necrosis Factor-α in the Normal 
Intervertebral Disc 
Stimuli that result in cytokine expression within the normal IVD are unknown, as are 
the exact roles that cytokines play in IVD cell biology.  However, cytokine 
expression occurs within the normal IVD and so it can be assumed that the stimuli 
form part of the normal physiological conditions to which native cells are exposed.   
IL-1α, IL-1β, IL-1Ra, IL-1RI and ICE are expressed by native cells of the IVD (Le 
Maitre et al., 2005; Le Maitre et al., 2007d).  Expression patterns of the agonists 
are similar (Le Maitre et al., 2005), and their function may be maintenance of tissue 
homeostasis through modulation of anabolic and catabolic cell activities.  
Characteristic in vitro responses of human NP cells to agonist stimulation include 
suppression of aggrecan transcription without affecting type I or II collagen
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(Le Maitre et al., 2005) and increased MMP -3, -9 and -13 transcription (Le Maitre 
et al., 2005; Millward-Sadler et al., 2009) without affecting that of ADAMTS -4 and -
5 (Le Maitre et al., 2005).   
TNF-α, TNF-RI, TNF-RII and TACE are expressed by native cells of the IVD 
(Weiler et al., 2005; Bachmeier et al., 2007; Le Maitre et al., 2007d).  Expression is 
greater in the NP than in the AF and increases with aging (Bachmeier et al., 2007).  
TNF-α may also function to maintain homeostasis through modulation of anabolic 
and catabolic cell activities and through modulation of IL-1 expression.  
Characteristic in vitro responses of human NP cells to TNF-α stimulation include 
suppression of type I and II collagen transcription without affecting that of aggrecan 
(Millward-Sadler et al., 2009) and increased MMP -3 and -13 transcription without 
affecting that of MMP-9 (Millward-Sadler et al., 2009). 
1.4.3.1 Interleukin-1 and Tumour Necrosis Factor-α Inter-Regulation 
The subtle differences in modulatory potential of these two cytokines may function 
to maintain the correct balance of ECM composition.  An inter-regulatory 
relationship exists between IL-1 and TNF-α, with IL-1 stimulation having no effect 
on transcription of IL-1 family members (Le Maitre et al., 2005) but increasing the 
transcription of TNF-α and receptor TNF-R75, without affecting that of receptor 
TNF-R55 (Millward-Sadler et al., 2009).  TNF-α stimulation increases transcription 
of IL-1β and IL-1Ra without affecting IL-1α or receptor IL-1RI (Millward-Sadler et 
al., 2009) and increases its own transcription alongside receptor, TNF-R75, without 
affecting TNF-R55 (Millward-Sadler et al., 2009).  The ability of TNF-α to modulate 
both its own transcription and that of IL-1 suggests that TNF-α has greater 
regulatory potential within the IVD however, catabolic responses to IL-1 stimulation 
are greater than those observed for TNF-α indicating that IL-1 has a greater 
potential to instigate catabolic changes.      
1.4.4 Interleukin-1 and Tumour Necrosis Factor-α in the Degenerate 
Intervertebral Disc 
In degenerate IVDs, expression of IL-1α, IL-1β, IL-1RI and ICE is greater than that 
seen in non-degenerate (Le Maitre et al., 2005; Le Maitre et al., 2007d), whilst 
expression of the antagonist, IL-1Ra, is unchanged (Le Maitre et al., 2005).  
Increased agonist expression correlates positively with increasing severity of 
degeneration (Le Maitre et al., 2005) as does the expression of MMPs (Weiler et 
al., 2002), however, a direct link to show that increased IL-1 expression causes the 
increased MMP expression in vivo is yet to be established.  In situ zymography of 
human IVD tissue shows that matrix degrading enzyme activity is greatly enhanced 
in both normal and degenerate samples following IL-1 stimulation, and suppressed 
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to levels much lower than those seen in un-stimulated controls by the antagonist, 
IL-1Ra (Le Maitre et al., 2007b; Hoyland et al., 2008).  Since increased expression 
of the IL-1 agonists in degenerate NP cells is seen without a concordant increase in 
IL-1Ra (Le Maitre et al., 2005), an imbalance between agonist and antagonist is 
thought to form the mechanism by which IL-1 may cause increased matrix 
degradation.      
The characteristic in vitro responses of human NP cells derived from degenerate 
tissue, to IL-1 agonist stimulation, are altered compared to those in NP cells 
derived from the normal IVD.  Modulation of anabolic genes is by suppression of 
type I collagen (Le Maitre et al., 2005), type II collagen (Studer et al., 2011) and 
aggrecan (Studer et al., 2011) transcription.  Modulation of catabolic genes is by 
increased MMP -3, -9, -13 (Millward-Sadler et al., 2009) and ADAMTS-4 
transcription (Le Maitre et al., 2005) without affecting ADAMTS-5 (Le Maitre et al., 
2005).  This indicates that the modulatory potential of IL-1 is altered, non-specific 
suppression of anabolic gene transcription occurs and an ability to modulate 
ADAMTS expression develops.  These changes in cellular response to IL-1 
stimulation would enhance the drift towards a catabolic microenvironment and ECM 
depletion.     
Expression of TNF-α, TNF-R75 and TACE is also greater in the degenerate IVD 
than in the non-degenerate (Bachmeier et al., 2007; Le Maitre et al., 2007d).  
Conflicting reports of receptor, TNF-R55, protein expression exist however, with 
some studies indicating expression is increased (Bachmeier et al., 2007) and 
others reporting no change when comparing degenerate to non-degenerate IVDs 
by the same immuno-detection technique (Le Maitre et al., 2007d).  TNF-R55 
transcription has been assessed and found to be consistent in both non-degenerate 
and degenerate IVDs (Le Maitre et al., 2007d; Tschoeke et al., 2008), and it may 
be that the differences reported in protein expression relate to antibody specificity 
and fragment detection since this receptor is known to be susceptible to MMP 
cleavage (Higuchi & Aggarwal, 1994; Solorzano et al., 1997).  Increased TNF-α 
expression correlates positively with increasing severity of degeneration 
(Bachmeier et al., 2007) however, the modulatory potential of TNF-α on catabolic 
metabolism appears to be reduced, indicating that increased TNF-α expression 
may not account for the increased MMP expression in the degenerate IVD.  This is 
demonstrated by the in vitro responses of human NP cells derived from degenerate 
tissue, to TNF-α stimulation, which are altered to those in cells derived from the 
normal IVD.  Modulation of catabolic genes is by increased MMP-3 transcription 
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without affecting that of MMP -9 or -13 (Millward-Sadler et al., 2009).  The 
modulatory effect on MMP-13 observed in NP cells from non-degenerate IVDs is 
lost and whilst up-regulation of MMP-3 transcription still occurs, the response 
observed (fold increase) is less than that seen in cells derived from the non-
degenerate IVD (Millward-Sadler et al., 2009).  This is confirmed by in situ 
zymography of human IVD tissue, that shows TNF-α stimulation of non-degenerate 
samples results in mildly increased matrix degrading enzyme activity that can be 
reduced to slightly below the level seen in un-stimulated controls by anti-TNF 
stimulation (Hoyland et al., 2008), but that stimulation of degenerate samples with 
either TNF-α or anti-TNF has no effect on matrix degrading enzyme activity 
(Hoyland et al., 2008).  This indicates either that TNF-α exerts a much lesser 
modulatory effect on catabolic metabolism in the degenerate IVD, or that the 
regulatory mechanism that prevents excessive TNF-α mediated catabolism 
remains functional within the degenerate IVD.     
In vitro, modulation of anabolic genes in response to TNF-α stimulation is also 
altered in NP cells derived from degenerate IVDs compared to those from non-
degenerate counterparts.  The response is characterised by suppression of type I 
collagen (Millward-Sadler et al., 2009), type II collagen (Studer et al., 2011) and 
aggrecan (Studer et al., 2011) transcription.  This indicates that differential 
modulation of ECM components is replaced by non-specific suppression of 
anabolic gene transcription.  Increased TNF-α expression in the degenerate IVD 
may exert detrimental modulatory effects on ECM integrity by down-regulating 
anabolic metabolism rather than adversely modulating catabolic metabolism.       
The inter-regulatory effects of the two cytokines are also altered in degeneration.  
TNF-α up-regulates its own transcription and that of IL-1 in a similar manner to that 
seen in the normal IVD.  Presumably this process is itself modulated since 
excessive cytokine expression does not occur in the normal IVD and TNF-α up-
regulates IL-1 agonist and antagonist to similar extents, maintaining equilibrium.  
However, the regulatory potential of IL-1 is greatly increased.  IL-1 stimulation up-
regulates transcription of both IL-1 agonists without affecting that of the antagonist  
indicating a positive feedback loop is established in NP cells derived from 
degenerate tissue (Le Maitre et al., 2005).   
Together these findings implicate dysregulated cytokine expression in the 
pathogenesis of IVD degeneration.  They indicate that the characteristic cellular 
changes – reduced anabolic metabolism and increased catabolic metabolism, may 
result directly from this dysregulation, and that the endogenous inhibitor of IL-1, IL-
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1Ra may abolish excessive catabolism in the degenerate IVD.  Further evidence to 
support this theory in the human IVD is shown by the introduction of autologus NP 
cells, transfected to over express IL-1Ra, into degenerate NP tissue explants, 
where MMP and ADAMTS-4 expression was reduced (Le Maitre et al., 2007b), 
however correlating enzyme activity was not quantified.   
IL-1Ra knockout mice spontaneously develop degenerative IVD changes, 
compared to their wild type counterparts (Phillips et al., 2013).  This indicates that 
the balance between IL-1 agonist and antagonist expression is important for 
maintaining the health of the IVD.       
1.4.5 Other Cytokines in the IVD 
1.4.5.1 Interleukins 
Whilst attention has been given to IL-1, more than 20 other interleukin series 
cytokines exist.  Some, including IL-4, IL-6, IL-10, IL-12, IL-17 and IL-20 have been 
identified within the IVD.  With the exception of IL-6 (described below), their role in 
IVD cell biology is largely unknown, Table 1-3 summarises current knowledge. 
1.4.5.2 Interleukin-6 
IL-6 is a secreted cytokine produced by many cell types.  The IL-6 gene product 
varies in molecular weight from 21 to 28kDa dependent on post-translational 
modification and has diverse biological activity (Kishimoto et al., 1995).  Depending 
on the target cell type, IL-6 can induce cellular proliferation or differentiation and 
activate the innate immune system (Baumann & Gauldie, 1994; Lenczowski et al., 
1999).  IL-6 and can also modulate the activity of other cytokines, in certain 
situations by down-regulating both IL-1 and TNF-α (Dinarello & Moldawer, 2000). 
Transduction of the IL-6 signal is dependent on the interaction of IL-6/IL-6 receptor 
(IL-6R) complex with the membrane bound G-protein coupled signal transducing 
protein, gp130.  This is a common signal transduction pathway shared with several 
other cytokines including IL-11, oncostatin-M (OSM) and leukaemia inhibitory factor 
(LIF) that show structural homology and related biological functions to IL-6 (Taga & 
Kishimoto, 1997).   
IL-6 is expressed by native IVD cells (Kang et al., 1996; Specchia et al., 2002; Lee 
et al., 2009) however, receptor expression has not been confirmed.  The only study 
to investigate IL-6R expression in the human IVD indicates that the receptor is not 
expressed in normal IVDs, but that receptor expression is spontaneously induced in 
prolapsed tissue (Specchia et al., 2002).   
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To determine potential in vitro responses of human NP cells (related to anabolic 
and catabolic metabolism) to IL-6 stimulation, soluble IL-6R was also supplemented 
(which may bind the ligand prior to signalling through gp130) (Studer et al., 2011).  
This study revealed that IL-6 stimulation affected anabolic metabolism by 
suppressing type II collagen and aggrecan transcription and affected catabolic 
metabolism by increasing MMP-3 translation (Studer et al., 2011).  The effects of 
stimulation on type I collagen, other MMPs or ADAMTSs were not investigated.  
Co-stimulation of IL-6 and soluble IL-6R with either IL-1 or TNF-α was seen to 
potentiate the effects of IL-1 or TNF-α stimulation alone, on all anabolic and 
catabolic parameters measured (Studer et al., 2011).  Stimulation with either IL-1, 
TNF-α or IL-6 and soluble IL-6R increased transcription of IL-6, with IL-1 inducing 
the most potent response (Studer et al., 2011).  The effect of IL-6 stimulation on 
transcription of IL-1 or TNF-α were not investigated however, the potentiating 
effects of co-stimulation indicate that in this experimental system, IL-6 stimulation 
does not have a down-regulatory effect on either IL-1 or TNF-α expression.  These 
studies were performed on human NP cells derived from degenerate tissue, as 
such the responses described may be altered from those in NP cells derived from 
normal IVDs. 
1.4.5.3 The Tumour Necrosis Factor Superfamily 
The TNF superfamily has at least 19 members including TNF-α, TNF-β 
(lymphotoxin-α), Fas Ligand (FasL), TNF-related apoptosis inducing ligand 
(TRAIL), TNF-like weak inducer of apoptosis (TWEAK) and CD40 ligand (CD40L) 
(Gruss & Dower, 1995; Bazzoni & Beutler, 1996).  With the exception of TNF-β, 
members are homotrimeric proteins presented on the extracellular plasma 
membrane (Bazzoni & Beutler, 1996).  Biological similarities between members 
exist and most function to regulate cellular proliferation and apoptosis, some are 
also involved in activation of the innate immune system (Dinarello & Moldawer, 
2000). 
The rate of apoptosis is increased in the degenerate IVD compared to that of the 
normal (Tschoeke et al., 2008; Wang et al., 2011).  Since TNF superfamily 
members are able to trigger apoptosis, several investigations have studied their 
expression in the IVD.   
Apoptosis, or programmed cell death, is in most cases a normal cellular event 
(Mera, 1997).  Cells that have reached the end of their useful lives undergo 
apoptosis and are replaced by division of neighbouring cells so that a balance of 
tissue cellularity is maintained (Mera, 1997).  The process is mediated by cysteinyl-
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aspartate-specific proteases (caspases) that instigate the cell shrinkage and DNA 
fragmentation characteristic of apoptosis (Hancock, 2005).  Intrinsic or extrinsic 
signalling pathways may activate caspases and trigger apoptosis.   
The intrinsic pathway is activated in response to DNA damage or cellular stress 
and results in increased permeability of mitochondria and release of mitochondrial 
cytochrome-c into the cytosol (Antonsson, 2004).  Cytochrome-c then complexes 
with other pro-apoptotic factors to form the apoptosome (Antonsson, 2004).  The 
extrinsic pathway is initiated by ligand binding to extracellular membrane presented 
death receptors (DRs) (Wang & El-Deiry, 2003).  The intracellular C-terminal of 
DRs contains a ‘death domain’ through which the signal is transduced to 
intracellular pro-apoptotic factors that form the death-induced signalling complex 
(Wang & El-Deiry, 2003).  The apoptosome and death-induced signalling complex 
contain precursor initiator caspase molecules that are activated by autocatalytic 
cleavage.  These in turn activate effector caspases and apoptosis results.   
Within the IVD, caspases specific to each signalling pathway have been 
investigated.  Caspase-9, an initiator caspase in the intrinsic pathway, is increased 
in tissue homogenate from degenerate samples compared to normal (Tschoeke et 
al., 2008; Wang et al., 2011), as is caspase-8, an initiator caspase in the extrinsic 
pathway (Tschoeke et al., 2008; Wang et al., 2011).  Expression of both caspases 
correlates positively with increasing severity of degenerative tissue changes, up to 
moderate levels after which no further increase occurs (Wang et al., 2011).  
Effector caspase activity (caspase -3 and -7) (Tschoeke et al., 2008), alongside 
rate of apoptosis (Tschoeke et al., 2008; Wang et al., 2011), is also increased and 
correlates positively with the severity of degenerative tissue changes (Wang et al., 
2011).  These findings indicate that increased apoptosis in the degenerate IVD is 
by up-regulation of both intrinsic and extrinsic pathways.   
Several pro-apoptotic TNF superfamily members may mediate apoptosis via the 
extrinsic pathway, including FasL and TNF-α.  Transduction of the FasL signal is 
dependent on interaction with Fas receptor, and transduction of an apoptotic signal 
by TNF-α is dependent on ligand interaction with TNF-RI (TNF-R55), both of which 
possess intracellular ‘death domains’ that may signal for death-induced signalling 
complex formation.   
FasL (Park et al., 2001a) and TNF-α are expressed by native IVD cells, as are Fas 
receptor (Park et al., 2001b) and TNF-RI.  Transcription of both FasL and Fas 
receptor is increased in degenerate tissue homogenate compared to non-
degenerate (Tschoeke et al., 2008; Wang et al., 2011).  Observed transcription 
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patterns are similar to that of caspase-8 activity, with transcription increasing 
concordant to severity of degenerative tissue changes up to moderate levels 
without a further increase between moderately and severely degenerate tissues 
(Wang et al., 2011).  As previously described, TNF-α expression is up-regulated in 
degenerate IVDs however, DR, TNF-RI, expression is unaffected.   
These findings indicate that the extrinsic pathway is, at least in part, responsible for 
the increased rates of apoptosis observed in IVD degeneration.  Excessive or 
dysregulated cytokine expression may drive this process through DR signalling.  
Apoptosis of native cells may also form part of the mechanism of spontaneous 
resorption of prolapsed IVD tissue.  FasL and Fas receptor transcription are 
increased in prolapsed IVD tissue compared to normal, as is caspase activity 
(Wang et al., 2011).  Further, extruded and sequestered tissue samples reveal 
greater expression and activity rates indicating that the more severe the degree of 
prolapse the greater the apoptotic response generated (Wang et al., 2011).  This 
mechanism may account in part for the destruction of displaced IVD tissue.           
Other roles for TNF superfamily members within the IVD have been postulated.  
Nerve growth factor (NGF) is produced by native IVD cells (Freemont et al., 1997; 
Freemont et al., 2002; Richardson et al., 2009; Lee et al., 2011) and may promote 
the innervation seen in severely degenerate IVDs (Lee et al., 2011). 
1.4.5.4 Chemokines 
The chemokines (chemo-attractive cytokines) are at least 50 small (8 - 10 kDa) 
secreted protein molecules, split between four major families based on structural 
similarity (Figure 1-10).  The tertiary structure of all chemokines is similar and 
accounted for by disulphide bonds that form between conserved cysteine residues 
(Clark-Lewis et al., 1995).  This structural similarity conveys characteristic 
chemokine properties.  Signal sequestration occurs so that chemokines become 
bound to GAG molecules on the cell surface or ECM via ionic interaction of basic 
residues in the C-terminal helix and core region (Chakravarty et al., 1998; Amara et 
al., 1999).  Bound chemokines retain their full biologic activity (Webb et al., 1993; 
Middleton et al., 1997) and receptor interaction is through the N-terminal domain 
and exposed ‘loop region’ that follows the second conserved cysteine residue 
(Thelen, 2001).  This property explains the locally focused response elicited by 
chemokine secretion.   
  
Figure 1-10
Four chemokine structural subfamilies exist based on the positioning of conserved cysteine 
residues within the N
XC chemokines (A) have only one N
(B) have two adjacent conserved cysteine residues, e.g. CCL3.  C
two conserved cysteine residues separated by one other amino acid residue, e.g. CXCL8.  
C-X3-C chemokines (D) have two conserved cysteine residues separated by th
amino acids, the only identified member of this structural subfamily, CX
terminal membrane
membrane.   
 
  Schematic Representation of 
-association domain that accounts for its anchoring to the plasma 
 
-terminal motif; C = cysteine residue; X = other amino acid residue.  
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The biological activities of chemokines are diverse however, all possess the 
common property of being able to induce chemotaxis, which is the selective 
directional migration of target cells.  As such chemokines are closely associated 
with the innate and adaptive immune responses.  They function to recruit 
leukocytes to sites of infection, injury and disturbed tissue homeostasis as well as 
modulating lymphocyte differentiation and activation in haematopoiesis (Moser et 
al., 2006).  Chemokines may also function to promote or dampen inflammatory 
responses (Wakugawa et al., 2001; Eddleston et al., 2002), neovascularisation 
(Romagnani et al., 2006), or pain sensation (Zhang & Oppenheim, 2006).  They 
stimulate superoxide production (Huber et al., 2002), protease release (Cross & 
Woodroofe, 1999), generation of reactive lipid products, phenotypic and 
cytoskeletal changes (Banas et al., 2004), proliferation (Bonacchi et al., 2001) and 
modulation of ECM synthesis (Banas et al., 1999; Romagnani et al., 1999; 
Schecter et al., 2000).   
Chemokine expression within the prolapsed IVD has been investigated, since 
expression may modulate the observed infiltration of inflammatory cells, therefore 
forming part of the mechanism of spontaneous resorption.  To this end several 
chemokines have been identified as expressed by native IVD cells within prolapsed 
tissue (Table 1-4).  For the majority of these chemokines it remains unknown 
whether their expression is a spontaneous response to tissue displacement or an 
event that occurs from the normal physiological conditions to which the native cells 
are exposed.  The only studies to use normal IVD tissue alongside prolapsed, 
indicated that CCL2, CCL3, CCL4 and CXCL8 expression is evident in normal 
IVDs, albeit increased in prolapsed tissue (Burke et al., 2002; Wang et al., 2012). 
1.4.5.5 Chemokine Intracellular Signalling 
Responses to chemokine signalling are generated through ligand binding to seven 
transmembrane trimeric G-protein coupled receptors (Thelen, 2001).  Chemokine 
receptors are split into families based on the N-terminal motif of the chemokines 
that they bind.  Most receptors recognise more than one chemokine and several 
chemokines bind to more than one receptor (Murphy et al., 2000).  
Ligand binding promotes conformational changes in the receptor, such that the α 
subunit is dissociated from the βγ subunit, dependent on the exchange of GDP for 
GTP (Thelen, 2001).  Dependent on the ligand that is bound, conformational 
changes in the receptor may result in generation of diacylglycerol (DAG) and 
inositol-1,4,5 triphosphate (IP3).  IP3 binding to its receptor at the endoplasmic 
reticulum triggers the release of intracellular calcium (Kiselyov et al., 2003).  
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Increased intracellular calcium alongside the presence of DAG causes activation of 
protein kinase C (PKC) and signalling through the phosphoinositide-specific 
phospholipase C (PLC) pathway (Kiselyov et al., 2003).  Receptor conformational 
changes may also activate the PI3K signalling pathway (Bonacchi et al., 2001) 
(described previously (section 1.4.1.1)). 
1.4.6 Cytokines and Chemokines in Other Arthropathies 
The roles of cytokines and chemokines in osteoarthritis (OA) and rheumatoid 
arthritis (RA) are well documented.  IL-1 and TNF-α are considered primary 
effectors capable of inducing other cytokines and chemokines regarded as second 
step mediators of disease (Van den Berg & Miossec, 2004).  Cytokines and 
chemokines implicated in the pathology of OA and RA are summarised in Table 
1-4. 
1.5 Low Back Pain 
The anatomic source of low back pain (LBP) is difficult to specify (Hancock et al., 
2007) and can arise from several or any combination of multiple sources.  The 
innervated structures of the vertebral bodies, facet joints, sacroiliac joints and local 
ligaments and musculature of the motion segment are all implicated (Cavanaugh et 
al., 1996; Hancock et al., 2007).  IVD degeneration increases the risk of LBP 
development (Luoma et al., 2000) and studies indicate that 40% of LBP cases are 
linked directly to IVD degeneration (Schwarzer et al., 1995) through direct 
mechanical and/or peripheral biochemical stimulation of local nerves.   
The application of force (tension, torsion, compression or pressure) abnormal to 
that physiologically expected, to an innervated structure may generate a pain signal 
propagated by local mechanoreceptors (Cavanaugh et al., 1996).  The altered 
biomechanics of a motion segment that contains a degenerate IVD, results in 
abnormal loading of tissue structures during normal movement (Figure 1-11).  The 
lumbar IVD becomes a further source of LBP when structural disruption is sufficient 
to result in abnormal loading of the innervated outer AF.  Progressively, neo-
innervation of the IVD occurs with enhanced nociceptive (pain sensing) nerve fibre 
penetration (Freemont et al., 1997; Freemont et al., 2002).  Therefore, whilst the 
progressive biomechanical failure of the IVD enhances generation of mechanical 
pain stimuli, the IVD itself becomes hyper-sensitised to pain detection.   
Biochemical factors may also enhance the propagation of pain signals. Local 
concentrations of cytokines (IL-1, TNF-α, IL-6), prostaglandins, phospholipases and 
neuropeptides (substance P) propagate pain signals through receptor-mediated 
 
  
 
 
Figure 1-11
Low back pain 
The innervated structures of the vertebral bodies, facet joints, sa
ligaments and musculature of the motion segment are all implicated.  The lumbar IVD may 
also be a source of 
abnormal loading patterns through the motion segment. Fi
Saftic (2010).
  Schematic Representation of the Anatomical Sources of Low Back Pain
can arise from many or any combination of multiple, anatomical sources.  
 
low back pain 
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binding to local nerve cells (Watkins et al., 1995).  This mechanism may further 
enhance painful stimulation of nerve endings within the IVD.   
Prolapse of the IVD may result in LBP from direct compression of adjacent nerve 
roots.  However, direct compression is not required since prolapse that does not 
result in compression of nerve roots is also seen to induce LBP (Mulleman et al., 
2006a; Mulleman et al., 2006b).  Biochemical irritation of adjacent nerve roots is 
thought to account for painful stimulation in these cases. 
1.6 Conclusions 
LBP is a prevalent, disabling condition that represents a significant economic 
burden in many Western industrialised societies (Maniadakis & Gray, 2000; 
Dagenais et al., 2008).  Progressing the development of effective treatment 
strategies can only arise from a greater understanding of the complex, multi-
factorial processes of the pathogenesis of LBP.   
Cytokines may represent a critical mechanism in the development of LBP, 
particularly related to IVD structural failure and biochemically mediated local 
hyperalgesic states.  Improvement in understanding in this area may lead to more 
effective treatment strategies by identifying potential therapeutic targets.  Currently, 
several research initiatives are investigating the regenerative potential of stem cell 
therapy in the IVD (Steck et al., 2005; Le Maitre et al., 2009; Collin et al., 2011; 
Yang et al., 2011).  To this end, an understanding of the micro-environmental 
conditions within the ‘degenerate niche’ would provide insights as to the effects that 
may be elicited on the behaviour of cells introduced to such an environment. 
1.7 Aims and Objectives 
The purpose of these studies is to investigate the hypothesis that; 
Cytokines and chemokines are integral to the pathogenesis of IVD 
degeneration and prolapse that may lead to the generation of LBP. 
Specifically; 
• To identify cytokines and chemokines produced within the NP of normal, 
degenerate and prolapsed IVDs 
• To identify the 'target cells' of these cytokines and chemokines based on 
receptor expression  
• To determine the inter-relationship that exists between these cytokines and 
chemokines within the IVD  
• To understand how the different expression patterns and inter-relationships 
may contribute to disruption of catabolic and anabolic cellular metabolism
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2 Materials and Methods 
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2.1 Tissue Sample Processing 
Human IVD tissue was obtained either at post-mortem (PM) examination or surgery 
with informed consent of the patient or relatives.  Details of all IVD tissue samples 
used in these studies are shown in Appendix 1.  Post-mortem (PM) IVD tissue 
samples were supplied by Leeds Institute of Molecular Medicine Tissue Bank.  
Research Ethics Committee approval to use human tissue taken at the time of 
spinal surgery was obtained from Sheffield Research Ethics Committee - REC 
09/H1308/70.   
2.1.1 Sample Collection 
2.1.1.1 Surgical Intervertebral Disc Tissue 
IVD tissue samples were obtained at surgery from patients undergoing micro-
discectomy procedures at the Northern General Hospital, Sheffield, for the 
treatment of sciatica and nerve compression.   
Upon removal IVD tissue was placed into sterile 50mL collection tubes containing 
20mL Serum Free Media (SFM; Dulbecco's Modified Eagles Media (DMEM; Gibco) 
supplemented with 200U/mL penicillin (Gibco), 200µg/mL streptomycin (Gibco), 
500ng/mL amphotericin B (Sigma), 50µg/mL ascorbic acid (Sigma) and 2mM L-
glutamine (Gibco)) and kept at 4°C for collection and transportation to the 
laboratory for processing.  Tissue samples were accompanied by a Disc Material 
Details form (Appendix 2) completed by the surgical team at the time of sample 
collection.   
2.1.1.2 Post-Mortem Intervertebral Disc Tissue 
PM tissue samples consisted of intact IVDs within the complete motion segment.  
Upon recovery, motion segments were placed into sterile 500mL collection vessels 
containing 200mL SFM and kept at 4°C for collection and transportation to the 
laboratory for processing. 
2.1.2 Sample Processing 
2.1.2.1 Surgical Intervertebral Disc Tissue 
Surgical samples consisted of multiple fragments of IVD tissue.  The majority of 
tissue fragments were NP however some were NP with CEP and/or AF attached.  
The tissue samples were examined and used either for embedding to paraffin wax 
as detailed in section 2.1.3, or to be split between embedding to wax and NP cell 
isolation.  In the case of the latter, fragments were examined and separated, tissue 
with CEP and/or AF attached was placed for embedding in all cases, only NP 
tissue was used for cell isolation as detailed in section 2.1.4.   
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2.1.2.2 Post-Mortem Intervertebral Disc Tissue 
In the laboratory, PM IVDs were dissected from within the motion segment.  From 
whole IVDs, blocks of tissue comprising NP and AF in continuity were cut and set 
for embedding to paraffin wax.  Remaining NP tissue was used for isolation of NP 
cells. 
2.1.3 Embedding to Paraffin Wax 
Tissue samples were fixed immediately by immersion in 10% Neutral Buffered 
Formalin at 4°C for between 48 and 72 hours.  Following fixation samples were 
processed to paraffin wax on a Shandon Elliott Duplex Processor in an automated 
process of dehydration by immersion in alcohol (IMS; Industrial Methylated Spirit, 
Fisher Scientific) and clearing in Sub-X (Xylene Substitute, Leica) prior to 
immersion in molten paraffin wax, full processing details are given in Appendix 3.  
Samples in molten wax were transferred to a JeioTech OV-11 vacuum oven and 
incubated at 60°C and 60cmHg for 1 hour to ensure complete penetration of wax 
throughout the sample.  Tissue samples were then oriented as desired into moulds 
containing molten wax and allowed to cool into blocks.  Once set tissue blocks 
were removed from moulds and stored at room temperature to be used as 
described in sections 2.2 and 2.3 for histology and immunohistochemistry.   
2.1.4 Isolation of Nucleus Pulposus Cells 
NP tissue was finely dissected and washed with 2U/mL protease (Sigma) in SFM 
for 30 minutes at 37°C, to lyse any blood cells contaminating the tissue surface.  
Tissue was washed twice in SFM and cells released by digestion of ECM in 
2mg/mL Collagenase type I (Sigma) in SFM for between 4 and 18 hours at 37°C 
rotating gently on a flatbed shaker.    The cell suspension was filtered through 
sterile 40µm cell strainers (Beckton Dickinson) and cells recovered by 
centrifugation at 400g for 10 minutes.  The resulting cell pellet was washed twice by 
re-suspension in SFM and centrifugation before being re-suspended in SFM.  
Isolated cells (‘directly extracted’; (DE)) were used immediately for total RNA 
extraction and/or cell culture as detailed in sections 2.1.5 and 2.4.   
2.1.5 Total   RNA   Extraction   from   Directly   Extracted   Nucleus   
Pulposus   Cells  
Isolated NP cells were counted using an Invitrogen Countess automated cell 
counter (Invitrogen) incorporating trypan blue (Gibco) to distinguish live and dead 
cells.  Two cell suspension aliquots containing 1.0 x 10
5 
live cells were taken to 
RNase free 1.5mL tubes and centrifuged at 400g for 10 minutes to recover cells.  
Supernatant was removed and the remaining cell pellet re-suspended in 1mL Trizol 
(Ambion) and incubated at room temperature for 5 minutes.  200µL Chloroform 
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(Sigma) was added per tube; samples were mixed by vortexing for 15 seconds and 
incubated at room temperature for 3 minutes prior to centrifugation at 12000g for 15 
minutes at 4°C.  Following centrifugation, the upper aqueous phase (RNA 
containing) was removed to a fresh 1.5mL tube and 500µL isopropanol (Sigma) 
added.  RNA samples were incubated for 10 minutes at room temperature and then 
at -80°C for 1 hour to precipitate RNA.  Samples were thawed on ice and 
centrifuged at 12000g for 30 minutes at 4°C to collect RNA precipitate.  The 
resulting pellet was re-suspended in 87.5µL sterile deionised water.  Samples were 
subjected to DNase digestion to remove any remaining traces of genomic DNA by 
addition of 12.5µL DNase solution containing 30U DNase I (Qiagen; RNase-Free 
DNase Kit) and incubation for 10 minutes at room temperature.  RNA was 
recovered and DNase removed using Qiagen Min-Elute Clean-Up Kit as per 
manufacturer’s protocol.  RNA samples were eluted in 14µL sterile deionised water 
and used immediately for cDNA synthesis as described in section 2.5.2.  Cell 
suspension remaining following collection of aliquots for total RNA extraction was 
used in cell culture as described in section 2.4.         
2.2 Histology 
All formalin fixed paraffin embedded (FFPE) tissue samples were subjected to 
histological assessment to determine the grade of tissue degeneration and the 
presence or absence of ‘infiltrating’ cells.   
2.2.1 Sectioning and Mounting 
Tissue sections were cut using a Leica SM2400 sledge microtome to 4µm 
thickness.  Tissue sections were placed onto the surface of a 45˚C water bath and 
mounted by floating onto positively charged adhesive slides (Leica).  Excess water 
was dried from slides and sections by 30 minute incubation on a 40˚C drying rack.  
Mounted sections were then transferred into a desiccating oven at 37˚C to 
complete drying and for storage until use. 
2.2.2 Haematoxylin and Eosin Staining 
Sections were de-waxed by immersion in Sub-X (Leica) for 5 minutes in triplicate 
followed by rehydration in IMS (Fisher Scientific) for 5 minutes in triplicate.  
Sections were incubated in Mayer’s Haematoxylin (Leica) for 60 seconds then 
‘blued’ by immersion in running water for 5 minutes prior to incubation in Eosin Y 
(Leica) for 60 seconds.  Sections were dehydrated by immersion in IMS for 3 
minutes in triplicate followed by clearing in Sub-X for 5 minutes in triplicate.  
Sections were mounted by application of 2 drops Pertex mountant (Leica) per 
tissue section and placement of 1µm thickness glass cover slips.   
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2.2.3 Grading of Tissue Sections 
Tissue sections were evaluated using an Olympus BX60 research microscope.  
Each section was assigned a grade between 0 and 12 based on the presence of 
histological features associated with IVD degeneration pathology.  A score of 0 - 3 
indicates a histologically normal (non-degenerate) IVD and a grade of 4 - 12 
indicates evidence of degeneration.  All sections were graded independently by two 
observers (KLEP and CLLM), the grade assigned being the average of the two 
observers’ scores.  Where deviations of greater than 2 grades were recorded 
between observers, sections were re-evaluated by both observers.             
The grading system used was developed by Professor Antony Freemont 
(Histopathologist, University of Manchester) and Dr Christine Le Maitre, and 
applied as previously published (Le Maitre et al., 2005).  Sections were scored for 
the presence of cell clusters, the presence of fissures, the loss of demarcation 
between AF and NP and the loss of proteoglycan within the NP based on 
haematoxyphilia.  In surgical tissue samples, it was often impossible to score the 
loss of demarcation since AF and NP in continuity was rarely obtained.  Grades 
were assigned to these samples by multiplying the sum of scores from the other 3 
factors by 0.75.  Table 2-1 gives full details of the grading system used and image 
illustrations are shown in Figure 2-1. 
2.2.3.1 Infiltrated Tissue Samples 
Tissue sections were also evaluated for the presence of ‘infiltrating’ cells within the 
NP.  Infiltrating cells were identified based on cell morphology – namely an 
elongated shape and an absence of surrounding lacunae as shown in Figure 2-2.        
2.2.4 Classification of Tissue Samples  
2.2.4.1 qPCR Studies 
For qPCR studies cDNA derived from tissue samples was classified into non-
degenerate, degenerate or infiltrated study groups based on histological evaluation 
of matched FFPE tissue.  Multiple sections from each paraffin block were subjected 
to histological evaluation.  Matched cDNA samples were classified ‘degenerate’ if 
any tissue section was graded greater than 4, and/or classified ‘infiltrated’ if 
infiltrating cells were observed on any tissue section. 
2.2.4.2 Immunohistochemistry Studies 
When FFPE tissue was sectioned for IHC studies adjacent serial sections were 
taken for histological assessment.  Classification into non-degenerate, degenerate 
and infiltrated study groups was based only on assessment of the IHC section and 
adjacent histology section.  Therefore sections are only classified ‘degenerate’ if  
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Histological Features;  Score 
Presence of Cell 
Clusters 
Cell clusters not present 
<25% Cells present in clusters 
25% - 75% cells present in clusters 
>75% cells present in clusters 
0 
1 
2 
3 
Presence and Extent of 
Fissures 
Fissures not present 
Fissures present within NP 
Fissures extending to junction of NP and AF 
Fissures extending into AF 
0 
1 
2 
3 
Loss of Demarcation 
between AF and NP 
Clear demarcation 
Limited loss of demarcation 
Substantial loss of demarcation 
Complete loss of demarcation 
0 
1 
2 
3 
Loss of Proteoglycan 
within NP 
No loss of haematoxyphilia 
Limited loss of haematoxyphilia 
Substantial loss of haematoxyphilia 
Complete loss of haematoxyphilia 
0 
1 
2 
3 
Table 2-1  Histological Grading System used to Score Degeneration in Tissue Sections 
All sections were evaluated independently by two researchers (KLEP and CLLM).  The grade 
assigned was the mean of the two observers’ scores. 
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Figure 2-1  Images Showing Characteristic Histological Features of Intervertebral Disc 
Degeneration as Assessed to Determine Grade of Degeneration in Nucleus Pulposus 
Tissue Sections 
Non-Degenerate, top to bottom:  In non-degenerate IVDs NP cells are found within distinct 
lacuna as single or doublet cells (HD89), fissures within the NP are not observed (HD52); 
there is clear demarcation between AF and NP (HD30) and consistent proteoglycan 
content throughout the NP (HD53).  Degenerate, top to bottom:  In degenerate IVDs 
clusters of cells within the same lacuna are commonly observed (HD3), fissures form 
within the NP that can extend into the AF (HD40), demarcation between the AF and NP is 
lost as the NP becomes more fibrous (HD41) and proteoglycan depletion becomes visible 
in the peri-cellular region (HD15).  Full details of samples (HD) are given in Appendix 1.   
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signs of degeneration are present on the tissue section evaluated for IHC staining.  
Similarly sections are only classified ‘infiltrated’ if the presence of infiltrating cells is 
observable on the tissue section evaluated for IHC staining. 
2.3 Immunohistochemistry 
2.3.1 The Principle of Immunohistochemistry 
Immunohistochemistry (IHC) is a technique used to localise target antigens in 
tissue sections.  A primary antibody specific to the antigen is applied to the tissue 
section and later a secondary antibody directed against a species-specific portion 
of the primary antibody is applied.  The secondary antibody is conjugated, usually 
to a fluorochrome, enzyme or biotin, and consequently the location of the bound 
primary antibody can be visualised, depending on the label, by either fluorescence 
emission or detection of the products of an enzymatic reaction. 
2.3.1.1 Streptavidin-Biotin-HRP DAB Method 
In these investigations a streptavidin-biotin-HRP DAB method of IHC was used.  
This method was chosen based on evaluation of tissue sections by light 
microscopy, facilitating a simple means of comparison between tissue sections 
stained for IHC targets and for histological evaluation. 
In this method, a biotin conjugated secondary antibody directed against the bound 
primary antibody is used to detect the target antigen (True, 2008).  Following 
secondary antibody binding the enzymatic ‘streptavidin-biotin’ complex forms on 
addition of ABC reagent (horseradish peroxidase (HRP) labelled streptavidin 
solution), since the streptavidin protein binds biotin molecules with strong affinity 
(Yamashita, 2007).  Visualisation is by enzymatic reaction, a dark brown precipitate 
forms at the site of secondary antibody binding following application of the 
chromagen, 3-3’-diaminobenzidine tetrahydrochloride (DAB), as a result of HRP 
activity (Yamashita, 2007).  It is therefore important during the experimental 
protocol to neutralise endogenous peroxidases within tissue sections to limit non-
specific visualisation.  Finally, counterstaining with haematoxylin allows for 
determination of cellular localisation of IHC-staining in relation to cell nuclei (True, 
2008). 
2.3.2 Preparation of Tissue Sections 
FFPE tissue samples were sectioned and mounted as described in section 2.2.1.  
All experimental procedures and incubations were performed at room temperature 
and all ‘wash steps’ were performed on a slow moving flatbed shaker for 5 minutes 
unless otherwise stated.   
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Sections in each batch were placed into slide racks and oriented so that primary 
antibody and isotype control sections from the same tissue block were adjacent.  
This minimised the effects of spatial separation particularly related to microwave 
irradiation and heat distribution during antigen retrieval.   
Sections were de-waxed and rehydrated as previously described in section 2.2.2.  
Endogenous peroxidases were blocked by immersion in 3% v/v hydrogen peroxide 
(Sigma) in methanol (Fisher Scientific) for 30 minutes.  Sections were washed once 
in deionised water then twice in Tris-Buffered Saline (TBS; 20mM Tris (Fisher 
Scientific), 150mM NaCl (Fisher Scientific), pH7.5).  Antigen retrieval was 
performed immediately. 
2.3.3 Antigen Retrieval 
2.3.3.1 Optimisation 
In order for successful antigen detection by immunohistochemical techniques 
antigens must be available for primary antibody binding.  In their native 
conformation proteins may be bound to intra-, inter- or extra-cellular proteins 
making them unavailable for primary antibody binding (Pileri et al., 1997).  In 
addition to this, the chemical fixation and processing of tissues to paraffin, 
performed here to preserve morphology, catalyses further formation of molecular 
cross links that may mask antigens (Shi et al., 2007).   
Antigen Retrieval (AR) is the process of ‘un-masking’ these antigens and is routine 
for FFPE tissues.  Many AR methods exist; most are based on either enzymatic 
digestion, treatment with protein denaturants or the application of heat (Kim et al., 
2004; Emoto et al., 2005; D'Amico et al., 2009).   
In these studies several methods of enzymatic digestion and heat treatment were 
investigated to achieve successful AR (Table 2-2).  Following these investigations a 
standard protocol of heat-induced AR by microwave irradiation in basic Tris-HCl 
buffer was adopted.         
2.3.3.2 Standard Protocol 
Sections were immersed in 400mL antigen retrieval buffer (0.05M Tris-HCl, pH 9.5) 
pre-heated to 60˚C and irradiated for 5 minutes in a Sanyo 800 watt microwave 
oven, set to deliver 40% of maximum power.  Sections were cooled for 60 seconds 
at room temperature then subjected to another period of irradiation as described 
above.  Sections were incubated in the hot buffer for 15 minutes at room 
temperature to allow cooling and re-folding of tissue antigens.   
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2.3.4 Antigen Detection 
Sections were washed three times in TBS then placed into humidified slide boxes.  
Non-specific protein interactions were blocked and secondary antibody host 
interactions neutralised, by application of 200µL per section 1% w/v Bovine Serum 
Albumin (BSA; Sigma) in 75% v/v TBS, 25% v/v normal serum (serum of secondary 
antibody host) and incubation for 90 minutes on a slow moving flatbed shaker.  
Blocking solution was tapped off slides prior to 200µL application of either primary 
antibody or isotype control at optimal concentrations pre-determined by titration 
(described in section 2.3.4.1).  Antibody dilutions were performed with 1% w/v BSA 
in TBS and sections were incubated overnight at 4˚C on a slow moving flatbed 
shaker, to probe for antigens. 
2.3.4.1 Titration of Primary Antibodies 
Prior to first experimental use, all primary antibodies were titrated to determine 
optimal experimental concentration.  Table 2-3 gives titration ranges investigated 
for each antibody alongside optimal experimental concentrations and antibody 
details.  Primary antibody titration is necessary to address the issue of sensitivity 
(false negativity) of IHC staining protocols (True, 2008).  During method 
optimisation the issue of specificity (false positivity) was also addressed by 
assessment of isotype and negative controls and secondary antibody binding as 
detailed in section 2.3.4.2.  
2.3.4.2 Isotype and Negative Controls, and Secondary Antibodies 
Isotype control sections were run alongside primary antibody sections at matched 
protein concentrations.  Primary antibody binding was only seen to be specific 
when no binding was observed on matched isotype control sections.   
Primary antibody solution was replaced by 1% BSA in TBS on negative control 
sections.  An absence of IHC staining on these sections confirmed that secondary 
antibody binding was specific to the presence of bound host species proteins 
(primary antibody or isotype control) (True, 2008).   
Both primary and secondary antibody solutions were replaced by 1% BSA in TBS 
on double-negative control sections.  An absence of IHC staining on these sections 
confirmed that positivity was not as a result of endogenous peroxidase or 
endogenous biotin activity (True, 2008).  Double-negative sections also provided 
reference for background stain levels as a result of non-specific absorption of 
conjugates to tissue sections.  Details of isotype controls and secondary antibodies 
used are given in Table 2-3. 
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2.3.5 Detection of Bound Primary Antibody 
Sections incubated with primary antibody and isotype control were washed 
separately to prevent any cross reaction, three times in TBS.  Detection of bound 
primary antibody or isotype control was by application of 200µL per section of 
relevant biotinylated secondary antibody (Table 2-3).  Antibody dilutions were 
performed with 1% w/v BSA in TBS and sections incubated for 30 minutes on a 
slow moving flatbed shaker.   
2.3.6 Visualisation of Bound Secondary Antibody 
Sections were washed three times in TBS.  2 – 3 drops of A.B.C. Elite Reagent 
(Vector Laboratories) was applied per section and incubated for 30 minutes on a 
slow moving flatbed shaker.  Following three washes in TBS, 200µL of 0.08% v/v 
hydrogen peroxide in 0.65mg/mL 3-3’-diaminobenzidine tetrahydrochloride (DAB) 
in TBS was applied per section and incubated for 20 minutes on a flatbed shaker.  
Sections were washed twice in deionised water for 1 minute then counter-stained 
by immersion in Mayer’s Haematoxylin (Leica) for 60 seconds and blued under 
running tap water for 5 minutes.     
2.3.7 Mounting of Sections 
Sections were dehydrated, cleared and mounted as described previously in section 
2.2.2.   
2.3.8 Microscopy and Image Capture 
Tissue sections were visualised using an Olympus BX60 research microscope.  
Images were captured using QCapture Pro v8.0 software (MediaCybernetics).   
2.3.9 Evaluation of Immunohistochemistry           
Evaluation of immuno-detection of target antigens was by counting immuno-
positive cells.  Within the NP 200 cells were counted and the number of immuno-
positive cells expressed as a percentage of this.  Cells were counted using x200 
magnification as shown in Figure 2-3.   
2.4 Cell culture 
2.4.1 Cell Culture Techniques 
The culture of mammalian cells in vitro is a fundamental technique that facilitates 
the investigation of cell behaviour under defined conditions.  Modification of these 
conditions, for example by addition of a specific cytokine or down-regulation of a 
specific gene, allows the effect of that variable to be examined and compared to 
normal physiological (basal) cell behaviour.     
2.4.1.1 Primary Nucleus Pulposus Cultures 
In these investigations primary NP cultures were utilised in an effort to gain the 
most physiologically relevant data.  Cultures were used for experimental purposes
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up to and including passage 2, however even under short-term primary culture NP 
cells dedifferentiate towards a fibroblastic phenotype.  Three-dimensional (3D) 
culture systems provide a means of maintaining the morphological and biochemical 
properties of primary NP cultures and even for restoring these features following 
dedifferentiation during monolayer expansion.  Here, the encapsulation of NP cells 
in alginate beads was investigated alongside monolayer culture, in an effort to 
develop a suitable in vitro model in which to investigate NP cell behaviour.    
2.4.1.2 Alginate Bead Culture 
Alginate bead culture is a 3D system originally developed as a model for studying 
chondrocyte behaviour (Hauselmann et al., 1992).  The system is based on the 
material properties of alginic acid from brown seaweed, which forms a viscous 
liquid in solution and can be polymerised in the presence of divalent cations.  
These material properties facilitate the incorporation of isolated cells prior to 
polymerisation, and the semi-solid support formed post polymerisation promotes 
the correct 3D orientation of cells.  This enhances maintenance of the parent 
phenotype.  Further, alginate beads can be easily dissolved by addition of chelating 
agents providing a means of recovering encapsulated live cells for analysis.   
The de-differentiation of articular chondrocytes in monolayer culture and their 
subsequent re-differentiation following encapsulation and culture within alginate 
beads has been well characterised (Bonaventure et al., 1994; Lemare et al., 1998).  
Alterations in the expression of phenotype markers are observed as early as 
passage 1 in monolayer cultures.  Decreased expression of type II collagen and a 
concordant increase in type I indicates a shift towards a fibroblastic phenotype 
(Bonaventure et al., 1994; Lemare et al., 1998).  Following expansion in monolayer 
to passage 2, cultures seeded to alginate beads show a further phenotype shift.  
Increased type II collagen expression and a concordant decrease in type I indicates 
re-differentiation back towards the chondrocyte phenotype (Bonaventure et al., 
1994; Lemare et al., 1998).  Morphological and biochemical characteristics 14 days 
post alginate encapsulation closely resemble those of the parent phenotype 
(Hauselmann et al., 1992; Bonaventure et al., 1994; Lemare et al., 1998).  The 
development of this culture system has meant that expansion in monolayer prior to 
re-differentiation in alginate can be used to generate sufficient cell numbers to 
permit extensive in vitro chondrocyte studies.   
NP cells are often referred to as 'chondrocyte-like' since morphological and 
physiological similarities exist.  As such the alginate bead culture system has been 
successfully applied to NP primary culture and similar phenotypic maintenance and 
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re-differentiation patterns to those seen in chondrocytes are observed (Baer et al., 
2001; Wang et al., 2001; Le Maitre et al., 2005).     
2.4.2 Nucleus Pulposus Cell Culture 
Isolated cells were seeded to 75cm
2
 filter-cap cell culture flasks (Nunc) containing 
Complete Media (SFM plus 10% v/v Heat Inactivated Foetal Bovine Serum 
(Gibco)).  Following passage 1, supplementation of complete media with penicillin, 
streptomycin and amphotericin B was decreased to 100U/mL, 100ug/mL and 
250ng/mL respectively.  Cultures were maintained at all times at 37°C and 5% CO2 
in a humidified environment.  Cell culture media were changed three times weekly 
unless specified otherwise.   
2.4.2.1 Sub-Culture 
Monolayer cultures were maintained up to 80% confluence before passaging:  
Culture media was removed and 1x Phosphate Buffered Saline (PBS; Gibco) was 
used to wash the cells removing all traces of serum.  Cultures were incubated with 
3mL 0.05% Trypsin-EDTA (Gibco) per 75cm
2
 flask at 37°C until detachment of cells 
was achieved.  The Trypsin-EDTA was inactivated by the addition of an equal 
volume of Complete Media.  The resulting cell suspension was seeded at a 1:3 split 
ratio.  Following expansion in monolayer to P2, NP cells were subjected to 48 hour 
cytokine/chemokine treatment in monolayer and/or seeded to alginate culture as 
described in sections 2.4.3 and 2.4.5. 
2.4.3 IL-1β, CCL2 and CXCL8 Treatment of Monolayer Cultures 
NP cells were cultured in monolayer up to 80% confluence at passage 2.  Following 
trypsinisation as described in section 2.4.2.1 and centrifugation at 400g for 10 
minutes, the cell pellet was re-suspended in Complete Media and cells counted as 
described in section 2.1.5.  Cells were seeded to 6 well plates at a density of 1 x 
10
5
 cells/well.  The 6 well plates were incubated overnight at 37°C to allow 
adherence of cells.  Complete media was removed and replaced with 1mL per well 
complete media supplemented with 0, 1, 10 or 100 ng/mL of treatment.  Each 
treatment was performed in triplicate and cultures were incubated for 48 hours prior 
to total RNA extraction.  Recombinant human cytokines and chemokines were 
supplied by Peprotech.      
2.4.4 Total RNA Extraction from Monolayer Cultures 
Complete media was removed and the wells washed in PBS.  1mL trizol was added 
per well and the plates incubated at room temperature for 5 minutes.  The trizol cell 
suspension was transferred to 1.5mL tubes and total RNA was isolated as 
previously described in section 2.1.5, up to centrifugation to recover RNA 
precipitate following isopropanol incubation at -80°C.  At this stage monolayer 
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extractions were not subjected to DNase treatment and Qiagen Min-Elute Clean-
up, this was replaced by washing with ethanol; RNA pellets were re-suspended in 
75% ethanol (Sigma) and re-centrifuged at 7500g for 15 minutes at 4°C.  
Supernatant was removed and remaining RNA pellet air dried on ice for 
approximately 20 minutes.  RNA pellets were then re-suspended in 14µL sterile 
deionised water and used immediately for cDNA synthesis as described in section 
2.5.2.   
2.4.5 Seeding Nucleus Pulposus Cells to Alginate Culture 
Monolayer cultures were trypsinised as described in section 2.4.2.1 and centrifuged 
at 400g for 10 minutes, following which cells were re-suspended in complete media 
and counted as described in section 2.1.5.  Cells were re-centrifuged at 400g for 10 
minutes, supernatant was discarded and the remaining pellet was re-suspended in 
sterile 1.2% w/v low viscosity alginic acid (Sigma) in 0.15M sodium chloride (Fisher 
Scientific) at a density of 2.0 x 10
6
 cells/mL.  Alginate beads were formed by 
‘dropping’ the alginate cell suspension through a 19 gauge needle into 12-well 
plates containing 2.5mL sterile 200mM calcium chloride (Fisher Scientific) per well.  
Plates were incubated at 37°C for 15 minutes to allow polymerisation of beads then 
each well was washed twice in 2.5mL of 0.15M sodium chloride once in 2.5mL of 
complete media.  Alginate bead cultures were maintained for 14 days in complete 
media prior to cytokine/chemokine treatment.  Cell culture media was changed 
twice weekly. 
2.4.6 IL-1β, IL-16, CCL3 and CCL7 Treatment of Alginate Cultures 
2 Alginate beads were placed into 96-well plates and 200µL complete media 
supplemented with 0, 1, 10 or 100ng/mL of treatment was added per well.  IL-1β 
treatments were performed at additional treatment concentrations of 1, 10 and 100 
pg/mL.  Each treatment was performed in triplicate and the cultures were incubated 
for 48 hours prior to total RNA extraction.   
2.4.7 Total RNA Extraction from Alginate Cultures 
Culture supernatant from alginate beads subjected to cytokine/chemokine 
treatment was removed into 1.5mL sterile tubes and frozen at -80°C for use in 
further Luminex studies as described in section 2.6.  Total RNA Extraction from 
Alginate Cultures was by Trizol or RNeasy method:   
2.4.7.1 Optimisation of Trizol RNA Extraction Protocol 
The downstream applications of cDNA synthesis and real-time polymerase chain 
reaction (PCR) are techniques based on enzyme activity.  As such they are 
sensitive to reaction conditions and RNA samples generated must be of sufficient 
quantity and quality to support these applications. 
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In simple extractions from monolayer or suspension cultures, care must be taken to 
minimise carry-over of the commonly used phenolic reagent, trizol, as phenol 
contamination can inhibit PCR.  Extractions from alginate bead cultures are further 
complicated by the additional procedures required to recover cells and subsequent 
exposure to potential contamination from EDTA contained within the alginate 
dissolving buffer.  In initial investigations, contaminants in RNA samples extracted 
from alginate cultures were seen to severely inhibit PCR.    
The effect of culture size and cell density on carry-over contamination was 
assessed:  Trizol RNA extractions were performed on 1, 2, 4, 6, 8, 10 and 12 
alginate beads seeded at 1, 2 and 4 x 10
6
 cells/mL, with and without RNA 
purification by Qiagen Min-Elute Clean-Up Kit.  Real-time PCR for GAPDH was 
performed on cDNA generated from all RNA samples.  Amplification was not 
observed in any PCR reaction without prior RNA purification.  Purified samples 
from 1, 2 and 4 beads generated amplification plots however, increasing bead 
number delayed amplification (Figure 2-4), indicating increased inhibition.  The 
earliest  values were seen in samples from 1 bead seeded at 2 x 106 cells/mL. 
RNA samples extracted from 1 bead were subjected to nanodrop 
spectrophotometer analysis.  Absorbance was measured at wavelengths of 260 
and 280 nm.  The ratio of these absorbances can be used as a measure of RNA 
purity, and samples seeded at 2 x 10
6
 cells/mL were seen to have greater purity 
than those seeded at 1 or 4 x 10
6 
cells/mL.  This likely explains the lower   values 
generated by these samples.  RNA integrity was also confirmed by 1% agarose gel 
electrophoresis and ethidium bromide staining in these samples (not shown).  1 
bead seeded from 2 x 10
6
 cells/mL alginate suspension was selected as optimal for 
experimental use.   
2.4.7.2 Optimisation of RNeasy RNA Extraction Protocol 
1mL of 2 x 10
6
 cells/mL alginate suspension was seen to generate 50 polymerised 
beads, equating to RNA from 0.4 x 10
5
 cells per extraction.  Certain genes were 
difficult to detect in these samples, possibly due to low copy number.  A further 
RNA extraction protocol was developed; using Qiagen RNeasy Mini Kit – instead of 
trizol, to prevent phenol contamination, and a shortened incubation in alginate 
dissolving buffer during cell recovery - to limit EDTA contamination.  By this 
method, it was possible to extract RNA from 2 beads (0.8 x 10
5
 cells) and low copy 
number genes were detectable in these samples.   
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2.4.7.3 Trizol RNA Extraction Standard Protocol 
1 alginate bead was removed from each well of the 96-well plates into RNase free 
1.5mL tubes.  500µL of alginate dissolving buffer (55mM sodium citrate (Sigma), 
30mM EDTA (Fisher Scientific), 0.15M NaCl, pH 6) was added per tube and 
samples incubated, rotating at 37°C for 20 minutes to dissolve alginate.  Samples 
were centrifuged at 600g for 15 minutes at 4°C to recover cells.  Supernatant was 
removed and the remaining pellet re-suspended in 500µL 0.06% w/v type I 
collagenase (Sigma) in SFM, samples were incubated rotating at 37°C for 20 
minutes to digest ECM.  Samples were centrifuged at 600g for 15 minutes at 4°C.  
Supernatant was removed and the remaining pellet was re-suspended in 1mL 
Trizol and incubated at room temperature for 5 minutes.   Total RNA was isolated 
as described previously in section 2.1.5 however, RNA extractions from alginate 
cultures were not subjected to DNase treatment therefore recovered RNA pellets 
were re-suspended in 100µL not 87.5µL, sterile deionised water and used 
immediately in Qiagen Min-Elute Clean-up to purify and recover RNA samples.  
RNA was eluted in 14µL sterile deionised water and used immediately for cDNA 
synthesis as described in section 2.5.2.        
2.4.7.4 RNeasy RNA Extraction Standard Protocol 
2 Alginate beads were removed from each well of the 96-well plates into RNase 
free 1.5mL tubes.  500µL of alginate dissolving buffer was added per tube and 
samples incubated rotating at 37°C for 10 minutes to dissolve alginate.  Samples 
were centrifuged at 600g for 10 minutes at 4°C to recover cells.  Supernatant was 
discarded and the remaining pellet was re-suspended in 500µL 0.06% w/v type I 
collagenase (Sigma) in SFM, and incubated rotating at 37°C for 10 minutes to 
digest ECM.  Samples were centrifuged at 600g for 10 minutes at 4°C.  
Supernatant was discarded and the remaining cell pellet was used immediately for 
RNA extraction by Qiagen RNeasy Mini Kit as per manufacturer's protocol.  RNA 
samples were eluted in 30µL RNase free water and used immediately in cDNA 
synthesis as described in section 2.5.2.    
2.5 Quantitative Polymerase Chain Reaction 
2.5.1 The Principle of qPCR 
Quantitative polymerase chain reaction (qPCR) is widely used to detect and 
quantify gene expression.  It involves reverse transcription (RT) of mRNA into 
cDNA followed by PCR to amplify a specific target cDNA molecule, which is 
quantified in real-time by the accumulation of fluorescence after each amplification 
cycle (Orlando et al., 1998).   
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Two distinct types of detection chemistry are used in qPCR, namely probe or non-
probe.  Probe based detection is amplicon specific, it utilises fluorescent probes 
that only generate a signal following replication of their complementary target, as 
this amplification removes an associated quencher molecule (Figure 2-5).  Non-
probe detection methods rely on fluorescent intercalating agents that emit minimal 
fluorescence in reaction solution but increase emission following intercalation with 
synthesised double stranded DNA as polymerisation proceeds.  Verification of PCR 
products is required in non-probe detection methods and so a disassociation curve 
of the amplicon is generated following the final PCR cycle.  Fluorescence is plotted 
as a function of temperature, identical amplicons are seen to dissociate at the same 
temperature (Orlando et al., 1998), thus confirming that only primer specific 
amplification has occurred. 
There are two established methods of PCR product quantification, relative and 
absolute.  Relative quantification is used to determine mRNA quantity relative to 
that of internal reference genes in separate samples; or changes in mRNA 
expression across multiple samples under varying experimental conditions, relative 
to both internal reference gene expression and basal expression of the target gene.  
Several mathematical algorithms have been developed to produce the corrected 
relative expression ratio; these include relative quantification without primer 
amplification efficiency correction – the comparative quantification method (2∆ 
/2∆∆ method) (Livak & Schmittgen, 2001), and relative quantification with primer 
amplification efficiency correction – the Pffafl method (Pfaffl, 2001). 
In order for the former model to be valid, the primer amplification efficiencies of the 
target and internal reference genes must be approximately equal (within 10%), 
which is not always the case.  Differences in primer amplification efficiencies are 
taken into consideration in the latter model.  It is generally considered that relative 
quantification is adequate for investigating physiological changes in gene 
expression levels, though care must be taken to select stably expressed internal 
reference genes that are not affected by any experimental variation under 
investigation (Dheda et al., 2004; Radonic et al., 2004).   
Absolute quantification can also be used to determine mRNA quantity in separate 
samples for comparative analysis, or changes in target mRNA quantity under 
varying experimental conditions.  Absolute quantification uses a standard curve of 
CT values, generated from a dilution series of an external standard with known 
initial target copy number.  Data generated is in the form of absolute starting 
quantity of target gene mRNA within an unknown sample, however reliability in this  
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method relies on the accuracy of standards used (Whelan et al., 2003; Larionov et 
al., 2005).   
2.5.2 cDNA Synthesis 
RNA samples were converted to cDNA using Moloney Murine Leukaemia Virus 
reverse transcriptase (Bioline):  RNA samples were incubated at 60°C for 5 minutes 
to denature RNA.  RT mastermix was added immediately, 36µL per 14µL RNA 
sample or 20µL per 30µL RNA sample, made up as shown in Table 2-4.  Samples 
were incubated at 42°C for 1 hour to permit cDNA synthesis, then 10 minutes at 
80°C to inactivate RT enzyme.  cDNA samples were diluted 1:10 by addition of 
450µL sterile deionised water and stored at -20°C for use in qPCR. 
 
For 1 Reaction: 
14µL RNA 
Sample 
(µL) 
30µL RNA 
Sample 
(µL) 
Deoxynucleotide triphosphates (dNTPs) 40mM (Bioline) 1.5 1.5 
Random Hexamers (AB) 1.0 1.0 
Bioscript 5x RT Buffer (Bioline) 5.0 5.0 
Bioscript RT Enzyme (Bioline) 0.5 0.5 
Sterile distilled H2O 28.0 12.0 
 36.0 20.0 
Table 2-4  Reverse Transcription Mastermix used in cDNA Synthesis Reactions 
 
2.5.3 Taqman
 
cDNA Low Density Array 
Prior systematic review of literature identified 25 cytokines and 18 chemokines that 
are implicated in the pathology of connective tissue degeneration (Chapter 1, 
section 01.4, summarised in Table 1-4).  These targets were selected for inclusion, 
and some related family members that have not yet been investigated in connective 
tissues were also included, alongside associated receptors, accessory proteins and 
activating enzymes for each cytokine or chemokine, on a Taqman cDNA LDA that 
was custom manufactured on FAST 96-well plate setup, by Applied Biosystems.  
Five stably expressed internal reference genes, from a previous study into 
expression of commonly used reference genes in human NP cells (Le Maitre, 
2003), were also selected for LDA inclusion.  LDA design is shown in Figure 2-6.  
Specific, probe based Taqman qPCR detection was used on cDNA samples from 
DE NP cells.  Separate reaction mastermixes were prepared for each cDNA 
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sample investigated, as shown in Table 2-5, and 20µL per well loaded into LDA 
plates.  Each cDNA sample was run in duplicate.  Plates were sealed with adhesive 
film and kept at 4°C until being run on an Applied Biosystems, StepOnePlus Real-
Time PCR machine on FAST programme incorporating 50 cycles of denaturation at 
95°C for 1 second followed by annealing and extension at 60°C for 20 seconds.      
 
For 1 Reaction: (µL) 
cDNA 1.0 
Taqman FAST Universal Mastermix (Applied Biosystems) 10.0 
Sterile deionised water 9.0 
 
20.0 
Table 2-5  qPCR Reaction Mastermix used in Low Density Array Analysis 
2.5.4 Analysis of Low Density Array Data 
Quantification of gene expression was by comparative quantification method 
(2∆).  This method was applicable since all primer sequences were pre-validated 
by manufactures to confirm equality of amplification efficiencies.  In order to 
generate reliable comparable data, particular attention was given to baseline and 
threshold settings (Figure 2-7) and to the selection of internal reference genes (see 
section 2.5.4.1).  Threshold settings for all 96 LDA targets are given in Appendix 4.   
Briefly, analysis was performed by: calculation of the arithmetical mean  values 
of internal reference and the target gene sample duplicates, and calculation of the 
arithmetical mean of the selected internal reference genes to generate the 'mean 
reference' value for each sample.  ∆ values were then calculated by the 
equation: 
∆   	

   	  
Target gene expression, relative to internal reference gene expression, was then 
calculated using the equation: 

     2∆ 
Relative gene expression values were multiplied by 10
6
 to give values on an 
acceptable scale when represented graphically.   
2.5.4.1 Internal Reference Gene Selection  
Selection of stably expressed internal reference genes is a pre-requisite for the 
accurate normalisation of real-time qPCR data (Vandesompele et al., 2002).  The 
geNorm applet for Microsoft Excel can be used to determine internal reference
 
  
Figure 2-7  
used to Set
Data generated in real
fluorescence emission is plotted as a function of time shown as thermo
Following amplification, and prior to data collection, basel
investigated 
normalised for the presence of inherent reaction solution background emission.  
Thresholds were set within the exponential phase of amplif
investigations.  This factor in particular provides method advantage over standard PCR 
since data collection in the exponential phase (prior to reaction saturation) makes this 
method fully quantifiable.         
Shown here are
LDA analysis of 
of 13 for 18S gene analysis 
threshold setting of 0.75 
indicates baseline setting of 33, and threshold is shown at 0.50 for CCL7 gene analysis.          
 
Low Density 
 Baselines 
at two cycles
 the amplification plots of 5 target and 2 internal reference genes following 
cDNA generated from DE NP cells
Array Amplification Plot Annotated to Illustrate the Methods 
and Thresho
-time PCR is expressed as an amplification plot where measured 
 prior to visible amplification thus
 
- 2 cycles prior to visible amplification at cycle 15, and 
- within the exponential phase of the plot.  The dark blue arrow 
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gene stability in a given cDNA sample panel.  The geNorm applet calculates the 
gene expression stability measure (M) for each reference gene as the average pair 
wise variation (V) for that gene with all other tested reference genes.  This measure 
relies on the principle that the expression ratio of ideal internal reference genes is 
identical in all samples, regardless of experimental conditions (Vandesompele et 
al., 2002; Huggett et al., 2005). 
In an ideal experimental system the gene expression stability measure (M) should 
be less than 1.5 (Vandesompele et al., 2002).  Use of the geNorm applet allows 
ranking of test reference genes according to their stability.  Exclusion of the least 
stable, and subsequent re-calculation can be performed stepwise to reach an M 
value of <1.5 in the experimental system investigated.   
This analysis was performed on internal reference gene expression data, 
generated in the 12 real-time qPCR LDA experiments.  Briefly,  values were 
measured for each gene at the same threshold in all samples.  The raw  values 
were transformed by first subtracting the highest  value from all others – 
generating the ‘change in’ ∆ value, and then applying the equation2∆.  
Transformed data was subjected to geNorm analysis.  The gene expression 
stability measure of the 5 combined internal reference genes included in the LDA 
was 1.08, and so LDA data was normalised to all 5 internal reference genes.  
2.5.5 qPCR on cDNA from Directly Extracted Nucleus Pulposus Cells 
Specific probe based Taqman qPCR detection was used on cDNA samples from 
DE NP cells.  Two internal reference genes were selected for use in all experiments 
to normalise for variations in total RNA in each sample (see section 2.5.7.1).   
2µL sample cDNA was loaded in duplicate into 96-well FAST PCR plates (Applied 
Biosystems).  8µL per well Real-Time PCR mastermix, prepared as shown in Table 
2-6, was added.  Plates were sealed with adhesive film and kept at 4°C until being 
run on a StepOnePlus Real-Time PCR machine as described previously in section 
2.5.3. 
 
For 1 Reaction: µL 
Taqman Gene Expression Assay 0.5 
2x Taqman FAST Mastermix 5.0 
Sterile distilled H2O 2.5 
 8.0 
Table 2-6  qPCR Reaction Mastermix used in Gene Expression Analysis 
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2.5.6 Analysis of qPCR data 
Real-time PCR data was analysed as previously described in section 2.5.4.  
Thresholds used in original LDA analysis were maintained across all samples 
investigated.   
2.5.6.1 Internal Reference Gene Selection 
The geNorm applet can also be used to determine the minimum number of 
reference genes required to calculate a reliable normalisation factor.  The use of a 
single reference gene is discouraged since no simple means to confirm that the 
gene is unaffected by experimental variation exists (Vandesompele et al., 2002).  
Reference gene instability can be detected in multiple reference gene experimental 
systems, as alteration in expression of one reference gene would affect its 
expression ratio compared to the others used.  For this reason it’s important to 
select multiple internal reference genes (Vandesompele et al., 2002) and to ensure 
that genes are selected from different functional classes (Radonic et al., 2004).  
This minimises the chances that the genes will be co-regulated and so equally 
affected by any experimental variation.     
Prior geNorm analysis (section 2.5.4.1), indicated that whilst the 5 internal 
reference genes analysed by LDA provided an accurate normalisation factor (M = 
1.08), HPRT1 and ACTB were the least stable and 18S, GAPDH and PGK the 
most.  The pair wise variation (V) calculated in geNorm is a measure of the 
increased accuracy in normalisation factor generation that can be gained from 
including the next most stably expressed reference gene, according to M value 
rank.  The accepted V cut-off value is 0.15, below which the inclusion of an 
additional reference gene will have no significant effect but above which inclusion is 
required for accurate normalisation (Vandesompele et al., 2002).  Pair wise 
variation in the 3 most stably expressed genes (V2/3) was 0.132 indicating little 
increase in normalisation accuracy could be gained from using 3 internal reference 
genes rather than 2.  Therefore, eukaryotic 18S rRNA (18S) and glyceraldehyde-3-
phosphate dehydrogensase (GAPDH) were selected as internal reference genes 
for qPCR data analysis, based on excellent gene expression stability (M = 0.402) 
and no requirement for an additional third reference gene (V = 0.132).       
2.5.7 qPCR on cDNA from Monolayer and Alginate Cultures 
Specific probe based Taqman qPCR detection was used alongside relative 
quantification by comparative quantification method (2∆∆), as described 
previously (section 2.5.1).  Taqman gene expression assays were selected or 
designed so as to span exon-exon boundaries ensuring amplification of cDNA from 
spliced mRNA transcripts only (Table 2-7).  Amplification efficiencies of internal 
1
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reference gene expression assays and target gene expression assays were 
confirmed to be equivalent prior to experimental use (section 2.5.8.1).  qPCR was 
performed as described previously in section 2.5.5.  Target gene expression was 
investigated in monolayer and alginate cultures following cytokine or chemokine 
treatment, for specified target genes as shown in Table 2-8. 
2.5.7.1 Reaction Amplification Efficiency 
Prior to experimental use, the amplification efficiency of each gene expression 
assay was confirmed to be within 10% of internal reference gene amplification 
efficiency by template titration.  Amplification efficiencies were confirmed using 
template cDNA from both monolayer and alginate culture derived samples.  
Thresholds used for template titration were maintained across all experimental 
samples investigated (Table 2-7).   
Briefly, template cDNA was prepared so that an undiluted (neat) sample was run 
alongside 1:2, 1:4, 1:8, 1:16 and 1:32 dilutions.  Amplification plot data was 
analysed by plotting the experimental  values for each dilution against Log2 of 
cDNA concentration (expressed as a percentage of the neat).  The amplification 
efficiency was calculated as the slope of the best linear fit of the expected increase 
in  versus the  value obtained.  A slope of -1 corresponds to one additional 
cycle required to reach the threshold after halving template copy number, and 
would indicate 100% amplification efficiency (Martin et al., 2001).   
2.5.8 Analysis of qPCR Data 
Quantification of gene expression was by comparative quantification method 
(2∆∆).  This method was applicable since all primer sequences were pre-
validated by template titration to confirm equality of amplification efficiencies.  
Particular attention was given to baseline and threshold settings (Figure 2-7) and to 
confirming the stability of internal reference gene expression under treatment 
conditions (see section 2.5.9.1).   
Briefly, ∆ values were obtained as described previously (section 2.5.4).  The 
arithmetical mean ∆ and standard error of the mean (∆ SE) for each triplicate 
data set (untreated control and treatment groups) was calculated.  ∆∆ values 
were calculated using the equation: 
∆∆   ∆	


     ∆ 	

 
 
Target gene expression, relative to internal reference gene and basal expression, 
was calculated using the equation: 
1
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Relative gene expression was represented graphically and error bars representing 
standard error of ∆ values for each triplicate data set were calculated using the 
equations: 
 
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2.5.8.1 Internal Reference Gene Stability 
Internal reference gene stability was confirmed under treatment conditions using 
the geNorm applet, as described previously (section 2.5.4.1), to calculate the gene 
expression stability measure (M; Table 2-9).   
 
Treatment Average Stability Expression Measure (M) 
IL-1β 
HD2; M = 0.406 
HD4; M = 1.454 
HD6; M = 0.531 
IL-16 
HD8; M = 0.685 
HD23; M = 0.830 
HD56; M = 1.364 
CCL2 
HD2; M = 1.031 
HD4; M = 0.682 
HD6; M = 0.418 
CCL3 
HD8; M = 0.609 
HD23; M = 0.169 
HD56; M = 1.416 
CCL7 
HD8; M = 0.675 
HD23; M = 0.709 
HD56; M = 1.499 
CXCL8 
HD2; M = 0.214 
HD4; M = 1.372 
HD6; M = 0.481 
Table 2-9  Confirmation of Internal Reference Gene Stability in Cultured Nucleus 
Pulposus Cells Subjected to 48 Hour Cytokine or Chemokine Stimulation 
The geNorm algorithm was used to confirm internal reference gene (GAPDH and 18S) 
stability under treatment conditions.  In ideal experimental systems, M = <1.5, providing 
an accurate normalisation factor for comparative analysis of qPCR data. 
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2.6 Luminex Multiplex Bead Immunoassay 
2.6.1 The Principle of Luminex Technology 
Luminex technology is based on the use of 5.6µm polystyrene microspheres 
(beads) each internally dyed with a unique combination of red and infrared dyes.  
The combination of the different intensities of the two dyes allows for the 
identification of each bead by its unique spectral properties when excited by a laser 
beam (Carson & Vignali, 1999).    
The bead surface can be coated with a number of different targets (e.g. antibodies, 
antigens, oligonucleotide probes).  Coated beads can then be used to interrogate 
samples for the presence or absence of specific analytes.  The Luminex platform 
uses the principles of flow cytometry to stream beads in single file past a pair of 
lasers (Carson & Vignali, 1999).  A red laser is used to excite and therefore identify 
the specific bead, and a green laser is used to excite and therefore identify any 
reporter dyes captured on the bead during the assay.  As both the bead 
identification and reporter dye readings are made on each individual bead, a 
multiplex system can be developed with up to 100 beads (Carson & Vignali, 1999).    
2.6.1.1 Immunoassays  
Multiplex bead immunoassays are solid phase protein immunoassays (Vignali, 
2000).  Beads of defined spectral properties are conjugated to capture antibodies 
directed against the specific analyte/s of interest.  These are used to interrogate 
analyte standards of known concentration alongside test samples.  Later analyte 
specific biotinylated detector antibodies are added and these bind to the 
appropriate analyte that is immobilised on the bead surface.  Streptavidin 
conjugated to the fluorescent protein, R-Phycoerythrin, is added and binds to the 
biotinylated detector antibodies, forming a four member solid phase sandwich 
(Vignali, 2000).  Beads are analysed on the Luminex platform by monitoring the 
spectral properties of the beads and the amount of associated R-Phycoerythrin 
fluorescence (Figure 2-8).  A standard curve is generated based on bead readings 
from standards of known analyte concentration.  From this, the concentration of 
protein in test samples can be determined.     
2.6.2 Multiplex Bead Immunoassays 
Commercially available Luminex Multiplex Bead Immunoassays (Invitrogen) were 
performed on supernatant samples recovered from cytokine/chemokine treated 
alginate cultures (section 2.4.7) as per manufacturers’ protocol.  Culture 
supernatant samples were brought to room temperature prior to analysis and assay 
standards were reconstituted in complete media.  Standards and samples were 
analysed in duplicate.  Immunoassay microplates were analysed on Luminex
  
 
Figure 2-8  
and Analyse 
Assay procedure; Luminex 
microplates.  Each well contains a different analyte standard or test sample and is 
interrogated by incubation with beads conjugated to analyte
(A-C Beads).  After washi
detector antibodies that bind the appropriate immobilised analyte.  Following washing, 
the beads are incubated with Streptavidin conjugated to fluorescent R
(Streptavidin RPE) that bi
complexes on the beads.
Analyte detection; Assay microplates are analysed on Luminex 100 instrument.  Beads 
from each well are streamed in single file past red and green lasers.  The red laser
bead internal red and infrared dyes allowing for bead identification.  The green laser 
excites bound R
excitation allowing for the identification of individual beads and quantifi
analyte.     
 
Schematic Representation of the Principle of 
Multiplex Bead Immunoassay
-Phycoerythrin.  Detectors monitor emissions from red and green laser 
multiplex bead immunoassays are performed in filter
ng, beads are incubated with analyte
nds the biotinylated detector antibodies associated with immune 
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xMap Technology 100 machine with Luminex 100 Integrated System v2.3 software 
(Luminex Corporation).  Luminex analysis was performed at the Transplant 
Immunology Department, St James’s University Hospital, Leeds, UK.   
2.6.2.1 Conditioned Media Samples 
Conditioned media from HD9, HD23, HD54, HD85 and HD89 alginate cultures 
subjected to 48 hour treatment with IL-1β was selected for used in this study (Table 
2-8).   
2.6.2.2 Cytokine and Chemokine Targets 
The commercially available human cytokine 10-plex and human chemokine 10-plex 
bead immunoassays were used in this study to facilitate simultaneous 
quantification of 20 targets (Table 2-10) in each conditioned media sample.  Target 
cytokines and chemokines for these kits are shown in Table 2-10. 
 
Cytokine 10-plex Chemokine 10-plex 
Target 
Sensitivity 
(pg/mL) 
Correlation 
Coefficient 
Target 
Sensitivity 
(pg/mL) 
Correlation 
Coefficient 
IL-1β <15 0.97 CCL2 <1 0.97 
IL-2 <10 0.94 CCL3 <5 0.99 
IL-4 <5 0.99 CCL4 <2 0.99 
IL-5 <3 0.99 CCL5 <2 0.99 
IL-6 <3 0.97 CCL7 <7 0.96 
CXCL8 <10 0.97 CCL8 <2 0.98 
IL-10 <5 0.93 CCL11 <1 0.95 
CSF2 <15 0.99 CXCL1 <4 0.96 
TNF-α <10 0.92 CXCL9 <5 0.98 
IFN-γ <5 0.98 CXCL10 <1 0.97 
Table 2-10  Details of Multiplex Bead Immunoassays used in Luminex Analysis of 
Conditioned Media from Alginate Nucleus Pulposus Cultures With and Without 
Interleukin-1β Stimulation 
   
2.6.3 Analysis of Luminex Data 
Luminex Integrated System produces a standard curve for each analyte 
investigated based on analysis of assay standards on each microplate.  Sample 
data is expressed as a concentration reading in pg/mL for each analyte in each 
sample.  Data was transferred to an Excel file where sample duplicate readings 
were averaged and then combined for each treatment group.  
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2.7 Statistical Analysis 
Statistical analysis was applied to experimentally generated data following 
consultation with Dr Karen Kilner, Statistician, Sheffield Hallam University.  In all 
cases, results were considered statistically significant if P values of less than 0.05 
were recorded upon statistical analysis of experimentally generated data sets.   
2.7.1 Statistical Analysis of Immunohistochemistry Data 
2.7.1.1 Assessment of Percentage Immunopositivity in NP Tissue Sections 
from Non-degenerate, Degenerate and Infiltrated Study Groups 
Percentage immunopositivity values were combined for non-degenerate, 
degenerate and infiltrated study groups.  Data sets were examined by Shapiro-
Wilkes test, to assess the probability that samples included in this study were 
derived from a population with a normal distribution.  The results of Shapiro-Wilkes 
testing indicated that samples used were not derived from a population with a 
normal distribution (P<0.05).  Accordingly, data were assessed by Kruskal-Wallis 
test, to identify significant differences in percentage immunopositivity across study 
groups.  Where significant differences were indicated across study groups 
(P<0.05), Conover-Inman post hoc testing was applied to identify data sets that 
were significantly different, and to generate ‘P’ values specific to that difference.  
Analysed data was represented graphically, by box and whisker plot of median 
immunopositivity and range values, using Prism v5 (GraphPad Software Inc.).  
Shapiro-Wilkes and Kruskal-Wallis statistical analysis was performed using 
StatsDirect software (StatsDirect Ltd.).   
2.7.1.2 Assessment  of  Correlation  between  Percentage  Immunopositivity  
and  Histologically  Determined  Grade  of  Degeneration  in  Nucleus  
Pulposus  Tissue  Sections 
Percentage immunopositivity values and histologically determined grades of 
degeneration were examined by Linear Regression analysis.  Data was 
represented graphically by XY scatter plot with line of best fit.  Graphical 
representations and Linear Regression Analysis was performed using Prism v5 
(GraphPad Software Inc.). 
2.7.2 Statistical Analysis of qPCR Low Density Array Data 
2.7.2.1 Assessment of Relative Gene Expression Levels in Mildly Degenerate 
and Moderately Degenerate Study Groups 
Relative gene expression values (2∆) were combined for mildly degenerate and 
moderately degenerate study groups.  Data sets were examined by Shapiro-Wilkes 
test, to assess the probability that samples included in this study were derived from 
a population with a normal distribution.  The results of Shapiro-Wilkes testing 
indicated that samples used were not derived from a population with a normal 
distribution (P<0.05).  Accordingly, data were assessed by Mann Whitney test, to 
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identify significant differences in relative gene expression levels between study 
groups.  Data was represented graphically by scatter plot and statistical analysis 
performed using Prism v5 (GraphPad Software Inc.). 
2.7.2.2 Assessment of Frequency of Gene Expression Detection in Mildly 
Degenerate and Moderately Degenerate Study Groups    
The proportion of samples where gene expression was detected was calculated for 
mildly degenerate and moderately degenerate study groups.  Two-sample test of 
proportionality was used to determine whether the frequency of detection of any 
gene investigated was significantly different between mildly degenerate and 
moderately degenerate study groups, based only on the binomial distribution of 
presence or absence of expression.  Two-sample test of proportionality was 
performed by the equation shown below to calculate a test statistic or ‘z value’.  
Using a 95% confidence interval for a one-tailed test the significance value, 
P<0.05, is achieved for z values ≥1.65 (Currell & Dowman, 2005).    
'    (   )
* +	1   + - . 1( /  
1)0 
 
Where   is the experimentally measured proportion and hence the best estimate of 
the unknown true proportion for the population.  1 and " are the two study groups 
for comparison and  is the number of samples investigated.   2 is a pooled value 
for the proportions of the two samples calculated using the equation: 
 +   ( ( / ) )( /  )  
 
2.7.3 Statistical Analysis of qPCR Gene Expression Data from Directly 
Extracted Nucleus Pulposus Cells  
2.7.3.1 Assessment of Relative Gene Expression Levels in Non-degenerate, 
Degenerate and Infiltrated Study Groups 
Relative gene expression values (2∆) were combined for non-degenerate, 
degenerate and infiltrated study groups.  Data sets were examined by Shapiro-
Wilkes test, to assess the probability that samples included in this study were 
derived from a population with a normal distribution.  The results of Shapiro-Wilkes 
testing indicated that samples used were not derived from a population with a 
normal distribution (P<0.05).  Accordingly, data were assessed by Kruskal-Wallis 
test, to identify significant differences in relative gene expression across study 
groups.  Where significant differences were indicated across study groups 
(P<0.05), Conover-Inman post hoc testing was applied to identify data sets that 
were significantly different, and to generate ‘P’ values specific to that difference.  
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Analysed data was represented graphically, by scatter plot using Prism v5 
(GraphPad Software Inc.).  Shapiro-Wilkes and Kruskal-Wallis statistical analysis 
was performed using StatsDirect software (StatsDirect Ltd.).   
2.7.3.2 Assessment of Frequency of Gene Expression Detection in Non-
degenerate, Degenerate and Infiltrated Study Groups    
Statistical analysis was performed as described previously in section 2.7.2.2. 
2.7.4 Statistical  Analysis  of  qPCR  Gene  Expression  Data  from  
Monolayer  and  Alginate  Cultured  Nucleus  Pulposus  Cells  
Subjected  to  Cytokine  Stimulation 
Relative gene expression values (2∆) were combined for untreated and treated 
study groups.  Data sets were examined by Shapiro-Wilkes test, to assess the 
probability that samples included in this study were derived from a population with a 
normal distribution.  The results of Shapiro-Wilkes testing indicated that samples 
used were not derived from a population with a normal distribution (P<0.05).  
Accordingly, data were assessed by Kruskal-Wallis test, to identify significant 
differences in relative gene expression across study groups.  Where significant 
differences were indicated across study groups (P<0.05), Conover-Inman post hoc 
testing was applied to identify data sets that were significantly different, and to 
generate ‘P’ values specific to that difference.  Analysed data was represented 
graphically, by histogram using Excel 2010 (Microsoft Corporation).  Shapiro-
Wilkes and Kruskal-Wallis statistical analysis was performed using StatsDirect 
software (StatsDirect Ltd.).   
2.7.5 Statistical Analysis of Luminex Data 
Protein concentration in conditioned media values were combined for untreated 
and treated study groups.  Data sets were examined by Shapiro-Wilkes test, to 
assess the probability that samples included in this study were derived from a 
population with a normal distribution.  The results of Shapiro-Wilkes testing 
indicated that samples used were not derived from a population with a normal 
distribution (P<0.05).  Accordingly, data were assessed by Kruskal-Wallis test, to 
identify significant differences in protein concentration across study groups.  Where 
significant differences were indicated across study groups (P<0.05), Conover-
Inman post hoc testing was applied to identify data sets that were significantly 
different, and to generate ‘P’ values specific to that difference.  Analysed data was 
represented graphically using Prism v5 (GraphPad Software Inc.).  Shapiro-Wilkes 
and Kruskal-Wallis statistical analysis was performed using StatsDirect software 
(StatsDirect Ltd.).   
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3 The Cytokine and Chemokine Gene 
Expression Profile of Nucleus 
Pulposus Cells 
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3.1 Introduction 
This chapter describes initial investigations to determine the cytokine and 
chemokine gene expression profile of human NP cells.  The cells used were 
profiled immediately upon their isolation from fresh human NP tissue and attention 
was given to some 91 cytokine, chemokine, receptor, accessory protein and 
activating enzyme targets.  Real-time qPCR LDA was used to investigate target 
gene expression relative to internal reference gene expression in samples collected 
from 6 tissue donors.  Comparative analysis of generated data was performed 
against two parameters; the frequency that gene expression of targets was 
detected, and when detected, the level at which expression was measured.   
3.1.1 Study Design 
3.1.1.1 Samples 
Three cDNA samples were selected for analysis from each of two study groups; 
mildly degenerate and moderately degenerate (Table 3-1).  
Mildly Degenerate Moderately Degenerate 
Samples Used; Average Grade Samples Used; Average Grade 
HD3 (S) 4.8 HD5 (S) 9.0 
HD9 (S) 2.8 HD23 (S) 7.8 
HD30 (PM) 1.9 HD36 (S) 6.7 
Mean Ages;  
 
 
34 years (range 25 – 45) 32 years (range 29 – 33) 
Table 3-1  cDNA Samples from Directly Extracted Nucleus Pulposus Cells used in LDA 
qPCR Analysis 
S, surgical; PM, post-mortem.  Full details of samples used in this study can be found in 
Appendix 1 and details of histological grading of tissue samples can be found in Chapter 2, 
section 2.2.3.   
3.1.2 Methods      
Full details of methods used in this study are given in Chapter 2, sections; 
• 2.1 Tissue Sample Processing 
• 2.2 Histology 
• 2.5 Quantitative Polymerase Chain Reaction 
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3.1.3 Specific Objectives 
This chapter aimed to address the hypothesis that: 
Cytokines and chemokines are expressed in the IVD and expression is 
increased during IVD degeneration. 
The specific objectives were: 
• To determine the cytokine and chemokine mRNA expression profile of NP 
cells derived from mildly and moderately degenerate tissue 
• To identify differences in expression profile between mildly and moderately 
degenerate study groups 
• To select differentially expressed cytokines and chemokines for inclusion in 
further studies 
• To investigate the stability of internal reference gene expression in NP cells 
and to select appropriate controls for use in further real-time qPCR gene 
expression studies         
3.2 Results  
3.2.1 Cytokine mRNA Expression in Nucleus Pulposus Cells  
3.2.1.1 The Interleukin-1 Family 
Relative IL-1 family mRNA values in DE NP cells are shown in Figure 3-1A.  The 
frequency and level of mRNA detection of the agonist IL-1α was increased in 
moderately degenerate samples compared to mildly degenerate however, this was 
not significant (P>0.05 for both parameters).  The frequency of mRNA detection of 
the agonist IL-1β was significantly increased in moderately degenerate samples – 
3/3, compared to mildly degenerate – 1/3 (z value = 1.73; P<0.05).  IL-1β mRNA 
expression, relative to internal reference gene expression, was also increased in 
moderately degenerate samples compared to mildly degenerate, however this was 
not significant (P>0.05).  mRNA expression of the signalling receptor for these 
ligands, IL-1RI, and the signalling receptor accessory protein, IL-1RAcP, was 
detected in all samples and at equivalent levels between study groups.  mRNA 
expression of the decoy receptor, IL-1RII, the receptor antagonist, IL-1Ra and the 
converting enzyme, ICE, was detected only in moderately degenerate samples.  
Both IL-1RII and IL-1Ra were detected in 2/3 samples and ICE was detected in 3/3 
samples, indicating significantly increased frequency of mRNA expression in 
moderately degenerate samples compared to mildly degenerate (z value = 1.73; 
P<0.05, z value = 1.73; P<0.05 and z value = 2.45; P<0.05 respectively).   
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3.2.1.2  IL-6, IL-7 & IL-11       
Relative mRNA values in DE NP cells for the cytokines IL-6, IL-7, IL-11 and 
associated receptors are shown in Figure 3-1B.  The frequency of mRNA detection 
for IL-6 was significantly increased in moderately degenerate samples – 3/3, 
compared to mildly degenerate – 1/3 (z value = 1.73; P<0.05).   IL-6 mRNA 
expression, relative to internal reference gene expression, was also increased in 
moderately degenerate samples compared to mildly degenerate, however this was 
not significant (P>0.05).  mRNA expression for the signalling receptor, IL-6R, and 
the signalling accessory protein, gp130, was detected in all samples and at 
equivalent levels between study groups.  IL-7 mRNA expression was not detected 
in any sample investigated.  IL-7R mRNA expression was detected in 5/6 samples 
investigated and at equivalent frequencies and relative expression levels between 
study groups.  The frequency of mRNA detection of IL-11 was significantly 
increased in moderately degenerate samples – 3/3, compared to mildly degenerate 
– 1/3 (z value = 1.73; P<0.05) however relative expression levels were seen to be 
equivalent between groups.  The frequency of detection and relative expression 
level of IL-11Rα mRNA was equivalent between groups.   
3.2.1.3 IL-15, IL-16, IL-18 & IL-23 
Relative mRNA values in DE NP cells for the IL-15, IL-16, IL-18, IL-23 and 
associated receptors are shown in Figure 3-1C.  IL-15 mRNA was not detected in 
any DE NP sample investigated however, the signalling receptor IL-15Rα was 
detected in 5/6 samples.  The frequency of mRNA detection and relative 
expression levels were equivalent between study groups.  The frequency of mRNA 
detection of IL-16 was equivalent between study groups although mRNA 
expression, relative to internal reference gene expression, was decreased in 
moderately degenerate samples compared to mildly degenerate, although this was 
not significant (P>0.05).  Signalling receptor, CD4 mRNA expression was detected 
in 5/6 samples investigated and at equivalent frequency and relative expression 
level between study groups. 
The frequency of mRNA detection of IL-18 was significantly increased in 
moderately degenerate samples – 3/3, compared to mildly degenerate – 1/3 (z 
value = 1.73; P<0.05).  IL-18 mRNA expression, relative to internal reference gene 
expression, was also increased in moderately degenerate samples compared to 
mildly degenerate, although this was not significant (P>0.05).  The frequency of 
mRNA detection of one of the signalling receptors for this ligand, IL-18Rα, was 
significantly increased in moderately degenerate samples – 3/3, compared to mildly  
 
 
1
2
4
 
 
α
IL
-1
β
IL
-1
IL
-1
R
I
IL
-1
R
II IL
-1
R
A
cP
IL
-1
R
a
IC
E
1
1
0
1
0
0
1
0
0
0
1
0
0
0
0
1
0
0
0
0
0




Relative Gene Expression (log scale)
IL
-6
IL
-6
R
gp
13
0
IL
-7
IL
-7
R
IL
-1
1
α
IL
-1
1R
1
1
0
1
0
0
1
0
0
0
1
0
0
0
0
1
0
0
0
0
0


M
ild
 D
e
g
e
n
e
ra
ti
o
n
M
o
d
e
ra
te
 D
e
g
e
n
e
ra
tio
n
Relative Gene Expression (log scale)
IL
-1
5
α
IL
-1
5R
IL
-1
6
C
D
4
IL
-1
8
α
IL
-1
8R
β
IL
-1
8R
IL
-2
3 IL
-2
3R
1β
IL
-1
2R
1
1
0
1
0
0
1
0
0
0
1
0
0
0
0
1
0
0
0
0
0




Relative Gene Expression (log scale)
A
B
C
 
F
ig
u
re
 3
-1
  C
y
to
k
in
e
s;
 T
h
e
 I
L-
1
 F
a
m
il
y
, 
IL
-6
, 
IL
-7
, 
IL
-1
1
, 
IL
-1
5
, 
IL
-1
6
, 
IL
-1
8
 a
n
d
 I
L-
2
3
 m
R
N
A
 E
x
p
re
ss
io
n
 i
n
 D
ir
e
ct
ly
 E
x
tr
a
ct
e
d
 N
u
cl
e
u
s 
P
u
lp
o
su
s 
C
e
ll
s 
C
y
to
k
in
e
 g
e
n
e
 e
xp
re
ss
io
n
 r
e
la
ti
v
e
 t
o
 i
n
te
rn
a
l 
re
fe
re
n
ce
 g
e
n
e
 e
xp
re
ss
io
n
 i
n
 D
E
 N
P
 c
e
ll
s.
  
In
 t
o
ta
l,
 D
E
 N
P
 c
e
ll
s 
d
e
ri
v
e
d
 f
ro
m
 s
ix
 I
V
D
s 
w
e
re
 i
n
v
e
st
ig
a
te
d
 f
o
r 
e
a
ch
 
ta
rg
e
t 
g
e
n
e
. 
 G
ra
p
h
ic
a
l 
d
a
ta
 r
e
p
re
se
n
ts
 m
e
a
su
re
d
 r
e
la
ti
v
e
 m
R
N
A
 e
xp
re
ss
io
n
 i
n
 s
a
m
p
le
s 
w
h
e
re
 e
xp
re
ss
io
n
 w
a
s 
d
e
te
ct
e
d
, 
i.
e
. 
fo
r 
IL
-1
α
; 
m
R
N
A
 e
xp
re
ss
io
n
 w
a
s 
d
e
te
ct
e
d
 i
n
 o
n
e
 m
il
d
ly
 d
e
g
e
n
e
ra
te
 s
a
m
p
le
 a
n
d
 i
n
 t
w
o
 m
o
d
e
ra
te
ly
 d
e
g
e
n
e
ra
te
 s
a
m
p
le
s.
  

 i
n
d
ic
a
te
s 
si
g
n
if
ic
a
n
t 
a
lt
e
ra
ti
o
n
 i
n
 f
re
q
u
e
n
cy
 o
f 
m
R
N
A
 d
e
te
ct
io
n
 
b
e
tw
e
e
n
 m
il
d
ly
 a
n
d
 m
o
d
e
ra
te
ly
 d
e
g
e
n
e
ra
te
 s
tu
d
y
 g
ro
u
p
s 
(P
<
0
.0
5
) 
 
 
125 
 
degenerate – 1/3 (z value = 1.73; P<0.05) although relative expression was 
equivalent between groups.  mRNA expression of the second signalling receptor for 
this ligand, IL-18Rβ was not detected in any sample investigated.  
The frequency of mRNA detection of the agonist IL-23 and one of the signalling 
receptors for this ligand, IL-12RβI was significantly increased in moderately 
degenerate samples – 2/3, compared to mildly degenerate – 0/3 (z value = 1.73; 
P<0.05 in both cases).  mRNA expression of another signalling receptor for this 
ligand, IL-23R, was not detected in any sample investigated.   
3.2.1.4 The IL-17 Family 
Relative mRNA values in DE NP cells for the IL-17 family cytokines IL-17A, -B, -C, -
D, -E and –F and associated receptors are shown in Figure 3-2A.  mRNA 
expression of the agonists IL-17A and IL-17E was not detected in any DE NP 
sample investigated.  mRNA expression of IL-17B, -C and –F was detected in only 
one of all samples investigated.  The frequency of mRNA detection of the agonist 
IL-17D was significantly increased in moderately degenerate samples – 3/3, 
compared to mildly degenerate – 1/3 (z value = 1.73; P>0.05).  IL-17D mRNA 
expression, relative to internal reference gene expression, was also increased in 
degenerate samples compared to non-degenerate, although this was not significant 
(P>0.05).  The signalling receptors for these ligands, IL-17RA and IL-17RC, were 
detected in all samples investigated and at equivalent relative expression levels 
between study groups.  The frequency of mRNA detection of the receptors, IL-
17RB and IL-17RD, was equivalent between study groups although relative 
expression level was decreased in moderately degenerate samples compared to 
mildly, although this was not significant (P>0.05 in both cases).   
3.2.1.5 IL-20 
Relative mRNA values in DE NP cells for IL-20 and associated receptors are 
shown in Figure 3-2B.  The frequency of mRNA detection and relative expression 
levels of the agonist IL-20, and signalling receptors, IL-20RII and IL-22RAI, was 
equivalent across study groups.  mRNA expression of another signalling receptor 
for this ligand, IL-20RI was not detected in any sample investigated.   
3.2.1.6 IL-4 and IL-10 
Relative mRNA values in DE NP cells for the cytokines, IL-4 and IL-10 and 
associated receptors are shown in Figure 3-2C.  mRNA expression of the agonist 
IL-4 was not detected in any DE NP sample investigated.  The frequency of mRNA 
detection of the signalling receptor for this ligand, IL-4R was significantly increased 
in moderately degenerate samples – 3/3, compared to mildly degenerate – 1/3 (z   
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value = 1.73; P<0.05).  IL-4R mRNA expression, relative to internal reference gene 
expression, was also increased in moderately degenerate samples compared to 
mildly, although this was not significant (P>0.05).  The frequency of mRNA 
detection of the agonist IL-10 was significantly increased in moderately degenerate 
samples – 3/3, compared to mildly degenerate – 1/3 (z value = 1.73; P<0.05) 
although relative expression levels were equivalent between study groups.  The 
frequency of mRNA detection of the signalling receptors for this ligand, IL-10Rα 
and IL-10Rβ, were equivalent between study groups, as was relative expression 
level of IL-10Rβ.  Relative expression of IL-10Rα was increased in moderately 
degenerate samples compared to mildly, although this was not significant (P>0.05). 
3.2.1.7 The TNF Family 
Relative mRNA values in DE NP cells for the cytokines TNF-α and TNF-β, 
alongside associated receptors and converting enzyme are shown in Figure 3-3A.  
The frequency of mRNA detection of the agonist TNF-α was equivalent between 
study groups although mRNA expression, relative to internal reference gene 
expression, was increased in moderately degenerate samples compared to mildly, 
although this was not significant (P>0.05).  The frequency of mRNA detection of the 
agonist TNF-β was equivalent in moderately degenerate – 1/3, and mildly 
degenerate – 1/3, samples.  Expression of the signalling receptor, TNF-R55 and 
the activating enzyme, TACE was detected in all samples investigated; relative 
expression levels were equivalent between study groups.  The frequency of mRNA 
detection of the signalling receptor, TNF-R75 was significantly increased in 
degenerate samples – 2/3, compared to non-degenerate – 0/3 (z value = 1.73; 
P<0.05).   
3.2.1.8 CSF2, CSF3 and IFN-γ 
Relative mRNA values in DE NP cells for the cytokines CSF2, CSF3 and IFN-γ 
alongside associated receptors are shown in Figure 3-3B.  mRNA expression of 
CSF2 was only detected in 1/6 DE NP samples investigated.  mRNA expression of 
CSF2Rα was detected only in moderately degenerate samples – 2/3, indicating 
significantly increased frequency of mRNA expression in moderately degenerate 
samples compared to mildly degenerate (z value = 1.73; P<0.05).  The frequency 
of mRNA detection of signalling receptor, CSF2Rβ was equivalent between study 
groups as was relative expression level.  Expression of the agonist CSF3 was not 
detected in any sample investigated.  The frequency of mRNA detection of the 
receptor CSF3R was equivalent between study groups as was relative expression 
level.  Expression of the agonist IFN-γ was not detected in any sample  
 
 
1
2
8
 
 
α
TN
F-
β
TN
F
TN
F-
R
55
TN
F-
R
75
TA
C
E
1
1
0
1
0
0
1
0
0
0
1
0
0
0
0
1
0
0
0
0
0
1
0
0
0
0
0
0

Relative Gene Expression (log scale)
C
S
F2
α
C
SF
2R
β
C
S
F2
R
C
SF
3
C
S
F3
R
γ
IF
N
α
Rγ
IF
N
β
Rγ
IF
N
1
1
0
1
0
0
1
0
0
0
1
0
0
0
0
1
0
0
0
0
0
1
0
0
0
0
0
0

M
ild
 D
e
g
e
n
e
ra
ti
o
n
M
o
d
e
ra
te
 D
e
g
e
n
e
ra
ti
o
n
Relative Gene Expression (log scale)
O
SM
O
SM
R
LI
F
α
LI
FR
gp
13
0
1
1
0
1
0
0
1
0
0
0
1
0
0
0
0
1
0
0
0
0
0
1
0
0
0
0
0
0

Relative Gene Expression (log scale)
A
B
C
 
F
ig
u
re
 3
-3
  C
y
to
k
in
e
s;
 T
h
e
 T
N
F
 F
a
m
il
y
, 
C
S
F
2
, 
C
S
F
3
, 
IF
N
-γ
, 
O
S
M
 a
n
d
 L
IF
 m
R
N
A
 E
x
p
re
ss
io
n
 i
n
 D
ir
e
ct
ly
 E
x
tr
a
ct
e
d
 N
u
cl
e
u
s 
P
u
lp
o
su
s 
C
e
ll
s 
C
y
to
k
in
e
 g
e
n
e
 e
xp
re
ss
io
n
 r
e
la
ti
v
e
 t
o
 i
n
te
rn
a
l 
re
fe
re
n
ce
 g
e
n
e
 e
xp
re
ss
io
n
 i
n
 D
E
 N
P
 c
e
ll
s.
  
In
 t
o
ta
l,
 D
E
 N
P
 c
e
ll
s 
d
e
ri
v
e
d
 f
ro
m
 s
ix
 I
V
D
s 
w
e
re
 i
n
v
e
st
ig
a
te
d
 f
o
r 
e
a
ch
 
ta
rg
e
t 
g
e
n
e
. 
 G
ra
p
h
ic
a
l 
d
a
ta
 r
e
p
re
se
n
ts
 m
e
a
su
re
d
 r
e
la
ti
v
e
 m
R
N
A
 e
xp
re
ss
io
n
 i
n
 s
a
m
p
le
s 
w
h
e
re
 e
xp
re
ss
io
n
 w
a
s 
d
e
te
ct
e
d
, 
i.
e
. 
fo
r 
T
N
F
-α
; 
m
R
N
A
 e
xp
re
ss
io
n
 
w
a
s 
d
e
te
ct
e
d
 i
n
 t
w
o
 m
il
d
ly
 d
e
g
e
n
e
ra
te
 s
a
m
p
le
s 
a
n
d
 i
n
 t
h
re
e
 m
o
d
e
ra
te
ly
 d
e
g
e
n
e
ra
te
 s
a
m
p
le
s.
  

 i
n
d
ic
a
te
s 
si
g
n
if
ic
a
n
t 
a
lt
e
ra
ti
o
n
 i
n
 f
re
q
u
e
n
cy
 o
f 
m
R
N
A
 
d
e
te
ct
io
n
 b
e
tw
e
e
n
 m
il
d
ly
 a
n
d
 m
o
d
e
ra
te
ly
 d
e
g
e
n
e
ra
te
 s
tu
d
y
 g
ro
u
p
s 
(P
<
0
.0
5
) 
 
 
129 
 
investigated.  mRNA expression of the signalling receptors for this ligand, IFN-γRα 
and IFN-γRβ, were detected in all samples investigated and at equivalent relative 
expression levels between study groups.   
3.2.1.9 OSM and LIF 
Relative mRNA values in DE NP cells for the cytokines OSM and LIF alongside 
associated receptors and accessory protein are shown in Figure 3-3C.  OSM 
mRNA expression was detected only in moderately degenerate samples indicating 
significantly increased frequency of expression in moderately degenerate samples 
– 2/3, compared to mildly – 0/3 (z value = 1.73; P<0.05).  mRNA expression of the 
signalling receptor for this ligand, OSMR, was detected in all samples investigated 
and relative expression levels were equivalent between study groups.  The 
frequency of mRNA detection of LIF was equivalent in moderately degenerate – 
3/3, and mildly degenerate – 3/3, study groups as was relative expression level.  
mRNA expression of the signalling receptor for this ligand, LIFR was only detected 
in 1/6 DE NP samples investigated.  Signalling receptor accessory protein, gp130 
was detected in all samples as previously described (section 3.2.1.2). 
3.2.2 Chemokine mRNA Expression in NP Cells 
3.2.2.1 The C-C Chemokine Family 
Relative mRNA values in DE NP cells for the chemokines CCL2, CCL3, CCL4, 
CCL5, CCL7, CCL8, CCL13, CCL19 and CCL20 are shown in Figure 3-4A.  The 
frequency of mRNA detection of CCL2 was equivalent in moderately degenerate 
samples – 3/3, compared to mildly degenerate – 2/3, although relative expression 
was increased in moderately compared to mildly degenerate samples, however this 
was not significant (P>0.05).  The frequency of mRNA detection of CCL3 was 
significantly increased in moderately degenerate samples – 3/3, compared to mildly 
degenerate – 1/3 (z value = 1.73; P<0.05) and relative expression level was also 
increased, although this was not significant (P>0.05).  The frequency of mRNA 
detection of CCL4 and CCL5 was significantly increased in moderately degenerate 
samples – 3/3, compared to mildly degenerate – 0/3 (z value = 2.45; P<0.05 in both 
cases).  The frequency of mRNA detection of CCL7 was significantly increased in 
moderately degenerate samples – 3/3, compared to mildly degenerate – 1/3 (z 
value = 1.73; P<0.05) although relative expression levels were equivalent between 
groups.  The frequency of mRNA detection of CCL8 was significantly increased in 
moderately degenerate samples – 2/3, compared to mildly degenerate – 0/3 (z 
value = 1.73; P<0.05).  mRNA expression of CCL13 and CCL19 was only detected 
in 1/6 DE NP samples investigated.  The frequency of mRNA detection of CCL20 
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was equivalent in moderately degenerate – 1/3, and mildly degenerate – 1/3, 
samples.   
3.2.2.2 The C-X-C Chemokine Family and CX3CL1 
Relative mRNA values in DE NP cells for the chemokines CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCL8, CXCL9, CXCL10 and CX3CL1 are shown in Figure 3-4B.  
The frequency of mRNA detection of CXCL1 was significantly increased in 
moderately degenerate samples – 3/3, compared to mildly degenerate – 1/3 (z 
value = 1.73; P<0.05).  The frequency of mRNA detection of CXCL2 was equivalent 
between study groups; moderately degenerate – 3/3, compared to mildly 
degenerate – 2/3, although relative expression level was increased in moderately 
degenerate samples, however this was not significant (P>0.05).  The frequency of 
mRNA detection of CXCL3 was significantly increased in moderately degenerate 
samples – 3/3, compared to mildly degenerate – 0/3 (z value = 2.45; P<0.05).  The 
frequency of mRNA detection of CXCL5 was equivalent between study groups, 
moderately degenerate – 2/3, compared to mildly degenerate – 1/3.  mRNA 
expression of CXCL6 was only detected in 1/6 DE NP samples investigated.  The 
frequency of mRNA detection of CXCL8 was equivalent in moderately degenerate– 
3/3, and mildly degenerate – 3/3, samples.  CXCL8 mRNA expression, relative to 
internal reference gene expression, was increased in moderately degenerate 
samples compared to mildly degenerate, although this was not significant (P>0.05).  
The frequency of mRNA detection of CXCL9 was significantly increased in 
degenerate samples – 2/3, compared to non-degenerate – 0/3 (z value = 1.73; 
P<0.05).  CXCL10 mRNA was not detected in any sample investigated.  The 
frequency of mRNA detection of CX3CL1 was equivalent in degenerate – 3/3, and 
non-degenerate – 3/3, samples as was relative expression level.   
3.2.2.3 Chemokine Receptors     
Relative mRNA values in DE NP samples for the chemokine receptors, CCR1, 
CCR2, CCR3, CCR5, CCR6, CCR7, CCR8, CXCR1, CXCR2, CXCR3, CX3CR1 
and the decoy receptors Duffy and D6 are shown in Figure 3-4C.  The frequency of 
mRNA detection of CCR1 was significantly increased in degenerate samples – 2/3, 
compared to non-degenerate – 0/3 (z value = 1.73; P<0.05).  CCR2, CCR6 and 
CCR8 mRNA expression was not detected in any DE NP sample investigated.  The 
frequency of mRNA detection of CCR3 was equivalent between study groups, 
moderately degenerate – 2/3, compared to mildly degenerate – 1/3.  The frequency 
of mRNA detection of CCR5 was significantly increased in degenerate samples – 
2/3, compared to non-degenerate – 0/3 (z value = 1.73; P<0.05).    
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The frequency of mRNA detection of receptors CXCR1 and CXCR3 was equivalent 
between study groups, moderately degenerate – 2/3, compared to mildly 
degenerate – 1/3.  The frequency of mRNA detection of CXCR2 was significantly 
increased in degenerate samples – 2/3, compared to non-degenerate – 0/3 (z value 
= 1.73; P<0.05).  mRNA expression of CX3CR1 was only detected in 1/6 DE NP 
samples investigated.  The frequency of mRNA detection of decoy receptors, Duffy 
and D6, was equivalent between study groups, moderately degenerate – 1/3, and 
mildly degenerate – 1/3, samples.  
3.2.3 Summary of Results      
The results of cytokine and chemokine ligand gene expression, presented in this 
chapter are summarised in Table 3-2 and Table 3-3. 
3.3 Discussion 
The objectives of this investigation were to determine the cytokine and chemokine 
gene expression profile of DE NP cells, and to identify potentially differentially 
expressed cytokines and chemokines between mildly and moderately degenerate 
study groups. 
The data presented highlights transcription of numerous cytokines and chemokines 
by NP cells.  Of the 18 cytokines detected, 6 are novel findings not previously 
reported in the IVD (IL-11, IL-16, IL-18, IL-23, OSM and LIF).  Our findings, in 
relation to these targets within diseased IVD tissue agree with previous reports of 
their expression in OA and RA (Franz et al., 1998; Klimiuk et al., 1999; Abramson & 
Yazici, 2006; Andreas et al., 2008; Sandell et al., 2008; Moran et al., 2009) (Table 
1-4).  Gene expression was not detected for 7 of the investigated cytokines (IL-7, 
IL-15, IL-17A, IL-17E, IL-4, CSF3 and IFN-γ) although some of these have been 
previously reported in the IVD.  IL-17A and IL-17E gene expression was not 
detected in this study; however protein expression of IL-17 within the human IVD 
has been demonstrated previously by IHC (Shamji et al., 2010).  In the 
investigation by Shamji et al. (2010) the primary IL-17 antibody used was not 
isoform specific and hence protein detected may be translated from any of the six 
IL-17 family ligands, four of which (-B, -C, -D and –F) were identified here at the 
gene expression level.  Also reported at the protein level in the human IVD are IL-4 
and IFN-γ (Shamji et al., 2010).  Neither target was detected in this investigation 
however, in light of the small number of samples it’s possible that the gene 
expression profiles of targets IL-17A, IL-17E, IL-4 and IFN-γ generated here are not 
representative of their expression in the wider population.   
 
 
 
133 
 
Target Mildly Degenerate Moderately Degenerate 
Differential Expression 
Pattern 
IL-1α + +  ↑ 
IL-1β + + ↑* 
IL-6 + +  ↑* 
IL-7 - -  
IL-11 + +  ↑* 
IL-15 - -  
IL-16 + +  ↓ 
IL-18 + +  ↑* 
IL-23 - +  ↑* 
IL-17A - -  
IL-17B + -  
IL-17C - +  
IL-17D + +  ↑* 
IL-17E - -  
IL-17F - +  
IL-20 + +  
IL-4 - -  
IL-10 + +  ↑* 
TNF-α + +  ↑ 
TNF-β + +  
CSF2 - +  
CSF3 - -  
IFNγ - -  
OSM - +  ↑* 
LIF + +  
Table 3-2  Summary of Cytokine mRNA Expression in Directly Extracted Nucleus Pulposus 
Cells from Mildly and Moderately Degenerate Study Groups and Observed Differential 
Expression Patterns 
+, mRNA expression detected; -, mRNA expression not detected; ↑, increased in 
moderately degenerate study group in comparison to mildly degenerate study group; ↓ 
decreased in moderately degenerate study group compared to mildly degenerate study 
group, *, significant difference between frequency of mRNA detection between study 
groups (P<0.05) 
134 
 
Target Mildly Degenerate Moderately Degenerate 
Differential Expression 
Pattern 
CCL2 +  +  ↑ 
CCL3 + +  ↑* 
CCL4 - +  ↑* 
CCL5 - +  ↑* 
CCL7 + +  ↑* 
CCL8 - +  ↑* 
CCL13 - +  
CCL19 - +  
CCL20 + +  
CXCL1 + +  ↑* 
CXCL2 + +  ↑ 
CXCL3 - +  ↑* 
CXCL5 + +  
CXCL6 - +  
CXCL8 + +  ↑ 
CXCL9 - +  ↑* 
CXCL10 - -  
CX3CL1 + +  
Table 3-3  Summary of Chemokine mRNA Expression in Directly Extracted Nucleus 
Pulposus Cells from Mildly and Moderately Degenerate Study Groups and Observed 
Differential Expression Patterns 
+, mRNA expression detected; -, mRNA expression not detected; ↑, increased in 
moderately degenerate study group in comparison to mildly degenerate study group; ↓ 
decreased in moderately degenerate study group compared to mildly degenerate study 
group, *, significant difference between frequency of mRNA detection between study 
groups (P<0.05) 
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Of the 18 chemokine targets investigated, gene expression of 17 was detected in 
DE NP cells, 10 of which are novel findings not previously reported in the IVD 
(CCL3, CCL4, CCL8, CCL19, CCL20, CXCL2, CXCL3, CXCL5, CXCL6 and 
CX3CL1).  Our findings in relation to 9 of these targets within the diseased IVD 
agree with previous reports of their expression in OA and RA (Borzi et al., 1999; 
Yuan et al., 2001; Pulai et al., 2005; Andreas et al., 2008; Sandell et al., 2008; 
Kelchtermans et al., 2009) (Table 1-4).  However, one other novel IVD chemokine, 
CCL19, has not previously been reported in OA or RA.          
Gene expression of cytokine and chemokine receptors, signalling accessory 
molecules and activating enzymes were also considered.  Frequently, receptor 
gene expression was detected alongside that of the ligand, indicating that autocrine 
or paracrine signalling mechanisms may function within NP tissue.   
The major objective addressed in this chapter was the identification of cytokines 
and chemokines that are differentially expressed with increasing disease severity.  
Significant differences in transcription patterns between mildly and moderately 
degenerate study groups were apparent for several cytokines (Table 3-2) and 
chemokines (Table 3-3).  However, data presented must be interpreted with 
caution.  Firstly, because of the small number of tissue samples in each study 
group the data generated may not be representative of the wider population.  
Secondly, because five of the six tissue samples in this study are from prolapsed 
IVDs (protrusions constrained within the AF), the transcription patterns observed 
may be related to the pathology of prolapse rather than degeneration.  And thirdly, 
since mRNA expression profiles may not be representative of expression profiles at 
a protein level.  Nevertheless, data generated is useful to assist in the selection of 
cytokines and chemokines to be targeted for further investigation.  
3.3.1 Target Selection for Further Gene Expression Studies 
NP cytokines identified here were considered for inclusion in further gene 
expression studies initially based on differential expression patterns between mildly 
and moderately degenerate study groups.  Targets were then prioritised according 
to detection of receptor mRNA transcription, since this may indicate the potential of 
cells to respond to signalling.  Consideration was also given to current literature 
and documented links to IVD pathology.  By these criteria, seven cytokines were 
selected for inclusion in further gene expression studies; IL-1β, IL-6, IL-16, IL-18, 
IL-17D, TNF-α and OSM (Table 3-4).  An additional two cytokines were added to 
this selection; IL-20, which did not show a differential expression profile however, 
receptor transcription was detected and current literature indicates that this
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cytokine has regulatory potential on other cytokines within the IVD (Huang et al., 
2008).  And LIF, which also did not show a differential expression profile but was 
detected in all samples investigated and is a novel IVD cytokine.  Selected cytokine 
targets are shown in Table 3-4.    
Chemokines were selected for inclusion in further gene expression studies based 
on the criteria described above.  However, priority was given to targets that signal 
through receptors CCR1 and CXCR2 as differential expression patterns were 
observed for these two molecules.  10 chemokines were selected as shown in 
Table 3-5.  
3.3.2 Target Selection for Protein Expression and Localisation Studies 
The gene expression profile may not be an accurate representation of molecules 
expressed by cells since intracellular regulatory mechanisms may function to 
prevent mRNA transcripts from being translated to proteins.  Protein expression of 
cytokines is essential for them to function as extracellular signals and so must be 
confirmed before molecules can be implicated in cell biology.  Cytokines from the 
panel selected for further mRNA expression studies were considered as potential 
targets for experimental work to confirm translation and to localise produced protein 
to cells of origin.     
As expected, mRNA expression of both IL-1 agonists was detected in DE NP cells.  
Expression patterns were similar and transcription was increased in moderately 
compared to mildly degenerate samples, as has been shown previously (Le Maitre 
et al., 2005; Le Maitre et al., 2007d).  Signalling receptor, IL-1RI, and receptor 
accessory protein, IL-1RAcP, transcription was detected in all samples indicating 
that NP cells are both producers and targets of IL-1 within the IVD.  Interestingly, 
transcription of the antagonist, IL-1Ra, was significantly up-regulated in moderately 
compared to mildly degenerate samples as was that of the decoy receptor, IL-1RII, 
both of which function to dampen local IL-1 responses.  Previously it has been 
demonstrated that IL-1Ra transcription is not up-regulated with increasing disease 
severity in the degenerate IVD (Le Maitre et al., 2005) and this difference may be 
related to the pathology of prolapse rather than degeneration since tissue samples 
used here are both degenerate and prolapsed.  Transcription of IL-1RII has not 
been shown previously in the IVD.  IL-1β was selected for inclusion in further gene 
expression studies over IL-1α since the differential expression between study 
groups was significant for IL-1β.  IL-1β was also selected for inclusion in further 
protein expression and localisation studies to facilitate comparison of data 
generated with that previously published.  By this means it may be possible to 
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determine whether expression patterns are similar in degenerate NP tissue and 
prolapsed degenerate NP tissue.  IL-1RI expression is well documented in the IVD 
(Le Maitre et al., 2005; Le Maitre et al., 2007d) and for this reason IL-1RI was not 
selected for further inclusion in gene or protein expression and localisation studies.    
Transcription of IL-16 was detected in DE NP cells and data suggests that 
transcription may be decreased in line with increased disease severity.  Further, 
transcription of the signalling receptor for this ligand, CD4 (Cruikshank et al., 2000), 
was detected in DE NP cells indicating that NP cells have the capacity to respond 
to IL-16 signalling.  Neither IL-16 nor CD4 have been described previously in the 
IVD.  In fact, the finding of CD4 expression within DE NP cell samples may be 
considered unusual, since CD4 expression is normally only associated with T 
lymphocytes (Cruikshank et al., 2000).  However, since the cells used in this study 
were isolated from prolapsed tissue and leukocyte infiltration is a feature of 
prolapsed IVDs  (Kanerva et al., 1997; Habtemariam et al., 1998; Kawaguchi et al., 
2002; Kobayashi et al., 2009) in which T lymphocytes are identified as one 
population of infiltrating immune cells (Kanerva et al., 1997; Habtemariam et al., 
1998) it is possible that the CD4 gene expression detected here is derived from 
contaminating T lymphocytes in the cell samples.  Interestingly, CD4 gene 
expression was detected in all 5 of the DE NP cell samples derived from surgically 
obtained prolapsed IVD tissue but not in the DE NP cell sample derived from HD30, 
the only post-mortem non-degenerate sample included in the study.  Since the 
normal IVD is considered an immune privileged site (Naylor, 1962; Bobechko & 
Hirsch, 1965), this observation may further indicate T lymphocyte contamination of 
surgically obtained prolapsed samples.  As such, these two novel IVD targets were 
selected for inclusion in further gene expression studies and in protein expression 
and localisation studies to allow determination of the cellular source of IL-16 and 
CD4 within the IVD.   
CCL2 and CXCL8 transcription was detected in DE NP cells and data indicates 
transcription of these two targets may be increased in line with increasing disease 
severity.  CCL2 and CXCL8 have been identified previously in healthy and 
prolapsed IVD tissue, but not localised to the native IVD cells (Burke et al., 2002).  
The study by Burke et al. (2002) reported expression of CCL2 in 40% of, and 
CXCL8 in 20% of, healthy IVD tissue samples indicating that physiological roles for 
CCL2 and CXCL8 within the normal IVD are likely.  Both CCL2 and CXCL8 were 
selected for inclusion in further gene expression and protein expression studies.   
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CCL2 signals through receptors CCR1 and CCR2 (Murphy et al., 2000).  CCR1 
transcription was detected in DE NP cells and transcription was increased in line 
with increasing disease severity.  CCR2 transcription was not detected in any 
sample investigated however, in light of the small number of samples investigated 
this cannot be considered conclusive.  Both receptors have been identified in 
articular chondrocytes (Silvestri et al., 2003) and were selected as targets for 
inclusion in further gene expression studies.  CCR1 was also selected for inclusion 
in protein expression and localisation studies.   
CXCL8 signals through receptors CXCR1 and CXCR2 (Murphy et al., 2000).  
Transcription of both receptors was detected in DE NP cells and data suggests 
CXCR2 transcription may be increased in line with increasing disease severity.  
Both receptors have been identified in articular chondrocytes (Silvestri et al., 2003) 
and were selected for inclusion in further gene expression and protein expression 
and localisation studies.   
CCL3 and CCL7 transcription was detected in DE NP cells.  For both molecules 
differential transcription patterns indicate that transcription may be increased in line 
with increasing disease severity.  CCL3 has not been documented previously in the 
IVD although expression by articular chondrocytes has been identified (Borzi et al., 
1999; Yuan et al., 2001; Silvestri et al., 2003; Sandell et al., 2008).  CCL7 gene 
expression has been reported previously in prolapsed IVDs (Kawaguchi et al., 
2002).  Both chemokines signal through detected receptor CCR1 and were 
selected in preference to CCL4, CCL5 and CCL8 for inclusion in protein expression 
and localisation studies based on detection of mRNA transcripts in a greater 
proportion of samples investigated.  Of the remaining C-C chemokines investigated 
here, CCL4 was also selected for inclusion in further protein studies since CCL5 
mRNA expression has been investigated previously (Ahn et al., 2002; Kawaguchi 
et al., 2002) and CCL4 expression was detected at greater frequencies than that of 
CCL8.  However, CCL4 and CCL5 were included alongside CCL3 and CCL7 in 
further gene expression studies.      
3.3.3 Selection of Cytokine and Chemokine In Vitro Treatments 
For continuity, cytokines and chemokines selected for investigation in protein 
expression and localisation studies were selected as treatments for in vitro 
experimental work.  
3.3.4 Summary 
Data presented in this chapter illustrates the diverse cytokine and chemokine gene 
expression profile of human NP cells and identifies expression of 16 cytokines and 
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chemokines not previously reported in the human IVD.  Further, these preliminary 
investigations indicate that certain cytokines and chemokines may be differentially 
expressed according to severity of pathology in the IVD.      
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4 The Cytokine and Chemokine Gene 
Expression Profile of Nucleus 
Pulposus Cells derived from Non-
degenerate, Degenerate and Infiltrated 
Intervertebral Discs 
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4.1 Introduction 
This chapter describes further qPCR investigations to determine the cytokine, 
chemokine and associated receptor gene expression profile of human NP cells.  
Attention is given to some 30 cytokine, chemokine and receptor genes selected 
following analysis of LDA data discussed in Chapter 3, sections 3.3.1 and 0, 
summarised in Table 3-4 and Table 3-5.   Real-time qPCR was used to investigate 
mRNA expression in NP cells derived from 30 additional tissue samples, combined 
with 5/6 of the original samples used in previous studies (insufficient sample 
remaining for inclusion of HD5).  Comparative analysis of generated data was 
performed against two parameters; the frequency that gene expression of targets 
was detected, and when detected, the level at which expression was measured.     
4.1.1 Study Design  
This study was performed to address the limitations of previous experimental work 
in determining the cytokine and chemokine gene expression profile of human NP 
cells.  By expanding the number of samples included in the study data generated 
should be more representative of the wider population.  Further, refining the study 
groupings used may help to identify mRNA expression profiles associated with the 
different pathologies of degeneration and prolapse.  In this study samples were 
allocated to one of three categories; non-degenerate, degenerate or infiltrated.  The 
rationale for these groupings was based on the requirement to analyse separately 
data generated from tissue undergoing the process of spontaneous resorption.  
These samples were identified by the presence of infiltrating cells (leukocytes) that 
form part of the inflammatory and/or auto-immune mechanisms of spontaneous 
resorption (see Chapter 1, sections 1.3.2.1, 1.3.2.2 and 1.3.2.3).  Separating out 
this data should allow for the more accurate determination of differential expression 
profiles based on histological evidence of degenerative tissue changes (see 
Chapter 2, section 2.2.3).   
4.1.1.1 Samples 
35 cDNA samples derived from NP cells isolated from human tissue were selected 
for analysis from non-degenerate, degenerate and infiltrated study groups (Table 
4-1).         
Non-Degenerate Degenerate Infiltrated 
Samples Used; 
  
HD9 (S) HD3 (S) HD1 (S) 
HD22 (S) HD16 (S) HD2 (S) 
HD24 (S) HD17 (S) HD21 (S) 
HD30 (PM) HD33 (S) HD23 (S) 
HD31 (PM) HD34 (S) HD25 (S) 
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Non-Degenerate Degenerate Infiltrated 
HD44 (S) HD45 (S) HD26 (S) 
 
HD46 (S) HD36 (S) 
 
HD51 (S) HD49 (S) 
 
HD54 (S) HD50 (S) 
 
HD56 (S) HD52 (S) 
 
HD57 (S) HD53 (S) 
 
HD58 (S) HD66 (S) 
 
HD59 (S) HD79 (S) 
 
HD61 (S) 
 
 
HD63 (S) 
 
 
HD75 (S) 
 
Mean Ages (range); 
  
37 years (23-45) 38 years (23-52) 38 years (26-62) 
Table 4-1  cDNA Samples from Directly Extracted Nucleus Pulposus Cells used in qPCR 
Gene Expression Studies  
(S, Surgical; PM, Post Mortem).  Full details of samples used in this study can be found in 
Appendix 1 and details of histological grading of tissue samples can be found in Chapter 2, 
section 2.2.3. 
4.1.1.2 Target Genes 
9 target cytokines and 10 target chemokines were selected for investigation (see 
Chapter 3, section 3.3).  Associated receptors were also included in this study to 
investigate the potential of NP cells to respond to cytokine and chemokine 
signalling (Table 4-2).   
Cytokines & Receptors Chemokines & Receptors 
IL-1β 
 
CCL2 CCR1 
IL-6 IL-6R & gp130 CCL3 CCR2 
IL-16 CD4 CCL4 
 
IL-17D 
 
CCL5 
 
IL-18 
 
CCL7 
 
IL-20 
 
CXCL1 CXCR1 
TNF TNF-R55 & TNF-R75 CXCL2 CXCR2 
LIF LIFR CXCL3 
 
OSM 
 
CXCL8 
 
  
CX3CL1 CX3CR1 
Table 4-2  Cytokine and Chemokine Target Genes Investigated by qPCR in Directly 
Extracted Nucleus Pulposus Cells  
4.1.2 Methods 
Full details of methods used in this study are given in Chapter 2, sections; 
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• 2.1 Tissue Sample Processing 
• 2.2 Histology 
• 2.5 Quantitative Polymerase Chain Reaction 
4.1.3 Specific Objectives 
This chapter aimed to address the hypothesis that: 
Cytokine and chemokine expression is increased during degeneration and 
prolapse of the IVD. 
The specific objectives were: 
• To determine the cytokine and chemokine mRNA expression profile of NP 
cells derived from non-degenerate, degenerate and infiltrated human NP 
tissue 
• To identify differences in mRNA expression profile between non-
degenerate, degenerate and infiltrated study groups 
4.2 Results   
4.2.1 Cytokine mRNA Expression in Human Nucleus Pulposus Cells 
4.2.1.1 The Interleukins; IL-1β, IL-6, IL-16, IL-17D, IL-18, IL-20 
Relative IL-1β mRNA values for DE NP cells are shown in Figure 4-1A.  IL-1β 
mRNA was detected in 1/6 non-degenerate, 6/16 degenerate and 9/13 infiltrated 
samples.  The frequency of mRNA detection was increased in degenerate samples 
compared to non-degenerate, although this was not significant (P>0.05).  The 
frequency of mRNA detection was significantly increased in infiltrated samples 
compared to both non-degenerate (z value = 2.13; P<0.05) and degenerate (z 
value = 1.70; P<0.05), and relative mRNA expression level was also increased in 
infiltrated samples compared to both non-degenerate and degenerate however, this 
parameter was not significant (P>0.05).  
Relative IL-6 mRNA values for DE NP cells are shown in Figure 4-1B.  IL-6 mRNA 
was detected in 3/6 non-degenerate, 9/16 degenerate and 9/13 infiltrated samples.  
The frequency of mRNA detection was equivalent across study groups.  IL-6 
relative mRNA expression level was equivalent in non-degenerate and degenerate 
samples, but increased in infiltrated.  This increase was significant against 
degenerate (P=0.0014) samples, but not against non-degenerate (P>0.05).  
Relative IL-6R mRNA values for DE NP cells are shown in Figure 4-1C.  IL-6R 
mRNA was detected in 6/6 non-degenerate, 15/16 degenerate and 10/13 infiltrated 
samples.  The frequency of mRNA detection was equivalent across study groups.   
 1
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IL-6R relative mRNA expression level was significantly decreased in both 
degenerate and infiltrated samples compared to non-degenerate (P=0.0161 and 
P=0.0467 respectively).  Relative expression levels were equivalent in degenerate 
and infiltrated samples.   
Relative gp130 mRNA expression levels in DE NP cells are shown in Figure 4-2A.  
gp130 mRNA expression was detected in all samples investigated.  Relative mRNA 
expression levels were equivalent in non-degenerate, degenerate and infiltrated 
samples.  
Relative IL-16 mRNA expression in DE NP cells are shown in Figure 4-2B.  IL-16 
mRNA expression was detected in 6/6 non-degenerate, 15/16 degenerate and 
11/13 infiltrated samples.  The frequency of mRNA detection, and relative mRNA 
expression levels were equivalent between study groups.   
Relative CD4 mRNA expression in DE NP cells is shown in Figure 4-2C.  CD4 
mRNA expression was detected in 4/6 non-degenerate, 15/16 degenerate and 
12/13 infiltrated samples.  The frequency of mRNA detection was increased in both 
degenerate and infiltrated samples compared to non-degenerate, this difference 
was significant against degenerate (z value = 1.65; P<0.05), but not against 
infiltrated (P>0.05) samples.  CD4 relative mRNA expression level was equivalent 
across study groups.   
Relative IL-17D mRNA expression in DE NP cells is shown in Figure 4-3A.  IL-17D 
mRNA expression was detected in 3/6 non-degenerate, 11/16 degenerate and 7/13 
infiltrated samples.  The frequency of mRNA detection was equivalent across study 
groups.  IL-17D relative mRNA expression level was significantly decreased in 
degenerate samples compared to non-degenerate (P=0.0309).  Relative mRNA 
expression levels were equivalent in non-degenerate and infiltrated samples.     
Relative IL-18 mRNA expression in DE NP cells is shown in Figure 4-3B.  IL-18 
mRNA expression was detected in 2/6 non-degenerate, 1/16 degenerate and 3/13 
infiltrated samples.  The frequency of mRNA detection was decreased in 
degenerate samples compared to both non-degenerate and infiltrated samples, this 
was significant against non-degenerate (z value = 1.65; P<0.05), but not against 
infiltrated (P>0.05).  The frequency of mRNA detection between non-degenerate 
and infiltrated samples was equivalent.   
Relative IL-20 mRNA expression in DE NP cells is shown in Figure 4-3C.  IL-20 
mRNA expression was detected in 3/6 non-degenerate, 8/16 degenerate and 4/13
 1
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infiltrated samples.  The frequency of mRNA detection, and relative mRNA 
expression levels were equivalent across study groups.   
4.2.1.2 Other Cytokines; TNF, LIF, OSM 
Relative TNF mRNA expression in DE NP cells is shown in Figure 4-4A. TNF 
mRNA expression was detected in 5/6 non-degenerate, 9/16 degenerate and 8/13 
Infiltrated samples.  The frequency of mRNA detection was decreased in both 
degenerate and infiltrated samples compared to non-degenerate although these 
differences were not significant (P>0.05).  The frequency of mRNA detection was 
equivalent between degenerate and infiltrated samples.  TNF relative mRNA 
expression level was equivalent in non-degenerate and degenerate samples, but 
increased in infiltrated.  This increase was significant against degenerate samples 
(P=0.0028), but not non-degenerate (P>0.05).   
Relative TNF-R55 mRNA expression in DE NP cells is shown in Figure 4-4B.  TNF-
R55 mRNA expression was detected in 6/6 non-degenerate, 15/16 degenerate and 
10/13 infiltrated samples.  The frequency of mRNA detection was equivalent 
between non-degenerate and degenerate samples and decreased in infiltrated 
although these differences were not significant (P>0.05).  TNF-R55 relative mRNA 
expression level was increased in degenerate samples compared to both non-
degenerate and infiltrated samples.  This increase was significant against infiltrated 
samples (P=0.0092), but not against non-degenerate (P>0.05).  Expression levels 
between non-degenerate and infiltrated samples were equivalent.     
Relative TNF-R75 mRNA expression in DE NP cells is shown in Figure 4-4C.  TNF-
R75 mRNA expression was detected in 1/6 non-degenerate, 3/16 degenerate and 
4/13 infiltrated samples.  The frequency of mRNA detection was equivalent across 
study groups.  TNF-R75 relative mRNA expression level was increased in infiltrated 
samples compared to degenerate (P=0.0286).   
Relative LIF mRNA expression in DE NP cells is shown in Figure 4-5A.  LIF mRNA 
was detected in 6/6 non-degenerate, 16/16 degenerate and 11/13 infiltrated 
samples.  The frequency of mRNA detection was equivalent across study groups.  
LIF relative mRNA expression level was significantly decreased in degenerate 
samples compared to both non-degenerate (P=0.0301) and infiltrated samples 
(P=0.0256).  mRNA expression levels were equivalent between non-degenerate 
and infiltrated samples.    
Relative LIFR mRNA expression in DE NP cells is shown in Figure 4-5B.  LIFR 
mRNA expression was detected in only 1/35 samples investigated.   
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Relative OSM mRNA expression in DE NP cells is shown in Figure 4-5C.  OSM 
mRNA was detected in 2/6 non-degenerate, 4/16 degenerate and 3/13 infiltrated 
samples.  The frequency of mRNA detection, and relative mRNA expression levels 
were equivalent across study groups.   
4.2.2 Chemokine mRNA Expression in Human NP Cells 
4.2.2.1 C-C Chemokines; CCL2, CCL3, CCL4, CCL5, CCL7 
Relative CCL2 mRNA expression in DE NP cells is shown in Figure 4-6A.  CCL2 
mRNA expression was detected in 5/6 non-degenerate, 13/16 degenerate and 
13/13 infiltrated samples.  The frequency of mRNA detection was equivalent in non-
degenerate and degenerate samples but increased in infiltrated.  This difference 
was significant against degenerate (z value = 1.65; P<0.05), but not against non-
degenerate samples (P>0.05).  CCL2 mRNA expression level was significantly 
decreased in degenerate samples compared to both non-degenerate (P=0.0151) 
and infiltrated (P=0.0069).  Relative mRNA expression levels were equivalent in 
non-degenerate and infiltrated samples.  
Relative CCL3 mRNA expression in DE NP cells is shown in Figure 4-6B.  CCL3 
mRNA expression was detected in 2/6 non-degenerate, 8/16 degenerate and 10/13 
infiltrated samples.  The frequency of mRNA detection was equivalent between 
non-degenerate and degenerate study groups but increased in infiltrated.  This 
difference was significant against non-degenerate (z value = 1.83; P<0.05), but not 
against degenerate samples (P>0.05).  CCL3 relative mRNA expression level was 
equivalent in non-degenerate and degenerate samples but increased in infiltrated.  
This difference was significant against degenerate (P=0.0273), but not against non-
degenerate (P>0.05) samples.  
Relative CCL4 mRNA expression in DE NP cells is shown in Figure 4-6C.  CCL4 
mRNA was detected in 2/6 non-degenerate, 5/16 degenerate and 9/13 infiltrated 
samples.  The frequency of mRNA detection was equivalent in non-degenerate and 
degenerate samples but increased in infiltrated.  This difference was significant 
against degenerate (z value = 2.04; P<0.05), but not against non-degenerate 
samples (P>0.05).  CCL4 relative mRNA expression level was equivalent across 
study groups.  
Relative CCL5 mRNA expression in DE NP cells is shown in Figure 4-7A.  CCL5 
mRNA was detected in 3/6 non-degenerate, 10/16 degenerate and 9/13 infiltrated 
samples.  The frequency of mRNA detection was equivalent between non-
degenerate and degenerate study groups but increased in infiltrated, although this 
difference was not significant.  CCL5 relative mRNA expression level was 
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equivalent between non-degenerate and degenerate samples but increased in 
infiltrated.  This difference was significant against degenerate (P=0.0066), but not 
against non-degenerate samples (P>0.05).  
Relative CCL7 mRNA expression in DE NP cells is shown in Figure 4-7B.  CCL7 
mRNA expression was detected in 4/6 non-degenerate, 6/16 degenerate and 7/13 
infiltrated samples.  The frequency of mRNA detection, and relative mRNA 
expression levels were equivalent across study groups.  
Relative CCR1 mRNA expression in DE NP cells is shown in Figure 4-7C.  CCR1 
mRNA expression was detected in 2/6 non-degenerate, 8/16 degenerate and 7/13 
infiltrated samples.  The frequency of mRNA detection, and relative mRNA 
expression levels were equivalent across study groups.   
CCR2 mRNA expression was not detected in any of the 35 DE NP samples 
investigated.   
4.2.2.2 C-X-C Chemokines; CXCL1, CXCL2, CXCL3, CXCL8 
Relative CXCL1 mRNA expression in DE NP cells is shown in Figure 4-8A.  CXCL1 
mRNA expression was detected in 4/6 non-degenerate, 7/16 degenerate and 8/13 
infiltrated samples.  The frequency of mRNA detection was equivalent between 
non-degenerate and infiltrated study groups but decreased in degenerate, although 
this difference was not significant.  Relative mRNA expression levels were also 
equivalent between non-degenerate and infiltrated samples but decreased in 
degenerate.  This difference was significant against infiltrated samples (P=0.0270) 
but not against non-degenerate (P>0.05).  
Relative CXCL2 mRNA expression in DE NP cells is shown in Figure 4-8B.  CXCL2 
mRNA expression was detected in 5/6 non-degenerate, 11/16 degenerate and 9/13 
infiltrated samples.  The frequency of mRNA detection was equivalent across study 
groups.  CXCL2 relative mRNA expression level was significantly decreased in 
degenerate samples compared to both non-degenerate (P=0.0207), and infiltrated 
(P=0.0061) samples.  Relative mRNA expression levels were equivalent between 
non-degenerate and infiltrated samples. 
Relative CXCL3 mRNA expression in DE NP cells is shown in Figure 4-8C.  CXCL3 
mRNA expression was detected in 4/6 non-degenerate, 7/16 degenerate and 8/13 
infiltrated samples.  The frequency of mRNA detection was equivalent between 
non-degenerate and infiltrated study groups but decreased in degenerate, although 
this difference was not significant.  Relative mRNA expression levels were also 
equivalent between non-degenerate and infiltrated samples but decreased in 
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degenerate.  This difference was significant against infiltrated (P=0.0361), but not 
against non-degenerate (P>0.05) samples. 
Relative CXCL8 mRNA expression in DE NP cells is shown in Figure 4-9A.  CXCL8 
mRNA expression was detected in 5/6 non-degenerate, 16/16 degenerate and 
12/13 infiltrated samples.  The frequency of mRNA detection was equivalent 
between non-degenerate and infiltrated samples but increased in degenerate.  This 
difference was significant against non-degenerate samples (z value = 1.67; 
P<0.05), but not against infiltrated (P>0.05).  CXCL8 relative mRNA expression 
level was equivalent in non-degenerate and degenerate samples but increased in 
infiltrated.  This difference was significant against degenerate samples (P=0.0194), 
but not against non-degenerate (P>0.05). 
Relative CXCR1 mRNA expression in DE NP cells is shown in Figure 4-9B.  
CXCR1 mRNA was detected in 1/6 non-degenerate, 3/16 degenerate and 4/13 
infiltrated samples.  The frequency of mRNA detection, and relative mRNA 
expression levels were equivalent across study groups.   
Relative CXCR2 mRNA expression in DE NP cells is shown in Figure 4-9C.  
CXCR2 mRNA was detected in 0/6 non-degenerate, 3/16 degenerate and 5/13 
infiltrated samples.  The frequency of mRNA detection was equivalent between 
non-degenerate and degenerate study groups but increased in infiltrated.  This 
difference was significant against non-degenerate samples (z value = 1.77; 
P<0.05), but not against degenerate (P>0.05).  CXCR2 relative mRNA expression 
level was equivalent in degenerate and infiltrated samples.  
4.2.2.3 C-X3-C Chemokine; CX3CL1 
Relative CX3CL1 mRNA expression in DE NP cells is shown in Figure 4-10A.  
CX3CL1 mRNA expression was detected in 6/6 non-degenerate, 13/16 degenerate 
and 8/13 infiltrated samples.  The frequency of mRNA detection was equivalent 
between non-degenerate and degenerate study groups but decreased in infiltrated.  
This difference was significant against non-degenerate samples (z value = 1.77; 
P<0.05) but not against degenerate (P>0.05).  CX3CL1 relative mRNA expression 
level was decreased in degenerate samples compared to both non-degenerate and 
infiltrated samples.  This difference was significant against non-degenerate 
samples (P=0.0127) but not against infiltrated (P>0.05).  Relative mRNA 
expression levels were equivalent in non-degenerate and infiltrated samples.   
Relative CX3CR1 mRNA expression in DE NP cells is shown in Figure 4-10B.  
CX3CR1 mRNA expression was detected in 0/6 non-degenerate, 2/16 degenerate 
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and 1/13 infiltrated samples.  Comparative analysis of expression between study 
groups was not possible for this target due to low detection rates.   
4.2.3 Summary of Results 
The results presented in this chapter are summarised in Table 4-3 and Table 4-4. 
Target Non-Degenerate Degenerate Infiltrated  
Altered mRNA 
Expression Level 
IL-1β 1/6  6/16  9/13
¤¥
  
IL-6 3/6 9/16 9/13  ↑
¥
 
IL-6R 6/6  15/16  10/13 ↓*↓
¤
  
gp130 6/6 16/16 13/13  
IL-16 6/6 15/16 11/13  
CD4 4/6 15/16* 12/13  
IL-17D 3/6 11/16  7/13 ↓* 
IL-18 2/6 1/16* 3/13  
IL-20 3/6 8/16 4/13  
TNF-α 5/6 9/16 8/13 ↑
¥
 
TNF-R55 6/6 15/16 10/13 ↓
¥
 
TNF-R75 1/6 3/16 4/13 ↑
¥
 
LIF 6/6 16/16 11/13 ↓*↑
¥
 
LIFR 1/6 0/16 0/13  
OSM 2/6 4/16 3/13  
Table 4-3  Summary of Cytokine mRNA Expression in Directly Extracted Nucleus Pulposus 
Cells from Non-Degenerate, Degenerate and Infiltrated Study Groups 
Numbers represent proportions of DE NP cell samples that were positive for mRNA 
expression.  ↑, increase in relative mRNA expression level; ↓ decrease in relative mRNA 
expression level; *, significant difference between degenerate and non-degenerate study 
groups (P<0.05); ¤, significant difference between infiltrated and non-degenerate study 
groups (P<0.05); ¥, significant difference between infiltrated and degenerate study groups 
(P<0.05) 
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Target Non-Degenerate Degenerate Infiltrated 
Altered mRNA 
Expression Level 
CCL2 5/6 13/16 13/13
¥
 ↓*↑
¥
 
CCL3 2/6 8/16 +10/13
¤
  ↑
¥
 
CCL4 2/6 15/16 9/13
¥
  
CCL5 3/6 10/16 9/13 ↑
¥
 
CCL7 4/6 6/16 7/13  
CCR1 2/6 8/16 7/13  
CCR2 0/6 0/16 0/13  
CXCL1 4/6 7/16 8/13 ↑
¥
 
CXCL2 5/6 11/16 9/13 ↓*↑
¥
 
CXCL3 4/6 7/16 8/13 ↑
¥
 
CXCL8 5/6 16/16* 12/13 ↑
¥
 
CXCR1 1/6 3/16 4/13  
CXCR2 0/6 3/16 5/13
¤
  
CX3CL1 6/6 13/16 8/13
¤
 ↓* 
CX3CR1 0/6 2/16 1/13  
Table 4-4  Summary of Chemokine mRNA Expression in Directly Extracted Nucleus 
Pulposus Cells from Non-Degenerate, Degenerate and Infiltrated Study Groups 
Numbers represent proportions of DE NP cell samples that were positive for mRNA 
expression.  ↑, increase in relative mRNA expression level; ↓ decrease in relative mRNA 
expression level; *, significant difference between degenerate and non-degenerate study 
groups (P<0.05); ¤, significant difference between infiltrated and non-degenerate study 
groups (P<0.05); ¥, significant difference between infiltrated and degenerate study groups 
(P<0.05)
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4.3  Discussion 
4.3.1 Cytokines 
The objective of these investigations was to identify differentially expressed 
cytokines and chemokines in NP cells derived from non-degenerate, degenerate 
and infiltrated human NP tissue samples.     
The non-degenerate study group was characterised by gene expression of 
numerous cytokines, particularly IL-6, IL-16, IL-17D, IL-20, TNF-α and LIF that were 
detected at high frequencies in DE NP cells derived from non-degenerate IVDs.  
However, gene expression of all targets investigated was confirmed in non-
degenerate samples indicating a diverse cytokine expression profile.  Where 
investigated, associated receptor gene expression was also confirmed in non-
degenerate samples, with the exception of LIFR that was only detected in one 
sample (non-degenerate) of the 35 investigated, indicating a cytokine signalling 
network in these cells. 
Gene expression of the same cytokines and receptors identified in the non-
degenerate study group were confirmed in the degenerate, although the expression 
pattern was altered for some targets.  Comparative analysis identified five cytokines 
with differential expression patterns; IL-1β, IL-17D, IL-18, TNF-α and LIF.  IL-1β 
gene expression was not detected at high frequencies in non-degenerate or 
degenerate samples although a trend of up-regulated frequency was observed in 
degenerate samples.  Up-regulation of IL-1β expression has been described 
previously in the degenerate IVD (Le Maitre et al., 2005; Le Maitre et al., 2007d) 
and whilst the findings here are not significant this may be due to the comparisons 
made being between prolapsed non-degenerate and prolapsed degenerate study 
groups, where non-prolapsed samples were used in previous investigations by Le 
Maitre et al. (2005 & 2007d).  With the exception of IL-1β, differentially expressed 
cytokine targets were down-regulated in degeneration, IL-17D, IL-18 and LIF 
significantly so.  This was unexpected and in some cases conflicted with data 
generated in previous preliminary investigations (see Chapter 3, section 3.2) where 
IL-17D and IL-18 expression was significantly up-regulated in moderately 
degenerate samples compared to mildly degenerate.  IL-17D protein expression 
has been reported previously to be up-regulated in degenerate human IVDs and 
absent or present at very low concentration, in control IVD tissues (Shamji et al., 
2010).  Here, gene expression was detected in 50% of non-degenerate samples 
and expression levels in degenerate samples were decreased in comparison.  
These differences may be accounted for by the gene expression profile observed 
here not being an accurate reflection of protein expression pattern, or may be 
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associated with the pathology of prolapse rather than degeneration, since non-
prolapsed samples were used in studies by Shamji et al. (2010).  IL-18 detection 
frequencies were low across all study groups, therefore whilst the down-regulation 
observed was statistically significant, in light of the low detection rates it is not 
possible to conclude that IL-18 down-regulation is a feature of degeneration.  Our 
data indicates that TNF-α gene expression is down-regulated in degenerate IVDs 
compared to non-degenerate although this is not a significant finding.  This conflicts 
with previous gene expression studies that have demonstrated up-regulation of 
TNF-α in the degenerate human IVD compared to the normal (Le Maitre et al., 
2007d; Tschoeke et al., 2008) and with data generated in our previous preliminary 
investigation (Chapter 3, section 3.2.1.7) that indicated expression was up-
regulated in line with increasing disease severity.  Again this difference may be 
related to the use of prolapsed tissue in this study.  Previously Ahn et al. (2002) 
investigated TNF-α mRNA expression in 23 prolapsed IVD tissue samples and 
reported 65% of samples investigated exhibited expression.  Here, 33 of the 35 
samples investigated were from prolapsed IVDs and 21 of these samples were 
positive for TNF-α mRNA, equating to 64% of samples investigated.  Hence, our 
data confirms the previous report of TNF-α expression in prolapsed IVDs (Ahn et 
al., 2002) and further, indicates that a differential expression profile exists within 
these samples dependent on degenerative tissue changes, but that this profile is 
not the same as the profile observed in non-prolapsed degenerate tissues.   
LIF was identified in our previous preliminary investigation as a novel IVD cytokine 
(Chapter 3, section 3.2.1.9) and this is the first report of differential expression of 
this cytokine in non-degenerate and degenerate IVDs.  LIF expression has been 
identified previously in human articular chondrocytes (Sandell et al., 2008) and is 
found at elevated levels in the synovial fluid of RA sufferers (Okamoto et al., 1997) 
although its role in the pathogenesis of RA is not well understood.    
Comparative analysis of receptor gene expression between non-degenerate and 
degenerate study groups identified two differentially expressed target genes, IL-6R 
and CD4.  These findings may indicate alterations in NP cell sensitivity toward the 
cytokines, IL-6 and IL-16 in degeneration.  IL-6R expression was down-regulated 
whilst CD4 expression was up-regulated.  IL-6R expression has been identified 
previously by IHC in prolapsed IVD tissue (Specchia et al., 2002).  Further, this 
study by Specchia et al. (2002) investigated IL-6R expression in non-degenerate, 
non-prolapsed IVD tissue and found that IL-6R was not expressed in these 
samples.  In this study IL-6R gene expression was detected in all non-degenerate 
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samples investigated, two of which were derived from non-prolapsed, non-
degenerate post-mortem IVD tissue.  This would indicate that the receptor is 
expressed in non-degenerate IVDs.  The ligand for this receptor, IL-6, was detected 
frequently in non-degenerate and degenerate IVDs (>50%) however, since receptor 
expression was down-regulated in degeneration NP cell sensitivity to this cytokine 
may be decreased in degeneration.  Conversely, CD4 - the receptor for IL-16 
(Cruikshank et al., 2000) was up-regulated in degenerate samples compared to 
non-degenerate.  IL-16 gene expression was detected frequently in non-
degenerate and degenerate samples (>94%) and up-regulated receptor expression 
indicates increased NP cell sensitivity to this cytokine in degeneration.  Both IL-16 
and CD4 are novel IVD targets identified in our previous preliminary investigation 
(Chapter 3, section 3.2.1.3) and data generated in this study confirms our previous 
findings of expression by DE NP cells.  In this investigation, our methodologies for 
sample categorisation were amended in order to exclude samples contaminated 
with infiltrating leukocytes from the non-degenerate and degenerate study groups 
(see Chapter 2, section 2.2.3.1).  In light of the sample categorisation used here, 
data generated would indicate NP cell expression of CD4.  However, whilst all non-
degenerate samples were ligand (IL-16) positive only four of the six non-
degenerate samples were receptor, CD4, positive.  The two negative samples were 
non-degenerate, non-prolapsed post-mortem tissue and hence it remains to be 
resolved whether the CD4 gene expression observed here in surgical tissue 
samples relates to contaminating T lymphocyte expression, if perhaps the numbers 
of infiltrating cells are very small and imperceptible by our categorisation strategy.          
Gene expression of the same cytokines and receptors identified in the non-
degenerate study groups were confirmed in infiltrated.  Comparative analysis 
identified few differences in target cytokine expression - only IL-1β was significantly 
altered between study groups.  IL-1β mRNA expression was detected more 
frequently in infiltrated samples than in non-degenerate and degenerate samples 
although it’s unknown from these investigations whether this increased detection is 
due to NP cell expression and potentially a factor in the mechanism of leukocyte 
recruitment or due to leukocyte expression of IL-1β.  Investigations into IL-1β gene 
expression in the prolapsed IVD have reported 71% of samples investigated (n=9) 
were IL-1β mRNA positive (Le Maitre et al., 2007d).  This is comparable to our 
findings here in the infiltrated study group where 69% of samples investigated 
(n=11) were IL-1β positive, although overall we report a lower frequency of IL-1β 
detection in prolapsed samples with 16 out of the 33 investigated being mRNA 
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positive (48%).  Interestingly, the study by Le Maitre et al. (2007d) investigated IL-
1β mRNA expression in degenerate samples (n=22) and reported IL-1β expression 
in 100% of these whilst in non-degenerate samples expression was detected in 
63% of samples investigated (n=8).  Here only 38% of degenerate samples and 
17% of non-degenerate samples were IL-1β mRNA positive.   
Cytokine receptor gene expression was also similar between non-degenerate and 
infiltrated samples – only two differentially expressed cytokine receptor genes were 
identified; IL-6R and CD4.  IL-6R gene expression was down-regulated in infiltrated 
samples similarly to the down-regulation observed in degenerate samples and 
again this may indicate decreased sensitivity to IL-6.  CD4 gene expression was 
up-regulated in infiltrated samples similarly to the up-regulation observed in 
degenerate samples, although the increase was not significant in infiltrated 
samples.  Again, this may indicate an increased sensitivity to IL-16 signalling in 
infiltrated samples.  In contrast to comparative analysis between non-degenerate 
and degenerate study groups, IL-6 and TNF-α gene expression were up-regulated 
in infiltrated samples compared to non-degenerate.     
4.3.2 Chemokines 
Comparative analysis between non-degenerate and infiltrated study groups 
revealed a trend of up-regulated chemokine expression in infiltrated samples.  The 
non-degenerate study group was characterised by gene expression of numerous 
chemokines, particularly CCL2, CCL5, CCL7, CXCL1, CXCL2, CXCL3, CXCL8 and 
CX3CL1 that were detected at high frequencies in DE NP cells derived from non-
degenerate IVDs.  However, gene expression of all targets investigated was 
confirmed in non-degenerate samples indicating a diverse chemokine expression 
profile for these cells.  Receptor gene expression was also confirmed in non-
degenerate samples for CCR1 and CXCR1 indicating an active chemokine 
signalling network through these receptors in DE NP cells from the non-degenerate 
IVD.   
Gene expression of the same chemokines and receptors identified in the non-
degenerate study group was confirmed in the degenerate, alongside additional 
receptor gene expression detection for CXCR2 and CX3CR1.  Comparative 
analysis between non-degenerate and degenerate study groups revealed six 
differentially expressed chemokine targets; CCL2, CXCL1, CXCL2, CXCL3, CXCL8 
and CX3CL1.  With the exception of CXCL8, differentially expressed chemokine 
targets were down-regulated in degeneration, CCL2, CXCL2 and CX3CL1 
significantly so.  This was unexpected and in some cases conflicted with data 
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generated in previous preliminary investigations (see Chapter 3, section 3.23.2) 
where CXCL1 and CXCL3 expression was significantly up-regulated in NP cells 
from moderately degenerate samples compared to mildly degenerate.   
CCL2 gene expression was detected at high frequencies in both non-degenerate 
and degenerate samples with decreased relative expression levels seen in 
degenerate samples.  CCL2 protein detection has been reported previously in 
conditioned media from non-degenerate NP tissue explants (Burke et al., 2002), 
where CCL2 protein was detected in media from 4 out of 10 (40%) explants 
investigated.  Here, CCL2 gene expression was detected in 5 out of 6 (83%) non-
degenerate samples investigated and this increase may be related to the non-
degenerate samples used here being also prolapsed in 4 out of the 6 samples.  
CCL2 gene expression has been investigated previously in monolayer cultured 
primary human articular chondrocytes, where CCL2 gene expression was detected 
in cultures derived from OA sufferers but not from control specimens (Yuan et al., 
2001; Sandell et al., 2008).   
CXCL1 gene expression has been identified previously in prolapsed NP tissue 
(Kawaguchi et al., 2002), CXCL2, CXCL3 and CX3CL1 were identified in our 
previous preliminary investigation as novel IVD chemokines (Chapter 3, section 
3.2.2.2).  This is the first report of differential expression of these chemokines in 
non-degenerate and degenerate IVDs.  CXCL1, CXCL2, CXCL3 and CX3CL1 gene 
expression has been identified previously in cultured primary human chondrocytes 
derived from both normal articular cartilage and that of OA sufferers (Sandell et al., 
2008) with expression of CXCL1 and CXCL3 being increased in primary 
chondrocytes derived from OA sufferers compared to those from normal tissue 
donors (Sandell et al., 2008).  CXCL8 was the only chemokine that was up-
regulated in degenerate samples compared to non-degenerate.  CXCL8 protein 
production has been identified previously by ELISA in conditioned media from non-
degenerate NP tissue explants (Burke et al., 2002), where CXCL8 was produced 
by 2 out of 10 (20%) explants investigated.  Here, CXCL8 gene expression was 
detected in 5 out of 6 (83%) non-degenerate samples and this increase may again 
be related to the pathology of prolapse rather than degeneration.  CXCL8 gene 
expression has been identified in primary human articular chondrocytes and 
expression is increased in those derived from OA sufferers compared to normal 
tissue donors (Sandell et al., 2008).       
Gene expression of the same chemokines and receptors identified in the non-
degenerate study group were confirmed in the infiltrated, alongside additional 
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receptor gene expression detection for CXCR2 and CX3CR1.  Comparative 
analysis between non-degenerate and infiltrated study groups revealed nine 
differentially expressed chemokine targets; CCL2, CCL3, CCL4, CCL5, CXCL1, 
CXCL2, CXCL3, CXCL8 and CX3CL1.  With the exception of CX3CL1 differentially 
expressed chemokine targets were up-regulated in infiltrated samples, although 
only CCL3 and CX3CL1 expression was significantly altered compared to non-
degenerate samples.  CCL2 protein production has been identified previously by 
ELISA in the conditioned media of sequestered prolapsed NP tissue explants 
(Burke et al., 2002), where CCL2 was detected in conditioned media from 8 out of 8 
explants investigated.  Here, CCL2 gene expression was detected similarly in all 
infiltrated samples investigated (13 out of 13), although this finding directly 
contradicts a previous investigation into CCL2 gene expression in prolapsed IVD 
tissue where 8 out of 8 tissue samples investigated were negative for CCL2 gene 
expression (Kawaguchi et al., 2002).  CCL3 and CCL4 were identified as novel IVD 
chemokines in previous preliminary investigations (see Chapter 3, section 3.2.2.1) 
and this is the first report of differential expression of these chemokines in non-
degenerate, degenerate and infiltrated samples (Wang et al., 2012).  CCL3 gene 
expression was detected in 10 out of 13 infiltrated samples (77%) and CCL4 in 9 
out of 13 infiltrated samples (69%) although our report of CCL3 expression directly 
contradicts a previous study where 8 out of 8 prolapsed tissue samples 
investigated were negative for CCL3 gene expression (Kawaguchi et al., 2002).  
CCL5 gene expression has been identified previously in prolapsed IVDs (Ahn et al., 
2002; Kawaguchi et al., 2002), with reports of 4 out of 23 samples (17%) (Ahn et 
al., 2002) and 7 out of 8 samples (88%) (Kawaguchi et al., 2002) investigated being 
positive for CCL5 gene expression.  In this study, 9 out of 13 (69%) infiltrated 
samples investigated were positive for CCL5 gene expression.  CXCL1 gene 
expression has been identified previously in the prolapsed IVD (Kawaguchi et al., 
2002), where 5 out of 8 (63%) samples investigated were positive for CXCL1 gene 
expression.  In this study, 8 out of 13 (62%) of infiltrated samples investigated were 
positive for CXCL1 gene expression.   CXCL2 and CXCL3 were identified as novel 
IVD chemokines in previous preliminary investigations (see Chapter 3, section 
3.2.2.2) and this is the first report of differential expression of these chemokines in 
non-degenerate, degenerate and infiltrated IVDs.  CXCL8 gene expression has 
been identified previously in the prolapsed IVD (Ahn et al., 2002), where 16 out of 
23 (70%) samples investigated were positive for CXCL8 gene expression.  Here, 
12 out of 13 infiltrated samples (92%) investigated were positive for CXCL8 gene 
expression, although our report conflicts directly with a previous investigation into 
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CXCL8 gene expression in prolapsed NP tissue where 8 out of 8 samples 
investigated were CXCL8 negative (Kawaguchi et al., 2002).  CX3CL1 was 
identified as a novel IVD chemokine in our previous preliminary investigation (see 
Chapter 3, section 3.2.2.2) and this is the first report of differential expression of 
this chemokine in non-degenerate, degenerate and infiltrated NP samples.                  
Again, data generated here must be interpreted with caution.  Considering the non-
degenerate study group, four of the six samples are derived from prolapsed IVDs.  
There have been several previous reports of increased cytokine and chemokine 
expression in prolapsed NP tissue (Kang et al., 1996; Ahn et al., 2002; Burke et al., 
2002; Kawaguchi et al., 2002; Specchia et al., 2002; Le Maitre et al., 2007d; Shamji 
et al., 2010) and so data generated here cannot be relied upon to be an accurate 
representation of the cytokine and chemokine expression profile of a non-
degenerate IVD.  Considering the degenerate study group, previous preliminary 
investigations (see Chapter 3, section 3.2) indicated a trend of cytokine and 
chemokine expression up-regulation with increasing severity of degenerative tissue 
changes.  This was expected to translate here into a trend of up-regulation when 
considering degenerate samples to non-degenerate.  However, this was not the 
case and may result from difficulties in classifying samples as either non-
degenerate or degenerate.  It was noted on histological examination of matched 
tissue sections that degenerative changes were not consistent throughout tissue 
samples but rather present as ‘degenerative lesions’ surrounded by histologically 
normal tissue.  Upon this finding, multiple sections from each matched tissue 
sample were examined and corresponding cDNA samples were classified as 
‘degenerate’ on the finding of degenerative lesions in any area of the tissue 
sample.  Assuming that this variability was equivalent in adjacent tissue from which 
cell samples were extracted, it’s impossible to know what percentage of cells 
derived from any tissue sample are from a degenerate lesion or a histologically 
normal tissue region.  This factor may account for variability in expression levels of 
target cytokines and chemokines in the degenerate study group, and since data 
spread is a key parameter in statistical analysis this may directly affect the ability to 
identify significant differences in expression patterns.   
Infiltrated samples were excluded from comparative analysis between non-
degenerate and degenerate study groups on the basis of infiltration indicating 
active resorption.  However, spontaneous resorption may not be the only feature of 
prolapse and so data generated in non-degenerate and degenerate study groups 
may be skewed on account of pathological changes related to prolapse rather than 
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degeneration.  This scenario is reversed when considering the infiltrated study 
group, where variation in the severity of degenerative tissue changes between 
samples may account for some of the variation in observed expression levels.  
Whilst the expected up-regulatory trend of cytokine and chemokine expression was 
observed for the infiltrated study group, it remains unclear whether increased 
expression results from native NP cells or from the infiltrating leukocytes.  In the 
case of IL-6, TNF-α, CCL3 and CXCL8, expression levels in infiltrated samples 
were increased in relation to all other samples.  This would indicate that infiltration 
is a single factor associated with up-regulation, and provides evidence in support of 
contributing leukocyte production of these targets within the IVD.  
Of note, upon histological examination of matched tissue sections, infiltrating cells 
were identified in tissue samples from intact IVDs (protrusion type of prolapse).  
This was unexpected as it was thought that AF/CEP rupture and exposure of NP 
tissue to the external environment of the IVD would need to occur to trigger 
leukocyte infiltration.  One possible explanation for this finding is that NP tissue 
displaced down a radial fissure may eventually come into contact with the capillary 
network of the most outer AF.  This would provide a direct route between blood 
circulation and NP tissue for circulating leukocyte entry into the intact IVD.  
Resolution without medical intervention has been described previously for 
protrusion type IVD prolapse, retraction of the AF is postulated to mediate this 
process (Guinto et al., 1984; Teplick & Haskin, 1985).  Based on our observations, 
leukocyte mediated breakdown of displaced NP tissue within the intact IVD could 
occur and may represent a mechanism in the process of protrusion resolution.    
4.3.3 Summary 
NP cells derived from prolapsed IVDs are characterised by an extensive and 
diverse cytokine, chemokine and receptor gene expression profile.  Cells derived 
from degenerate prolapsed tissue exhibit significant differential expression patterns 
of cytokines and chemokines to those derived from non-degenerate prolapsed 
tissue; including down-regulation of IL-6R, IL-17D, LIF, CCL2, CXCL2 and CX3CL1, 
and up-regulation of IL-1β, CD4, and CXCL8.  Cells derived from infiltrated 
prolapsed tissue exhibit increased cytokine and chemokine gene expression 
compared to non-degenerate and degenerate prolapsed tissue including up-
regulation of IL-1β, IL-6, TNF-α, CCL3 and CXCL8.         
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5 Cytokine  and  Chemokine  Protein  
Production  in  the  Intervertebral  
Disc 
 173 
 
5.1 Introduction 
This chapter describes investigations by IHC into the production and localisation of 
cytokines, chemokines and their receptors in human NP tissue.  Further, 
microscopic evaluation of immunohistochemical and histological stains is used to 
determine the relationship between production of target molecules and the grade of 
degeneration in tissue samples.   
Targets investigated are the cytokines; IL-1β and IL-16, the chemokines; CCL2, 
CCL3, CCL4, CCL7 and CXCL8, and the receptors; CD4, CCR1, CXCR1 and 
CXCR2 (see Chapter 3, section 0).       
5.1.1 Study Design 
5.1.1.1 Human Intervertebral Disc Tissue Samples 
30 FFPE human IVD tissue sections were investigated for each target antigen, with 
the exception of IL-1β where 40 tissue sections were investigated.  Sections for 
each target antigen were run together and alongside 15 matched isotype control 
sections (20 for IL-1β).  For each IHC section investigated, an adjacent tissue 
section was stained with H&E for evaluation of degenerative tissue changes.  
Histological grades of adjacent sections for each IHC run are given in Table 5-1. 
5.1.2 Methods  
Full details of methods used in this study are given in Chapter 2, sections; 
• 2.1 Tissue Sample Processing 
• 2.2 Histology 
• 2.3 Immunohistochemistry  
5.1.3 Specific Objectives 
This chapter aimed to address the hypothesis that: 
Cytokines and chemokines are produced by the native cells of the IVD and 
production is increased during degeneration and prolapse of the IVD. 
The specific objectives were: 
• To confirm protein expression of target cytokines, chemokines and 
receptors in human NP tissue  
• To localise protein expression of target cytokines, chemokines and 
receptors to cells of origin within human NP tissue 
• To determine the relationship between production of target cytokines, 
chemokines and receptors and histologically determined grade of tissue 
degeneration 
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5.2 Results  
5.2.1 Cytokine Expression in Nucleus Pulposus Tissue  
5.2.1.1 IL-1β Expression 
IL-1β immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=6) degenerate (n=20), and infiltrated (n=14) IVDs.  NP cell 
immunopositivity was observed in all tissue sections.  In all instances staining was 
localised to the perinuclear region of NP cells (Figure 5-1). 
IL-1β immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-2A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 32.94%.  Increased immunopositivity 
was detected in tissue sections from degenerate IVDs, median 45.33%, and 
infiltrated IVDs, median 46.08%, although these differences were not significant 
(P>0.05).  Regression analysis considering IL-1β immunopositivity and 
histologically determined grade of degeneration confirms that no linear relationship 
exists between IL-1β immunopositivity and grade of degeneration in tissue sections 
from human IVDs (P>0.05; Figure 5-2B). 
5.2.1.2 IL-16 Expression 
IL-16 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=4) degenerate (n=15), and infiltrated (n=11) IVDs.  NP cell 
immunopositivity was observed in all tissue sections with the exception of 1 non-
degenerate.  In all instances staining was localised to the perinuclear region of NP 
cells (Figure 5-3).   
IL-16 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-4A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 28.87%.  Increased immunopositivity 
was detected in tissue sections from degenerate IVDs, median 36.10%, and 
infiltrated IVDs, median 35.15%, although these differences were not significant  
(P>0.05).  Regression analysis considering IL-16 immunopositivity and 
histologically determined grade of degeneration confirms that no linear relationship 
exists between IL-16 immunopositivity and grade of degeneration in tissue sections 
from human IVDs (P>0.05; Figure 5-4B). 
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5.2.2 Chemokine Expression in Nucleus Pulposus Tissue 
5.2.2.1 CCL2 Expression 
CCL2 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=5) degenerate (n=14), and infiltrated (n=11) IVDs.  NP cell 
immunopositivity was observed in all tissue sections with the exception of 1 non-
degenerate.  In all instances staining was localised to the perinuclear region of NP 
cells (Figure 5-5).   
CCL2 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-6A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 25.38%.  Increased immunopositivity 
was detected in tissue sections from degenerate IVDs, median 58.37%, and 
infiltrated IVDs, median 57.77%, although these differences were not significant 
(P=0.0526 against degenerate tissue sections, P=0.0870 against infiltrated).  
Regression analysis considering CCL2 immunopositivity and histologically 
determined grade of degeneration confirms a positive linear relationship exists 
between CCL2 immunopositivity and grade of degeneration in tissue sections from 
human IVDs (P=0.0067; Figure 5-6B). 
5.2.2.2 CCL3 Expression  
CCL3 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=5) degenerate (n=14), and infiltrated (n=11) IVDs.  NP cell 
immunopositivity was observed in each tissue section with the exception of 1 from 
the non-degenerate study group.  In all instances staining was localised to the 
perinuclear region of NP cells (Figure 5-7).   
CCL3 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-8A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 15.50%.  Increased immunopositivity 
was detected in tissue sections from degenerate IVDs, median 37.00%, and 
infiltrated IVDs, median 40.38%, compared to non-degenerate.  This difference was 
significant against degenerate tissue sections (P=0.0186) but not infiltrated 
(P>0.05).  Regression analysis considering CCL3 immunopositivity and 
histologically determined grade of degeneration confirms a positive linear 
relationship exists between CCL3 immunopositivity and grade of degeneration in 
tissue sections from human IVDs (P=0.0171; Figure 5-8B). 
5.2.2.3 CCL4 Expression  
CCL4 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=6) degenerate (n=13), and infiltrated (n=11) IVDs.  NP cell
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immunopositivity was observed in each tissue section.  In all instances staining was 
localised to the perinuclear region of NP cells as shown in Figure 5-9.   
CCL4 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-10A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 12.39%.  Increased immunopositivity 
was detected in tissue sections from degenerate IVDs, median 23.94%, and 
infiltrated IVDs, median 14.90%, compared to non-degenerate.  This difference was 
significant against degenerate tissue sections (P=0.0196), but not infiltrated 
(P>0.05).  Regression analysis considering CCL4 immunopositivity and 
histologically determined grade of degeneration confirms that no linear relationship 
exists between CCL4 immunopositivity and grade of degeneration in tissue 
sections from human IVDs (P>0.05; Figure 5-10B). 
5.2.2.4 CCL7 Expression  
CCL7 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=5) degenerate (n=14), and infiltrated (n=11) IVDs.  NP cell 
immunopositivity was observed in all tissue sections with the exception of 2 from 
the non-degenerate study group.  In all instances staining was localised to the 
perinuclear region of NP cells as shown in Figure 5-11.   
CCL7 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-12A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 5.769%.  Significantly increased 
immunopositivity was detected in tissue sections from degenerate IVDs, median 
16.06% (P=0.0288) and infiltrated IVDs, median 21.62% (P=0.0348), compared to 
non-degenerate.  Regression analysis considering CCL7 immunopositivity and 
histologically determined grade of degeneration indicates a linear relationship 
exists between CCL7 immunopositivity and grade of degeneration in tissue 
sections from human IVDs although this was not significant (P=0.0600; Figure 5-
12B).   
5.2.2.5 CXCL8 Expression  
CXCL8 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=5) degenerate (n=14), and infiltrated (n=11) IVDs.  Immunopositivity 
was observed in all tissue sections with the exception of 2 from the degenerate 
study group.  In all instances staining was localised to the perinuclear region of NP 
cells (Figure 5-13).   
CXCL8 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-14A.  Immunopositivity was detected in tissue
 1
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sections from non-degenerate IVDs, median 10.00%.  Significantly increased 
immunopositivity was detected in tissue sections from degenerate IVDs, median 
40.55% (P=0.0287) and infiltrated IVDs, median 27.04% (P=0.0349), compared to 
non-degenerate.  Regression analysis considering CXCL8 immunopositivity and 
histologically determined grade of degeneration confirms a positive linear 
relationship exists between CXCL8 immunopositivity and grade of degeneration in 
tissue sections from human IVDs (P=0.0067; Figure 5-14B).  
5.2.3 Receptor Expression in NP Tissue  
5.2.3.1 CD4 Expression 
CD4 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=3) degenerate (n=16), and infiltrated (n=11) IVDs.  NP cell 
immunopositivity was observed in each tissue section.  In all instances staining was 
localised to the perinuclear region of NP cells (Figure 5-15).  
CD4 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-16A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 16.67%.  Significantly increased 
immunopositivity was detected in tissue sections from degenerate IVDs, median 
36.92% (P=0.0146) and infiltrated IVDs, median 54.38% (P=0.0098), compared to 
non-degenerate.  Immunopositivity in infiltrated IVDs was also seen to be increased 
compared to degenerate (P=0.0228).  Regression analysis considering CD4 
immunopositivity in NP cells and histologically determined grade of degeneration 
confirms that no linear relationship exists between CD4 immunopositivity grade of 
degeneration in tissue sections from human IVDs (P>0.05; Figure 5-16B). 
5.2.3.2 CCR1 Expression 
CCR1 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=3) degenerate (n=16), and infiltrated (n=11) IVDs.  NP cell 
immunopositivity was observed in each tissue section.  In all instances staining was 
localised to the perinuclear region of NP cells (Figure 5-17).   
CCR1 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-18A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 38.91%.  Increased immunopositivity 
was detected in tissue sections from degenerate IVDs, median 46.32%, and 
infiltrated IVDs, median 42.92%, although these differences were not significant.  
Regression analysis considering CCR1 immunopositivity and histologically
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determined grade of degeneration confirms that no linear relationship exists 
between CCR1 immunopositivity in and grade of degeneration in tissue sections 
from human IVDs (P>0.05; Figure 5-18B). 
5.2.3.3 CXCR1 Expression  
CXCR1 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=3) degenerate (n=15), and infiltrated (n=12) IVDs.  Immunopositivity 
was observed in each tissue section.  In all instances staining was localised to the 
perinuclear region of NP cells (Figure 5-19).   
CXCR1 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-20A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 86.26%.  Increased immunopositivity 
was detected in tissue sections from degenerate IVDs, median 90.05%, and 
infiltrated IVDs, median 89.87%, although these differences were not significant 
(P>0.05).  Regression analysis considering CXCR1 immunopositivity and 
histologically determined grade of degeneration confirms that no linear relationship 
exists between CXCR1 immunopositivity and grade of degeneration in tissue 
sections from human IVDs (P>0.05; Figure 5-20B). 
5.2.3.4 CXCR2 Expression  
CXCR2 immunopositivity was localised to the NP cells of tissue sections from non-
degenerate (n=3) degenerate (n=16), and infiltrated (n=11) IVDs.  NP cell 
immunopositivity was observed in each tissue section.  In all instances staining was 
localised to the perinuclear region of NP cells (Figure 5-21).   
CXCR2 immunopositivity in tissue sections from non-degenerate, degenerate and 
infiltrated IVDs is shown in Figure 5-22A.  Immunopositivity was detected in tissue 
sections from non-degenerate IVDs, median 55.50%.  Increased immunopositivity 
was detected in tissue sections from degenerate IVDs, median 81.75%, and 
infiltrated IVDs, median 78.64%, compared to non-degenerate, although these 
differences were not significant (P>0.05).  Regression analysis considering CXCR2 
immunopositivity and histologically determined grade of degeneration confirms a 
positive linear relationship exists between CXCR2 immunopositivity and grade of 
degeneration in tissue sections from human IVDs (P=0.0371; Figure 5-22B). 
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5.2.4 Summary of Results  
The results presented in this chapter are summarised in Table 5-2.  
Target Non-Degenerate Degenerate Infiltrated Correlation 
IL-1β + + (↑ND) + (↑ND) None 
IL-16 + + + None 
CCL2 + + (↑ND) + (↑ND) Yes (p=0.0067) 
CCL3 + + (↑)* + (↑ND) Yes (p=0.0171) 
CCL4 + + (↑)* + None 
CCL7 + + (↑)* + (↑)
¤
 Yes (p=0.0600) 
CXCL8 + + (↑)* + (↑)
¤
 Yes (p=0.0067) 
CD4 + + (↑)* + (↑)
¤¥
 None 
CCR1 + + + None 
CXCR1 + + + None 
CXCR2 + + (↑ND) + (↑ND) Yes (p=0.0371) 
Table 5-2  Summary of Cytokine, Chemokine and Receptor Immunopositivity in Nucleus 
Pulposus Tissue from Non-Degenerate, Degenerate and Infiltrated Study Groups 
+, protein expression detected; -, protein expression not detected; (↑), increase; (↓) 
decrease;  ND, non-degenerate study group; D, degenerate study group;  *, significant 
difference between degenerate and non-degenerate study groups (P<0.05); ¤, significant 
difference between infiltrated and non-degenerate study groups (P<0.05); ¥, significant 
difference between infiltrated and degenerate study groups (P<0.05). 
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5.3 Discussion 
The objective of these investigations was to confirm protein expression of target 
cytokines, chemokines and receptors in human NP tissue.  To localise expression 
to cells producing cytokines and chemokines in the IVD, and to identify differences 
in expression between non-degenerate, degenerate and infiltrated study groups.   
Microscopic evaluation of IHC tissue sections confirmed protein expression of all 
targets investigated and localised this expression to the native NP cells of the IVD.  
Comparative analysis of percentage immunopositivity data revealed a trend of up-
regulated cytokine and chemokine expression in both degenerate and infiltrated 
study groups when compared to non-degenerate.  For certain targets, receptor 
expression was also up-regulated in both degenerate and infiltrated samples.  
It is worth noting at this point that protein expression levels represented by 
immunopositivity are only semi-quantitative.  The immunopositivity value represents 
the frequency that expression was observed in native NP cells, rather than the 
amount of protein that was being produced.  As such, it might be expected that the 
amount of protein, particularly for the chemokine targets, would be greater in 
infiltrated samples as this may drive the chemotaxis of leukocytes into the tissue 
and/or capillary in growth which facilitates increased infiltration (Gerard & Rollins, 
2001; Thelen, 2001; Gangur et al., 2002; Gerard, 2005; Wolf et al., 2008; Kiefer & 
Siekmann, 2011).  Indeed, this may be the case – even though few significant 
increases in immunopositivity were observed here between non-infiltrated 
degenerate samples and infiltrated, the amount of protein produced per positive cell 
may be greater in the infiltrated samples and therefore account for the leukocyte 
immigration.   
5.3.1 Cytokines  
IL-1β expression was localised to NP cells, as has been described previously (Le 
Maitre et al., 2005; Le Maitre et al., 2007d).  Comparative analysis between study 
groups indicates increased expression in degenerate and infiltrated samples 
however, these findings were not significant.  This trend mirrors that observed for 
IL-1β gene expression across the same study groups (see Chapter 4, section 
4.2.1.1) with the exception that gene expression in infiltrated samples was 
significantly increased compared to non-degenerate whereas here, the observed 
increase in protein expression was not significant.  However, immunopositivity 
quantification in this investigation was limited to that by native NP cells.  Previous 
gene expression data included expression by infiltrating cells and this may explain 
the greater increase observed in gene expression in the infiltrated study group.  
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Previously, significant up-regulation of IL-1β protein expression has been described 
in both degenerate and prolapsed IVDs compared to normal (Le Maitre et al., 2005; 
Le Maitre et al., 2007d).  Whilst a trend of up-regulation in degeneration was 
observed here our data is not entirely in agreement with previously published 
reports and this may be related to an altered IL-1β expression profile in prolapsed 
tissue.   
IL-16 expression was confirmed in the human IVD and expression localised to 
native NP cells.  The IL-16 receptor, CD4 (Cruikshank et al., 2000; Bernstein et al., 
2006; Liu et al., 2007; Fenster et al., 2010), was also localised to native NP cells.  
Neither target has been reported previously in the IVD, and similarly there are no 
reports of expression by chondrocytes.  Hence, we report a novel cytokine and 
receptor system potentially active through autocrine or paracrine signalling in the 
IVD.  IL-16 protein expression was equivalent across study groups, a trend 
mirrored in previous gene expression studies (see Chapter 4, section 4.2.1.1).  
However, receptor CD4 protein expression was increased in degenerate and 
infiltrated study groups compared to non-degenerate.  This may indicate increased 
sensitivity to IL-16 signalling by NP cells in degeneration.  Interestingly the increase 
in protein expression observed between degenerate and infiltrated study groups 
was also significant, indicating that factors regulating NP cell CD4 expression are 
further increased within the IVD by the presence of infiltrating cells, or that NP cell 
CD4 expression enhances leukocyte infiltration.  The observed protein expression 
pattern for CD4 is altered from that observed for CD4 gene expression where 
relative gene expression levels were equivalent between study groups, although 
detection frequency was increased in degenerate samples compared to non-
degenerate (see Chapter 4, section 4.2.1.1).  This would indicate translational 
regulatory mechanisms modulate the observed increases in CD4 protein 
expression, particularly in infiltrated samples.  Of note, two other studies have 
investigated CD4 expression in the human IVD, by IHC for the purpose of 
identifying CD4+ infiltrating T lymphocytes (Kawaguchi et al., 2001; Shamji et al., 
2010).  Kawaguchi et al. (2001) reported that the human IVD is CD4 negative 
however, primary antibody specificity and reaction conditions were not confirmed 
by use of positive control tissue and this may be one explanation for the conflict 
with data presented here.  Shamji et al. (2010) reported that <20% of cells stained 
positive for CD4 by IHC in tissue sections from degenerate and prolapsed IVDs.   
To return to a point of discussion un-resolved in Chapter 3, data generated in this 
investigation confirms the CD4 expression identified previously in gene expression 
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analysis, is attributable to NP cell expression and not derived entirely from T 
lymphocyte infiltration.  Indeed, although CD4 expression is classically associated 
with the T lymphocyte (Berman et al., 1985), the discovery that IL-16 requires cell 
surface expression of CD4 for induction of all its known biological activities 
(Cruikshank et al., 1991; Ryan et al., 1996) has led to the identification of other 
CD4 positive target cells of IL-16.  These include other immune cells such as 
monocytes (Cruikshank et al., 1987), eosinophils (Rand et al., 1991; Wan et al., 
1995; Lim et al., 1996) and dendritic cells (Kaser et al., 1999), some neuronal cells 
are also identified as CD4 expressing (Kurschner & Yuzaki, 1999; Fenster et al., 
2007).  Of the known biological activities of IL-16, most are associated with cell 
proliferation (Cruikshank et al., 1987; Parada et al., 1998) and differentiation 
(Szabo et al., 1998) although IL-16 is known to possess potent chemo-attractant 
properties to CD4 positive cells (Berman et al., 1985) and modulates the adhesion 
to ECM proteins by eosinophils (Wan et al., 1995).      
5.3.2  Chemokines 
Expression of the C-C chemokines; CCL2, CCL3, CCL4 and CCL7, and receptor 
CCR1 was localised to NP cells of the IVD.  NP cell CCL2 production has been 
identified previously by IHC in the prolapsed IVD (Ohba et al., 2008).  Data 
presented here indicated that CCL2 production is increased in degenerate and 
infiltrated tissue samples compared to non-degenerate, and that protein production 
is increased in line with increasing severity of degenerative tissue changes.  
Increased CCL2 protein production by prolapsed IVDs has been described 
previously where CCL2 concentration in conditioned media from tissue culture 
explants was interrogated for CCL2 presence by ELISA (Burke et al., 2002).  This 
same study reported CCL2 detection in culture supernatants from 40% of control 
tissue explants investigated (Burke et al., 2002).  Our study identified 
immunopositivity in 4 of the 5 (80%) non-degenerate samples investigated and this 
increase may be related to the use of prolapsed non-degenerate samples in this 
study.  The differential CCL2 protein expression profile observed here between 
non-degenerate and degenerate study groups revealed the opposite trend of up-
regulation in degeneration when compared to our previous gene expression 
investigation that indicated decreased expression in degeneration (see Chapter 4, 
section 4.2.2.1), and may indicate that translational modulation results in the 
observed increase in protein production.  The differential CCL2 protein expression 
profile observed here between non-degenerate and infiltrated study groups is 
similar to that observed previously in gene expression analysis (see Chapter 4, 
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section 4.2.2.1), in both cases a trend of increased expression in infiltrated samples 
was observed although this was not significant in either case.     
This is the first report of CCL3, CCL4 and CCL7 protein production by NP cells.  
Production of CCL3 and CCL4 has been investigated previously by IHC in articular 
cartilage from normal and OA tissue donors where the 3 normal tissue samples and 
5 OA tissue samples investigated were negative for CCL3 and CCL4 
immunostaining (Yuan et al., 2001).  This same study also reported that cultured 
primary human articular chondrocytes, derived from normal and OA tissue donors 
were CCL3 and CCL4 negative when assessed by immunocytochemistry, but that 
expression of both chemokines was induced following the application of pro-
inflammatory stimulus (IL-1 treatment) (Yuan et al., 2001) indicating that 
chondrocytes do have the capacity to produce these chemokines.  CCL7 protein 
production has not been investigated previously in NP cells or chondrocytes 
however, gene expression has been reported in prolapsed IVDs (Kawaguchi et al., 
2002) and our earlier gene expression investigations demonstrated NP cell gene 
expression (see Chapter 3, section 3.2.2.1 and Chapter 4, section 4.2.2.1).     
Comparative analysis between non-degenerate and degenerate study groups 
indicates CCL3, CCL4 and CCL7 production is increased in degeneration.  These 
trends were not observed previously in our gene expression investigation where 
relative mRNA transcription levels were equivalent between these same study 
groups (see Chapter 4, section 4.2.2.1).  Production of CCL3 and CCL7 but not 
CCL4, was seen to increase in line with increasing severity of degenerative tissue 
changes.     
Differential protein expression profiles were observed for CCL3 and CCL7 but not 
CCL4, between non-degenerate and infiltrated study groups.  For CCL3, our 
previous gene expression analysis identified an increase in the frequency of CCL3 
gene expression in infiltrated samples compared to non-degenerate (see Chapter 
4, section 4.2.2.1) and this was confirmed here at the level of protein production by 
NP cells.  For CCL4 our previous gene expression analysis indicated that relative 
mRNA expression levels were equivalent between non-degenerate and infiltrated 
study groups (see Chapter 4, section 4.2.2.1), a trend mirrored here at the level of 
protein production.  For CCL7, our previous gene expression analysis indicated that 
relative mRNA transcription levels were equivalent between study groups (see 
Chapter 4, section 4.2.2.1), whilst here protein production by NP cells was 
increased in infiltrated samples compared to non-degenerate samples.   
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The differences highlighted between the protein production and gene expression 
profiles of CCL3, CCL4 and CCL7 in non-degenerate and degenerate samples, and 
CCL7 in non-degenerate and infiltrated samples may have arisen from differences 
in stability between mRNA and protein molecules.  The half-life of mRNA is often 
short while protein molecules are more stable and remain detectable over greater 
time periods (Villiger et al., 1992).  It is also possible that translational regulatory 
mechanisms rather than transcriptional, modulate C-C chemokine expression by 
NP cells in these situations.    
CCR1 expression was confirmed to native NP cells indicating that NP cells are both 
the producers and targets of C-C chemokines.  This is the first report of chemokine 
receptor expression by NP cells and opens the possibility of autocrine and 
paracrine signalling mechanisms for chemokines in the IVD.  CCR1 expression was 
equivalent across study groups with approximately 40% immunopositivity of cells in 
all sections investigated.  This finding is remarkably similar to chondrocyte 
immunopositivity for CCR1 in articular cartilage where 37% (median value) 
immunopositivity (assessed by IHC) is reported in cartilage from normal tissue 
donors with no significant alteration in expression in OA tissue donors (Silvestri et 
al., 2003).  The CCR1 protein expression pattern here mirrors data generated in 
previous gene expression investigations between the same study groups (see 
Chapter 4, section 4.2.2.1).   
Expression of CXCL8 and receptors CXCR1 and CXCR2 were localised to the NP 
cells of the IVD.  CXCL8 has been identified previously as a product of NP tissue 
by interrogation of conditioned media from explant cultures (Burke et al., 2002).  
This study reported detection of CXCL8 in conditioned media from 20% of control 
tissue explants investigated (Burke et al., 2002).  In these studies CXCL8 
immunopositivity was detected in 5 of 5 (100%) non-degenerate samples 
investigated and this difference may be related to the use of prolapsed tissue in this 
study since increased frequency of detection and increased expression levels of 
CXCL8 were observed in conditioned media for prolapsed NP tissue explants 
(Burke et al., 2002).  Although, in this study 3 of the 5 non-degenerate tissue 
sections investigated were from non-prolapsed, non-degenerate post-mortem IVDs, 
all of which were positive for CXCL8 production.  The increased detection of 
CXCL8 reported in this study may therefore be due in part to differences in 
detection techniques.  Here, production and localisation by IHC identified CXCL8 
production in all non-degenerate tissue samples.  Previously, Burke et al., (2002) 
detected CXCL8 in conditioned media from non-degenerate NP tissue explants, 
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although in that study the actual parameter measured is protein release from the 
explant culture system and this may explain the differences reported.   
Comparative analysis across study groups indicates CXCL8 expression is 
increased in both degenerate and infiltrated samples compared to non-degenerate, 
a trend that was observed previously in CXCL8 gene expression analysis (see 
Chapter 4, section 4.2.2.2).  Protein expression analysis indicates CXCL8 
expression increases in line with increasing severity of degenerative tissue 
changes within the NP.     
This is the first report of C-X-C chemokine receptor protein expression by NP cells 
although expression of CXCR1 and CXCR2 has been reported previously by 
chondrocytes in articular cartilage (Silvestri et al., 2003).  This study reported 
CXCR1 and CXCR2 immunopositivity in articular cartilage from normal tissue 
donors at 45% with no significant alteration in expression pattern in tissue from OA 
tissue donors (Silvestri et al., 2003).  Here, measured immunopositivity in non-
degenerate NP tissue was 86% for CXCR1 and 55% for CXCR2, this increased 
expression pattern from that in articular cartilage may be a tissue specific 
difference.    
Comparative analysis indicates that CXCR1 protein production is equivalent across 
non-degenerate, degenerate and infiltrated study groups, a trend observed 
previously in gene expression analysis (see Chapter 4, section 4.2.2.2).  
Comparative analysis indicates CXCR2 protein production is increased in 
degenerate and infiltrated samples compared to non-degenerate, a trend observed 
previously in gene expression analysis (see Chapter 4, section 4.2.2.2).  CXCR2 
protein expression analysis also indicates that production increases in line with 
increasing severity of degenerative tissue changes.  These investigations indicate 
C-X-C receptor expression is increased in NP tissue compared to cartilage 
(Silvestri et al., 2003) and indicates the potential of NP cells to respond to produced 
C-X-C chemokines.     
5.3.3 Summary  
Data presented in this chapter confirms protein expression of cytokines, 
chemokines and receptors within the human IVD.  Further, cytokine and chemokine 
expression is increased in the degenerate and prolapsed IVD, particularly for the 
targets; IL-β, CCL2, CCL3, CCL4 and CXCL8.     
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6 The Effects of Cytokine and 
Chemokine Treatment on Cytokine, 
Chemokine, Extracellular Matrix 
Component and Extracellular Matrix 
Degrading Enzyme Gene Expression 
in Primary Human Nucleus Pulposus 
Cells In Vitro 
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6.1 Introduction 
This chapter describes investigations to determine the in vitro effects of cytokines; 
IL-1β and IL-16, and chemokines; CCL2, CCL3, CCL7 and CXCL8, on gene 
expression by primary NP cell cultures.  Real-time qPCR was used to determine 
the effect of cytokine or chemokine treatment on mRNA expression of cytokines, 
chemokines and ECM genes. 
6.1.1 Study Design 
6.1.1.1 Samples 
Primary NP cultures derived from 13 tissue samples; HD2, HD4, HD6, HD8, HD9, 
HD23, HD54, HD56, HD75, HD79, HD85, HD86 and HD89 were used in these 
studies.  Full details of samples used in this study can be found in Appendix 1. 
6.1.1.2 Selection of Culture System 
Initial investigations into the in vitro effects of IL-1β, CCL2 and CXCL8 were 
performed using monolayer cultures.  Comparison of the basal cytokine and 
chemokine expression profile of monolayer cultures with the expression profile of 
cells isolated directly from NP tissue revealed alterations in expression patterns, 
possibly associated with a phenotype ‘shift’ and dedifferentiation.  Basal cytokine 
and chemokine expression profiles following alginate culture were seen to 
resemble more closely the expression profile of cells isolated directly from tissue 
(Figure 6-1) and all subsequent investigations were performed on alginate cultures. 
6.1.1.3 Treatments 
The cytokines; IL-1β and IL-16, and the chemokines; CCL2, CCL3, CCL7 and 
CXCL8 were selected as culture treatments as discussed in Chapter 3, section 
3.3.3.  All treatments were 48 hours duration, performed on cultures derived from at 
least 3 different tissue samples, and performed in triplicate on cultures from each 
sample.  Monolayer cultures were subjected to treatment with IL-1β, CCL2 or 
CXCL8 as described in Chapter 2, section 2.4.3.  Alginate cultures were subjected 
to treatment with IL-1β, IL-16, CCL3 or CCL7 as described in Chapter 2, section 
2.4.6.       
6.1.1.4 Target Genes 
Target cytokines; IL-1β and IL-16, and target chemokines; CCL2, CCL3, CCL7 and 
CXCL8 were selected for gene expression analysis to determine the effects of 
treatment on cytokine and chemokine gene expression.  Two key ECM 
components and 3 major ECM degrading enzymes were also selected for gene 
expression analysis to determine the effects of treatment on ECM gene expression: 
• Aggrecan is a major proteoglycan constituent of NP ECM (Stevens et al., 
1979).  Its hydrophilic nature confers some of the structural capacity of the 
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• IVD (Roughley et al., 2006) and decreased proteoglycan content is 
associated with the pathogenesis of IVD degeneration (Urban & McMullin, 
1988).  
• Type II collagen expression is a phenotypic marker of NP cells (Chelberg et 
al., 1995) and type II is the prevalent collagen of NP ECM (Taylor et al., 
1992).  Alteration in the proportions of different collagen fibres is a feature of 
IVD degeneration (Antoniou et al., 1996a).  
• MMP-3 (stromelysin) has broad substrate specificity against proteoglycan 
core proteins (Nemoto et al., 1997).  Strong immunopositivity correlations 
have been made between expression and the NP fissures that are common 
features of IVD degeneration (Weiler et al., 2002).  
• MMP-13 (collagenase) has proteolytic activity against collagens (I, II and III), 
gelatin and aggrecan – all key NP ECM constituents (Roberts et al., 2000).  
• ADAMTS-4 has specific aggrecanase activity and is produced within the IVD 
(Pockert et al., 2009).  
6.1.2 Methods  
Full details of methods used in this study are given in Chapter 2, sections: 
• 2.1 Tissue Sample Processing 
• 2.4 Cell culture 
• 2.5 Quantitative Polymerase Chain Reaction 
6.1.3 Specific Objectives 
This chapter aims to address the hypothesis that: 
Regulatory inter-relationships exist between the cytokines and chemokines 
of the IVD and these cytokines and chemokines modulate anabolic and 
catabolic metabolism. 
The specific objectives are: 
• To determine in vitro the regulatory potential of IL-1β, IL-16, CCL2, CCL3, 
CCL7 and CXCL8 on cytokine and chemokine gene expression by primary 
NP cultures 
• To determine in vitro the regulatory potential of IL-1β, IL-16, CCL2, CCL3, 
CCL7 and CXCL8 on Aggrecan, type II collagen, MMP-3, MMP-13 and 
ADAMTS-4 gene expression by primary NP cultures 
• To select potentially regulatory cytokines and chemokines for further in vitro 
investigations into cytokine and chemokine protein expression in primary NP 
cultures  
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6.2 Results  
6.2.1 Cytokine and Chemokine Gene Expression in Monolayer Cultures 
6.2.1.1 IL-1β mRNA Expression 
Constitutive IL-1β mRNA expression was observed under basal conditions in 
monolayer cultured NP cells derived from the 5 IVDs investigated. 
Monolayer cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
IL-1β mRNA expression (Figure 6-2).  Up-regulation of IL-1β mRNA was observed 
separately in cells derived from all 5 IVDs investigated (data not shown).  
Treatment at 1ng/mL resulted in an 8.62 fold increase (P=0.0097), treatment at 
10ng/mL resulted in a 16.67 fold increase (P=0.0019) and treatment at 100ng/mL 
resulted in a 12.73 fold increase (P=0.003) in mRNA expression compared to un-
treated controls.  Differences in mRNA expression levels between treatment groups 
were not significant.       
No alteration in IL-1β mRNA expression was observed following 48 hour CCL2 or 
CXCL8 treatment at 1, 10 or 100ng/mL in monolayer cultured cells derived from the 
3 IVDs investigated (Figure 6-2).     
6.2.1.2 CCL2 mRNA Expression  
Constitutive CCL2 mRNA expression was observed under basal conditions in 
monolayer cultured NP cells derived from all 5 IVDs investigated. 
Monolayer cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
CCL2 mRNA expression (Figure 6-3).  Up-regulation of CCL2 mRNA expression 
was observed separately in cells derived from all 5 IVDs investigated (data not 
shown).  Treatment at 1ng/mL resulted in a 5.33 fold increase (P=0.0003), 
treatment at 10ng/mL resulted in a 9.72 fold increase (P<0.0001) and treatment at 
100ng/mL resulted in a 5.32 fold increase (P<0.0001) in mRNA expression 
compared to un-treated controls.  Differences in mRNA expression levels between 
treatment groups were not significant.    
No alteration in CCL2 mRNA expression was observed following 48 hour CCL2 or 
CXCL8 treatment at 1, 10 or 100ng/mL in monolayer cultured cells derived from the 
3 IVDs investigated (Figure 6-3). 
6.2.1.3 CXCL8 mRNA Expression 
Constitutive CXCL8 mRNA expression was observed under basal conditions in 
monolayer cultured NP cells derived from all 5 IVDs investigated. 
Monolayer cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
CXCL8 mRNA expression (Figure 6-4).  Up-regulation of CXCL8 mRNA expression 
was observed separately in cells derived from all 5 IVDs investigated (data not       
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shown).  Treatment at 1ng/mL resulted in a 496 fold increase (P<0.0001), 
treatment at 10ng/mL resulted in an 862 fold increase (P<0.0001) and treatment at 
100ng/mL resulted in a 527 fold increase (P<0.0001) in mRNA expression 
compared to un-treated controls.  Differences in mRNA expression levels between 
treatment groups were not significant.    
No alteration in CXCL8 mRNA expression pattern was observed following 48 hour 
CCL2 or CXCL8 treatment at 1, 10 and 100ng/mL in monolayer cultured cells 
derived from the 3 IVDs investigated (Figure 6-4). 
6.2.2 Cytokine and Chemokine Gene Expression in Alginate Cultures  
6.2.2.1 IL-1β mRNA Expression 
Expression of IL-1β mRNA in alginate cultured NP cells under basal conditions was 
not observed in cells derived from the 5 IVDs investigated.   
48 hour IL-1β treatment induced IL-1β expression and up-regulation in alginate 
cultured NP cells (Figure 6-5).  Induction and up-regulation of IL-1β mRNA 
expression was observed separately in cells derived from the 3 IVDs subjected to 
treatment (data not shown).  In all cases treatment at 1pg/mL was not sufficient to 
induce IL-1β mRNA expression.  In cells derived from one IVD, treatment at 
10pg/mL induced mRNA expression (2∆ x106 = 1.60; P>0.05).  In all cases, 
treatment at 100pg/mL induced mRNA expression (2∆ x106 = 736.70; 
P<0.0001), treatment at 1ng/mL induced mRNA expression (2∆ x106 = 844.97; 
P<0.0001), treatment at 10ng/mL induced mRNA expression (2∆ x106 = 978.77; 
P<0.0001) and treatment at 100ng/mL induced mRNA expression (2∆ x106 = 
1621.41; P<0.0001).  Differences in mRNA expression levels between treatment 
groups were not significant.   
Treatment with IL-16, CCL3 or CCL7 at 1, 10 or 100ng/mL was not seen to induce 
IL-1β mRNA expression in NP cells derived from the 3 IVD investigated (Figure 
6-5). 
6.2.2.2 IL-16 mRNA Expression 
Expression of IL-16 mRNA in alginate cultured NP cells was observed under basal 
conditions in cells derived from 6 IVDs out of a total of 9 that were investigated.   
In NP cells derived from 5 IVDs where basal IL-16 mRNA expression was 
observed, 48 hour IL-1β treatment resulted in down-regulation of IL-16 mRNA 
expression.  Down-regulation of IL-16 mRNA expression was observed separately 
in cells derived from the 5 IVDs investigated (data not shown).  Treatment at 
1pg/mL resulted in a 5.17 fold decrease (P>0.05), treatment at 10pg/mL resulted in 
a 5.14 fold decrease (P>0.05), treatment at 100pg/mL resulted in a 6.49 fold
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decrease (P>0.05), treatment at 1ng/mL resulted in a 8.07 fold decrease (P=0.007), 
treatment at 10ng/mL resulted in a 6.68 fold decrease (P>0.05) and treatment at 
100ng/mL resulted in a 8.35 fold decrease (P=0.0242) in mRNA expression 
compared to untreated controls.  Differences in mRNA expression levels between 
treatment groups were not significant with the exception of 1ng/mL treatment that 
resulted in significantly decreased expression compared to 1pg/mL treatment 
(P=0.0174).  In NP cells derived from 2 IVDs where basal IL-16 mRNA expression 
was not observed, 48 hour IL-1β treatment did not induce expression.   
In NP cells derived from 3 IVDs where basal IL-16 mRNA expression was 
observed, 48 hour IL-16 treatment resulted in up-regulation of IL-16 mRNA 
expression although this was not significant (Figure 6-6).  Up-regulation was 
observed separately in NP cells derived from the 3 IVDs investigated (data not 
shown).  Treatment at 1ng/mL resulted in a 6.16 fold increase (P>0.05), treatment 
at 10ng/mL resulted in an 8.00 fold increase (P>0.05) and treatment at 100ng/mL 
resulted in a 4.07 fold increase (P>0.05) in mRNA expression compared to 
untreated controls.  In NP cells derived from 2 IVDs where basal expression was 
not observed, 48 hour IL-16 treatment did not induce IL-16 mRNA expression.   
In NP cells derived from 1 IVD where basal IL-16 mRNA expression was observed, 
48 hour CCL3 or CCL7 treatment had no significant effect on IL-16 mRNA 
expression (Figure 6-6).  In NP cells derived from 2 IVDs where basal IL-16 mRNA 
expression was not observed, CCL3 or CCL7 treatment did not induce IL-16 mRNA 
expression. 
6.2.2.3 CCL2 mRNA Expression 
Constitutive CCL2 mRNA expression was observed under basal conditions in 
alginate cultured NP cells derived from the 5 IVDs investigated.     
Alginate cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
CCL2 mRNA expression (Figure 6-7).  Up-regulation of CCL2 mRNA expression 
was observed separately in cells derived from the 3 IVDs subjected to treatment 
(data not shown).  Treatment at 1pg/mL resulted in a 3.9 fold increase (P=0.0099), 
treatment at 10pg/mL resulted in a 2.84 fold increase (P=0.0252), treatment at 
100pg/mL resulted in a 6.76 fold increase (P=0.003), treatment at 1ng/mL resulted 
in a 6.03 fold increase (P=0.0018), treatment at 10ng/mL resulted in a 5.94 fold 
increase (P=0.0017) and treatment at 100ng/mL resulted in a 5.90 fold increase 
(P=0.0006) in CCL2 mRNA expression compared to untreated controls.  
Differences in mRNA expression levels between treatment groups were not 
significant.    
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No significant alteration in CCL2 mRNA expression pattern was observed following 
48 hour IL-16, CCL3 or CCL7 treatment at 1, 10 or 100ng/mL in alginate cultured 
NP cells derived from the 3 IVDs investigated (Figure 6-7). 
6.2.2.4 CCL3 mRNA Expression 
Expression of CCL3 mRNA in alginate cultured NP cells under basal conditions 
was not observed in cells derived from the 5 IVDs investigated.   
48 hour IL-1β treatment induced CCL3 mRNA expression and up-regulation in 
alginate cultured NP cells (Figure 6-8).  Induction and up-regulation of CCL3 mRNA 
expression was observed separately in cells derived from the 3 IVDs subjected to 
treatment (data not shown).  In all cases treatment at 1pg/mL was not sufficient to 
induce CCL3 mRNA expression.  In cells derived from 2 IVDs, treatment at 
10pg/mL induced mRNA expression (2∆ x106 = 2.51; P>0.05).  In all cases, 
treatment at 100pg/mL induced mRNA expression (2∆ x106 = 61.63; P<0.0001), 
treatment at 1ng/mL induced mRNA expression (2∆ x106 = 75.92; P<0.0001), 
treatment at 10ng/mL induced mRNA expression (2∆ x106 = 78.44; P<0.0001) 
and treatment at 100ng/mL induced mRNA expression (2∆ x106 = 115.66; 
P<0.0001).  A dose-dependent response to IL-1β treatment was observed with 
mRNA expression following 100pg/mL and 1, 10 and 100 ng/mL treatment 
significantly increased compared to 10pg/mL treatment (P=0.0006, P=0.0011, 
P=0.0016 and P=0.0079 respectively).  
Treatment with IL-16, CCL3 or CCL7 at 1, 10 or 100ng/mL was not seen to induce 
CCL3 mRNA expression in NP cells derived from the 3 IVDs investigated (Figure 
6-8). 
6.2.2.5 CCL7 mRNA Expression 
Constitutive CCL7 mRNA expression was observed under basal conditions in 
alginate cultured NP cells derived from the 5 IVDs investigated.     
Alginate cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
CCL7 mRNA expression (Figure 6-9).  Up-regulation of CCL7 mRNA was observed 
separately in cells derived from the 4 IVDs subjected to treatment (data not shown).  
Treatment at 1pg/mL resulted in a 1.64 fold increase (P>0.05), treatment at 
10pg/mL resulted in a 2.50 fold increase (P>0.05), treatment at 100pg/mL resulted 
in a 3.52 fold increase (P=0.017), treatment at 1ng/mL resulted in a 2.99 fold 
increase (P=0.0327), treatment at 10ng/mL resulted in a 3.56 fold increase 
(P=0.0213) and treatment at 100ng/mL resulted in a 6.35 fold increase (P=0.0027) 
in CCL7 mRNA expression compared to untreated controls.  Differences in 
expression level between treatment groups were not significant with 
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the exception of 100ng/mL treatment which was increased compared to 1pg/mL 
treatment (P=0.0388).   
No significant alteration in CCL7 mRNA expression pattern was observed following 
48 hour IL-16, CCL3 or CCL7 treatment at 1, 10 or 100ng/mL in alginate cultured 
NP cells derived from the 3 IVDs investigated (Figure 6-9).   
6.2.2.6 CXCL8 mRNA Expression 
Constitutive CXCL8 mRNA expression was observed under basal conditions in 
alginate cultured NP cells derived from the 5 IVDs investigated.     
Alginate cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
CXCL8 mRNA expression (Figure 6-10).  Up-regulation of CXCL8 mRNA was 
observed separately in cells derived from the 3 IVDs subjected to treatment (data 
not shown).  Treatment at 1pg/mL resulted in a 12.65 fold increase (P=0.0503), 
treatment at 10pg/mL resulted in a 82.72 fold increase (P<0.0001), treatment at 
100pg/mL resulted in a 834 fold increase (P<0.0001), treatment at 1ng/mL resulted 
in a 827 fold increase (P<0.0001), treatment at 10ng/mL resulted in a 844 fold 
increase (P<0.0001) and treatment at 100ng/mL resulted in a 909 fold increase 
(P<0.0001) in CXCL8 mRNA expression compared to untreated controls.  A dose-
dependent response was observed at treatment concentrations of up to 100pg/mL, 
with 10pg/mL treatment resulting in a significant up-regulation of mRNA expression 
compared to 1pg/mL (P=0.0151) and 100pg/mL treatment resulting in up-regulation 
compared to both 1pg/mL (P<0.0001) and 10pg/mL (P=0.0005).  No significant 
differences were observed between treatment groups at concentrations 100pg/mL 
and above.     
No significant alteration in CXCL8 mRNA expression was observed following 48 
hour IL-16, CCL3 or CCL7 treatment at 1, 10 or 100ng/mL in alginate cultured NP 
cells derived from the 3 IVDs investigated (Figure 6-10).  
6.2.3 Extracellular Matrix Gene Expression in Monolayer Cultures 
6.2.3.1 Aggrecan mRNA Expression 
Constitutive mRNA expression of aggrecan was observed in monolayer cultured 
NP cells derived from the 3 IVDs investigated. 
Monolayer cultured NP cells responded to 48 hour IL-1β treatment by down-
regulating aggrecan mRNA expression (Figure 6-11).  Down-regulation of aggrecan 
mRNA expression was observed separately in cells derived from all 3 IVDs 
investigated (data not shown).  Treatment at 1ng/mL resulted in an 8.59 fold 
decrease (P=0.014), treatment at 10ng/mL resulted in a 7.97 fold decrease 
(P=0.0165) and treatment at 100ng/mL resulted in a 8.54 fold decrease (P=0.008)  
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in mRNA expression compared to un-treated controls.  Differences in mRNA 
expression levels between treatment groups were not significant.       
No significant alteration in aggrecan mRNA expression was observed following 48 
hour CCL2 or CXCL8 treatment at 1, 10, or 100ng/mL in monolayer cultured NP 
cells derived from the 3 IVDs investigated (Figure 6-11).  Although a 7.44 fold 
decrease in aggrecan mRNA expression was seen following 100ng/mL CXCL8 
treatment however, this was not significant (P=0.0593).   
6.2.3.2 MMP-3 mRNA Expression 
Constitutive mRNA expression of MMP-3 was observed in monolayer cultured NP 
cells derived from the 3 IVDs investigated. 
Monolayer cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
MMP-3 mRNA expression (Figure 6-12).  Up-regulation of MMP-3 mRNA 
expression was observed separately in cells derived from all 3 IVDs investigated 
(data not shown).  Treatment at 1ng/mL resulted in a 22.27 fold increase 
(P<0.0001), treatment at 10ng/mL resulted in a 36.14 fold increase (P<0.0001) and 
treatment at 100ng/mL resulted in a 32.18 fold increase (P<0.0001) in mRNA 
expression compared to un-treated controls.  Differences in mRNA expression 
levels between treatment groups were not significant.       
No significant alteration in MMP-3 mRNA expression was observed following 48 
hour CCL2 or CXCL8 treatment at 1, 10 or 100ng/mL in monolayer cultured cells 
derived from the 3 IVDs investigated (Figure 6-12). 
6.2.3.3 MMP-13 mRNA Expression 
Constitutive mRNA expression of MMP-13 was observed in monolayer cultured NP 
cells derived from the 3 IVDs investigated. 
Monolayer cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
MMP-13 mRNA expression (Figure 6-13).  Up-regulation of MMP-13 mRNA 
expression was observed separately in cells derived from all 3 IVDs investigated 
(data not shown).  Treatment at 1ng/mL resulted in a 2.89 fold increase (P>0.05), 
treatment at 10ng/mL resulted in a 4.65 fold increase (P=0.0469) and treatment at 
100ng/mL resulted in a 3.53 fold increase (P>0.05) in mRNA expression compared 
to un-treated controls.  Differences in mRNA expression levels between treatment 
groups were not significant.       
No significant alteration in MMP-13 mRNA expression was observed following 48 
hour CCL2 or CXCL8 treatment at 1, 10 or 100ng/mL in monolayer cultured cells 
derived from the 3 IVDs investigated (Figure 6-13).      
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6.2.3.4 ADAMTS-4 mRNA Expression 
Constitutive mRNA expression of ADAMTS-4 was observed in monolayer cultured 
NP cells derived from the 3 IVDs investigated. 
No significant alteration in ADAMTS-4 mRNA expression was observed following 
48 hour IL-1β, CCL2 or CXCL8 treatment at 1, 10 or 100ng/mL in monolayer 
cultured cells derived from the 3 IVDs investigated (Figure 6-14). 
6.2.4 Extracellular Matrix Gene Expression in Alginate Cultures  
6.2.4.1 Aggrecan mRNA Expression 
Constitutive mRNA expression of aggrecan was observed in alginate cultured NP 
cells derived from the 7 IVDs investigated. 
Alginate cultured NP cells responded to 48 hour IL-1β treatment with a biphasic 
aggrecan mRNA expression pattern (Figure 6-15).  Up-regulation of aggrecan 
mRNA expression following low-dose treatment and down-regulation of aggrecan 
mRNA expression following high-dose treatment was observed separately in cells 
derived from all 7 IVDs investigated (data not shown).  Treatment at 1pg/mL 
resulted in a 2.61 fold increase (P>0.05), treatment at 10pg/mL resulted in a 3.82 
fold increase (P=0.063), treatment at 100pg/mL resulted in a 4.39 fold increase 
(P=0.0179) in mRNA expression compared to untreated controls.  Following 
treatment at 1ng/mL, aggrecan mRNA expression had returned to basal expression 
levels, treatment at 10ng/mL resulted in a 5.24 fold decrease (P>0.05) and 
treatment at 100ng/mL resulted in an 8.87 fold decrease (P=0.0245) in mRNA 
expression compared to un-treated controls.  Differences between treatment 
groups were observed with expression levels following 1pg/mL treatment 
significantly altered compared to treatment at 10ng/mL (P=0.0242) and 100ng/mL 
(P=0.0011).  Expression following treatment at 10pg/mL was altered compared to 
treatment at 10ng/mL (P=0.0035) and 100ng/mL (P=<0.0001).  Expression 
following treatment at 100pg/mL was altered compared to treatment at 1ng/mL 
(P=0.0416), 10ng/mL (P=0.0007) and 100ng/mL (P<0.0001).  Expression following 
1ng/mL treatment was altered compared to treatment at 100ng/mL (P=0.0093).         
No significant alteration in aggrecan mRNA expression was observed following 48 
hour IL-16, CCL3 or CCL7 treatment at 1, 10 and 100ng/mL in alginate cultured 
cells derived from the 3 IVDs investigated (Figure 6-15). 
6.2.4.2 Type II Collagen mRNA Expression 
Expression of type II collagen mRNA in alginate cultured NP cells was observed 
under basal conditions in cells derived from 3 IVDs, a total of 4 IVDs were 
investigated.   
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In NP cells derived from the 3 IVDs where basal expression was observed, 48 hour 
IL-1β treatment resulted in down-regulation of type II collagen mRNA (Figure 6-16).  
Down-regulation of type II collagen mRNA was observed separately in NP cells 
derived from all 3 IVDs investigated (data not shown).  Treatment at 1pg/mL 
resulted in a 8.66 fold decrease (P>0.05), treatment at 10pg/mL resulted in a 9.60 
fold decrease (P=0.0486), treatment at 100pg/mL resulted in a 8.48 fold decrease 
(P>0.05), treatment at 1ng/mL resulted in a 8.85 fold decrease (P>0.05), treatment 
at 10ng/mL resulted in a 9.46 fold decrease (P>0.05) and treatment at 100ng/mL 
resulted in a 9.59 fold decrease (P=0.0248) in mRNA expression compared to 
untreated controls.  Differences in mRNA expression levels between treatment 
groups were not significant.  In NP cells derived from 1 IVD where basal expression 
was not observed, 48 hour IL-1β treatment did not induce type II collagen mRNA 
expression.     
In NP cells derived from 2 IVDs where basal type II collagen mRNA expression was 
observed, 48 hour IL-16 treatment at 1, 10 or 100ng/mL had no significant effect on 
mRNA expression.  In NP cells derived from 1 IVD where basal expression was not 
observed, 48 hour IL-16 treatment did not induce type II collagen mRNA expression 
(Figure 6-16).   
6.2.4.3 MMP-3 mRNA Expression 
Constitutive mRNA expression of MMP-3 was observed in alginate cultured NP 
cells derived from the 3 IVDs investigated. 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
MMP-3 mRNA expression (Figure 6-17).  Up-regulation of MMP-3 mRNA 
expression was observed separately in cells derived from all 3 IVDs investigated 
(data not shown).  Treatment at 1pg/mL resulted in a 12.38 fold increase (P>0.05), 
treatment at 10pg/mL resulted in a 159 fold increase (P=0.0007), treatment at 
100pg/mL resulted in a 1779 fold increase (P<0.0001), treatment at 1ng/mL 
resulted in a 1068 fold increase (P<0.0001), treatment at 10ng/mL resulted in a 
1383 fold increase (P<0.0001) and treatment at 100ng/mL resulted in a 1931 fold 
increase (P<0.0001) in mRNA expression compared to un-treated controls.  The 
up-regulatory response was seen to be dose dependent at treatment 
concentrations of 100pg/mL and below, with mRNA expression following 10pg/mL 
treatment increased compared to 1pg/mL treatment (P=0.0139), and 100pg/mL 
treatment increased compared to both 1 and 10pg/mL treatments (P<0.0001 and 
P<0.0001 respectively).  Differences in mRNA expression levels between 
100pg/mL, 1, 10 and 100ng/mL treatment groups were not significant.       
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No significant alteration in MMP-3 mRNA expression was observed following 48 
hour IL-16, CCL3 or CCL7 treatment at 1, 10 or 100ng/mL in alginate cultured cells 
derived from the 3 IVDs investigated (Figure 6-17).        
6.2.4.4 MMP-13 mRNA Expression 
Constitutive mRNA expression of MMP-13 was observed in alginate cultured NP 
cells derived from the 3 IVDs investigated. 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
MMP-13 mRNA expression (Figure 6-18).  Up-regulation of MMP-13 mRNA 
expression was observed separately in cells derived from all 3 IVDs investigated 
(data not shown).  Treatment at 1pg/mL resulted in a 42.18 fold increase 
(P=0.0003), treatment at 10pg/mL resulted in a 17.40 fold increase (P=0.0118) and 
treatment at 100pg/mL resulted in a 61.77 fold increase (P<0.0001), treatment at 
1ng/mL resulted in a 71.57 fold increase (P<0.0001), treatment at 10ng/mL resulted 
in a 73.11 fold increase (P<0.0001) and treatment at 100ng/mL resulted in a 36.70 
fold increase (P<0.0001) in mRNA expression compared to un-treated controls.  
Differences in mRNA expression levels between treatment groups were not 
significant.       
No significant alteration in MMP-13 mRNA expression was observed following 48 
hour IL-16, CCL3 or CCL7 treatment at 1, 10 or 100ng/mL in alginate cultured cells 
derived from the 3 IVDs investigated (Figure 6-18). 
6.2.4.5 ADAMTS-4 mRNA Expression 
Constitutive mRNA expression of ADAMTS-4 was observed in alginate cultured NP 
cells derived from the 4 IVDs investigated. 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by up-regulating 
ADAMTS-4 mRNA expression (Figure 6-19).  Up-regulation of ADAMTS-4 mRNA 
was observed separately in cells derived from all 4 IVDs investigated (data not 
shown).  Treatment at 1pg/mL resulted in a 2.78 fold increase (P>0.05), treatment 
at 10pg/mL resulted in a 5.11 fold increase (P>0.05), treatment at 100pg/mL 
resulted in a 8.19 fold increase (P=0.0663), treatment at 1ng/mL resulted in a 10.10 
fold increase (P=0.024), treatment at 10ng/mL resulted in a 12.12 fold increase 
(P=0.0512) and treatment at 100ng/mL resulted in a 5.68 fold increase (P>0.05) in 
mRNA expression compared to un-treated controls.  Differences in mRNA 
expression levels between treatment groups were not significant.       
No significant alteration in ADAMTS-4 mRNA expression was observed following 
48 hour IL-16 treatment at 1, 10 or 100ng/mL in alginate cultured cells derived from 
the 3 IVDs investigated (Figure 6-19). 
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6.2.5 Summary of Results  
The results presented in this chapter are summarised in Table 6-1.   
6.3 Discussion 
The objective of this investigation was to determine the effects of cytokine and 
chemokine treatment on cytokine, chemokine, ECM component and ECM 
degrading enzyme gene expression.  Data generated confirms the transcriptional 
modulatory potential of IL-1β on cytokine and chemokine gene expression, and on 
anabolic and catabolic gene expression.  No significant transcriptional modulatory 
effects on gene expression were observed for IL-16, CCL2, CCL3, CCL7 or CXCL8 
on NP cell biology for the parameters measured.   
6.3.1 Modulation of Cytokine and Chemokine Gene Expression 
In other arthropathies, master cytokines such as IL-1 and TNF modulate the 
expression of themselves and other factors, including cytokines and chemokines 
that are considered second step mediators of disease (Van den Berg & Miossec, 
2004).  Here, the modulatory potential of IL-1β on cytokine and chemokine gene 
expression by primary NP cells is demonstrated.  IL-1β exerted modulatory 
potential over all cytokines and chemokines investigated, in both monolayer and 
alginate experimental systems.   
IL-1β gene expression under basal conditions was detected in monolayer cultures 
and IL-1β treatment up-regulated this expression.  Conversely, IL-1β gene 
expression was not detected in alginate cultures under basal conditions however, 
expression was induced by IL-1β treatment.  Auto-induction and up-regulation of IL-
1β gene expression has been described previously in primary NP cultures derived 
from degenerate IVDs (Le Maitre et al., 2005).  Further, it’s reported that NP cells 
derived from non-degenerate IVDs respond to IL-1β treatment by down-regulating 
IL-1β gene expression (Le Maitre et al., 2005).  However, this modulatory effect 
was not observed here.  NP cultures derived from prolapsed non-degenerate IVDs 
responded to IL-1β stimulation by up-regulating IL-1β gene expression similarly to 
NP cultures derived from prolapsed degenerate IVDs.  This difference may be 
related to the origin of cells used and hence the pathology of prolapse, rather than 
degeneration, since previous investigations by Le Maitre et al. (2005) were 
performed on cultures derived from non-prolapsed non-degenerate IVDs.   
Our findings in relation to the differential gene expression pattern of IL-1β under 
basal conditions in monolayer and alginate cultures suggest that phenotype, or 
differentiation state, exerts some influence over IL-1β gene expression by NP cells.  
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This finding may also account for the difference between data presented here and 
Le Maitre et al.’s previous report (2005) of down-regulation of IL-1β transcription 
following IL-1β stimulation, in cultures derived from non-degenerate IVDs.  Here, 
cultures expanded in monolayer were encapsulated in alginate and cultured for 14 
days to allow re-establishment of native cytokine and chemokine gene expression 
profiles, in Le Maitre et al.’s previous investigation (2005) monolayer expanded 
cultures were encapsulated in alginate for 28 days prior to IL-1β stimulation.  
Hence, since differentiation state exerts some influence over IL-1β transcription 
these studies are not directly comparable, although both clearly demonstrate the 
up-regulatory effect of IL-1β stimulation on IL-1β transcription in cultures derived 
from degenerate IVDs.      
The modulatory potential of IL-1β on IL-16 gene expression was investigated in 
alginate cultures.  Interestingly, IL-16 expression was not detected in alginate 
cultures under basal conditions derived from all tissue samples investigated.  Of the 
cultures investigated that were derived from 9 different tissue samples, only 6 
displayed IL-16 mRNA expression under basal conditions.  IL-16 expression in 
primary NP cultures may be related to tissue source and represent differences 
between individual tissue donors or previous modulatory events occurring in vivo 
prior to tissue harvest.  Where IL-16 gene expression was observed, NP cultures 
responded to IL-1β stimulation by down-regulating IL-16 transcription.   
This is the first report of IL-16 gene expression in NP cultures although gene 
expression has been shown previously in cultured primary human synovial 
fibroblasts derived from OA and RA tissue donors (Sciaky et al., 2000).  The effect 
of IL-1β stimulation on IL-16 transcript abundance in synovial fibroblasts was 
determined for treatment durations of up to 7 hours, although no alterations in 
transcript abundance were detected during this time frame (Sciaky et al., 2000).  
However, IL-16 protein production was increased and the authors conclude that IL-
1β stimulation induces translation of preformed IL-16 mRNA to increase expression 
of IL-16 protein (Sciaky et al., 2000). 
The modulation of CCL2 and CXCL8 gene expression by IL-1β was investigated in 
both monolayer and alginate culture systems.  Similar expression patterns were 
observed between monolayer and alginate cultures and IL-1β stimulation up-
regulated CCL2 and CXCL8 gene expression in both experimental systems.  The 
up-regulatory effect of IL-1β on CCL2 and CXCL8 gene expression has been 
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described previously in primary NP cultures stimulated with 30ng/mL IL-1β (Huang 
et al., 2008).    
CCL3 and CCL7 gene expression was investigated in alginate cultures only.  CCL3 
gene expression was not detected under basal conditions although IL-1β treatment 
induced expression.  CCL7 gene expression was detected under basal conditions 
and stimulation with IL-1β up-regulated this expression.  Expression of CCL3 or 
CCL7 in primary NP cultures has not been investigated previously however, CCL3 
expression has been investigated in cultured primary human articular chondrocytes 
(Yuan et al., 2001; Sandell et al., 2008).  The effect of IL-1β stimulation on articular 
chondrocytes was induction of CCL3 gene expression at treatment concentrations 
of 100pg/mL and above (Sandell et al., 2008), which is the same concentration 
required here to induce expression in primary NP cells.    
The effects of IL-16 stimulation on cytokine and chemokine gene expression were 
investigated in alginate cultured NP cells.  No significant modulatory effects were 
observed although a trend of auto up-regulation was observed in NP cultures that 
exhibited IL-16 gene expression under basal conditions.  This may indicate an 
autocrine or paracrine signalling circuit for this ligand in primary NP cells.  The 
effect of IL-16 stimulation on IL-1β transcription was not determined since alginate 
NP cultures did not exhibit IL-1β gene expression under basal conditions.  
However, IL-16 may have modulatory potential over IL-1β since it is demonstrated 
in animal models of RA that intra-articular injection of recombinant IL-16 reduces 
IL-1β transcription in associated pathological tissues (Klimiuk et al., 1999).    
The effects of CCL2 and CXCL8 stimulation on cytokine and chemokine gene 
expression were investigated in monolayer NP cultures only.  No modulatory 
effects were observed for these chemokines and there are no previous reports of 
transcriptional regulatory potential for these molecules in any cell type.  The effects 
of CCL3 and CCL7 stimulation on cytokine and chemokine gene expression were 
investigated in alginate cultures only.  No significant transcriptional modulatory 
effects were observed for these chemokines although a trend of CCL2 down-
regulation following CCL3 treatment and a trend of CXCL8 up-regulation following 
high dose (100ng/mL) CCL7 treatment was observed.   
6.3.2 Modulation of ECM Gene Expression 
In chronic inflammation or disease, prolonged or dysregulated cytokine production 
can drive the equilibrium of tissue homeostasis towards catabolism, which is 
associated with tissue destruction and degeneration (Dinarello & Moldawer, 2000).  
Here, IL-1β exerted transcriptional modulatory potential over all anabolic and 
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catabolic ECM genes investigated in a manner that suggests the effects of high 
concentrations of IL-1β in the extracellular milieu of native NP cells would be 
detrimental to ECM integrity.  The effects of IL-1β stimulation were investigated in 
both monolayer and alginate experimental systems.   
The modulatory potential of IL-1β stimulation on aggrecan gene expression was 
investigated in monolayer and alginate experimental systems.  Monolayer cultures 
responded to IL-1β stimulation by down-regulating aggrecan transcription.  This 
effect was investigated in monolayer cultures with IL-1β treatment concentrations of 
1, 10 and 100ng/mL.  Under these conditions the down-regulatory effect of IL-1β 
was not dose-dependent and the effect of treatment appeared maximal at the 
lowest treatment concentration (1ng/mL).  In subsequent alginate culture 
investigations lower concentrations of IL-1β treatment (1, 10 and 100pg/mL) were 
run alongside those previously investigated in monolayer.  The results of low-dose 
IL-1β stimulation of alginate cultures were interesting, revealing not only a dose-
dependent response but a differential expression pattern dependent on treatment 
concentration, whereby low-dose (≤100pg/mL) induced up-regulation of aggrecan 
transcription and high-dose (>1ng/mL) induced down-regulation.   
The effect of IL-1β stimulation on aggrecan transcription has been investigated 
previously in primary human NP cultures (Le Maitre et al., 2005; Studer et al., 
2011).  These studies demonstrate that cultures derived from both non-degenerate 
and degenerate IVDs respond to IL-1β stimulation by down-regulating aggrecan 
transcription (Le Maitre et al., 2005; Studer et al., 2011), although neither 
investigation used treatment concentrations of <10ng/mL.  Modulation of aggrecan 
transcription by IL-1β is also described in cultured articular chondrocytes, where 
treatment concentrations between 0.5 and 10ng/mL have been investigated 
(Richardson & Dodge, 2000).  Although the lowest treatment concentrations used 
in this investigation did not elicit a significant alteration in aggrecan transcription as 
was seen for higher treatment concentrations that down-regulated relative mRNA 
expression levels (Richardson & Dodge, 2000).   
Data generated in this investigation confirms these previous reports of down-
regulation of aggrecan transcription by high dose (≥10ng/mL) IL-1β stimulation 
(Richardson & Dodge, 2000; Le Maitre et al., 2005; Studer et al., 2011) in NP 
cultures derived from both non-degenerate (Le Maitre et al., 2005) and degenerate 
IVDs (Studer et al., 2011).  However, here we present a novel finding in that this is 
the first report of a differential expression pattern dependent on stimulation dose.  
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Indeed, this data suggests that low levels of IL-1β, as has been identified within NP 
tissue samples derived from normal tissue donors (Le Maitre et al., 2005; Le Maitre 
et al., 2007d) may be beneficial to ECM integrity, by up-regulating aggrecan 
transcription.    
The modulatory potential of IL-1β on type II collagen transcription was investigated 
in alginate cultures only.  The rationale for excluding type II collagen from 
monolayer culture investigations was that NP cell transcription of type II collagen is 
altered dependent on differentiation state notably, decreased or absent from 
monolayer cultures that adopt a fibroblastic phenotype (Baer et al., 2001; Wang et 
al., 2001; Le Maitre et al., 2005).  Hence, data generated in relation to type II 
collagen gene expression in monolayer cultures may not be physiologically 
relevant.    
Alginate NP cultures responded to IL-1β stimulation by down-regulating type II 
collagen transcription, significant modulation was observed following stimulation 
with as little as 10pg/mL.  The effect of IL-1β stimulation on type II collagen 
transcription has been investigated previously in primary NP cultures (Le Maitre et 
al., 2005; Studer et al., 2011).  These studies demonstrate a differential response 
to IL-1β stimulation dependent on tissue pathology, with IL-1β stimulation of NP 
cultures derived from non-degenerate IVDs eliciting no significant effect (Le Maitre 
et al., 2005), whilst stimulation of cultures derived from degenerate IVDs results in 
down-regulation (Studer et al., 2011).  Here, the down-regulatory effect of IL-1β 
stimulation on type II collagen transcription was observed in NP cultures derived 
from prolapsed non-degenerate IVDs, similarly to that observed in NP cultures 
derived from prolapsed degenerate IVDs.  This difference may again be related to 
the origin of the cells since previous investigations by Le Maitre et al. (2005) were 
performed on NP cultures derived from non-prolapsed non-degenerate IVDs.   
Data generated in this investigation confirms previous reports of down-regulation of 
type II collagen transcription by high dose (≥10ng/mL) IL-1β stimulation in NP 
cultures derived from degenerate IVDs (Studer et al., 2011).  Further, we report the 
modulatory potential of low dose IL-1β stimulation (≤100pg/mL) on type II collagen 
transcription in NP cultures derived from prolapsed non-degenerate and prolapsed 
degenerate IVDs.      
The modulatory potential of IL-1β stimulation on MMP-3 and -13 transcription was 
investigated in monolayer and alginate experimental systems.  Monolayer cultures 
responded to IL-1β stimulation by up-regulating MMP-3 and -13 transcription.  This 
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effect was investigated in monolayer cultures following stimulation with 1, 10 and 
100ng/mL IL-1β.  Under these conditions a dose-dependent response was not 
observed for either target, and for MMP-3 transcription the effect of treatment 
appeared maximal at the lowest treatment concentration (1ng/mL).   
In subsequent alginate culture investigations lower concentrations of IL-1β 
treatment (1, 10 and 100pg/mL) were run alongside those previously investigated in 
monolayer.  The results of low-dose IL-1β stimulation of alginate cultures revealed 
that the up-regulation of MMP-3 following IL-1β stimulation is dose-dependent at 
low treatment concentrations (≤100pg/mL).  MMP-13 transcription following IL-1β 
stimulation was also seen to follow the same up-regulatory trend observed in 
monolayer cultures, although dose dependency was not observed even following 
low dose (≤100pg/mL) stimulation and the effect of treatment appeared maximal at 
the lowest treatment concentration (1pg/mL).  Comparative analysis of equivalent 
IL-1β dose stimulation (1, 10 and 100ng/mL) between monolayer and alginate 
experimental systems indicates that whilst the same trend of up-regulation is 
observed, the response to stimulation is greater in alginate cultures.  In monolayer 
cultures, fold increases of <40 were observed, whereas in alginate cultures fold 
increases of >1000 in MMP-3 transcription were observed.  For MMP-13 
transcription, in monolayer cultures fold increases of <5 were observed, whereas in 
alginate cultures fold increases of >35 were observed.   
The modulatory potential of IL-1β on MMP-3 and -13 transcription has been 
investigated previously in primary human NP cultures (Le Maitre et al., 2005; 
Millward-Sadler et al., 2009). These studies demonstrate that cultures derived from 
both non-degenerate and degenerate IVDs respond to IL-1β stimulation by up-
regulating MMP-3 and -13 transcription (Le Maitre et al., 2005; Millward-Sadler et 
al., 2009), although neither investigation used treatment concentrations of 
<10ng/mL.  Modulation of MMP-3 and -13 transcription by IL-1β is also described in 
cultured articular chondrocytes, where treatment concentrations between 0.5 and 
10ng/mL have been investigated (Richardson & Dodge, 2000).  This study reports 
significant modulation of MMP-3 transcription at treatment concentrations of 
≥1ng/mL and significant modulation of MMP-13 transcription at 10ng/mL treatment 
concentration in chondrocyte suspension cultures (Richardson & Dodge, 2000).   
Data generated in this investigation confirms these previous reports of up-
regulation of MMP-3 and -13 transcription by high dose (≥1ng/mL) IL-1β stimulation 
(Richardson & Dodge, 2000; Le Maitre et al., 2005; Millward-Sadler et al., 2009) in 
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NP cultures derived from both non-degenerate (Le Maitre et al., 2005; Millward-
Sadler et al., 2009) and degenerate IVDs (Millward-Sadler et al., 2009).  Further, 
we report the modulatory potential of low dose IL-1β stimulation (≤100pg/mL) on 
MMP-3 and -13 transcription in NP cultures derived from prolapsed non-degenerate 
and prolapsed degenerate IVDs.    
The modulatory potential of IL-1β stimulation on ADAMTS-4 transcription was 
investigated in monolayer and alginate experimental systems.  Whilst gene 
expression of ADAMTS-4 mRNA was detected in monolayer cultures under basal 
conditions, transcription was not affected by IL-1β stimulation.  However, in 
subsequent alginate culture investigations IL-1β stimulation up-regulated ADAMTS-
4 transcription.  The effect of IL-1β stimulation on ADAMTS-4 transcription has 
been investigated previously in primary human NP cultures (Le Maitre et al., 2005).  
This study demonstrated a differential response to IL-1β stimulation dependent on 
tissue pathology, with IL-1β stimulation of NP cultures derived from non-degenerate 
IVDs eliciting no significant effect (Le Maitre et al., 2005), whilst stimulation of 
cultures derived from degenerate IVDs resulted in up-regulation (Le Maitre et al., 
2005) of ADAMTS-4 transcription.  Here, the up-regulatory effect of IL-1β 
stimulation in alginate cultures on ADAMTS-4 transcription was observed in NP 
cultures derived from prolapsed non-degenerate IVDs, similarly to that observed in 
NP cultures derived from prolapsed degenerate IVDs.  This difference may again 
be related to the origin of the cells since previous investigations by Le Maitre et al. 
(2005) were performed on NP cultures derived from non-prolapsed non-degenerate 
IVDs.  
Data generated in this investigation confirms this previous report of up-regulation of 
ADAMTS-4 transcription by IL-1β stimulation in NP cultures derived from 
degenerate IVDs (Le Maitre et al., 2005).  Further, we report the modulatory 
potential of IL-1β stimulation on ADAMTS-4 transcription in alginate NP cultures 
derived from prolapsed non-degenerate and prolapsed degenerate IVDs.    
In relation to the transcriptional modulatory effects of IL-1β on ECM degrading 
enzymes, cell phenotype, or differentiation state appears to have some influence 
over the response elicited.  For MMP-3 and -13, modulatory effects were greater in 
alginate cultures that are thought to more closely resemble the in vivo phenotype 
than in de-differentiated monolayer cultures.  For ADAMTS-4, IL-1β had no 
modulatory potential over monolayer cultures but elicited an up-regulatory response 
in alginate cultures indicating that this response is phenotype dependent. 
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No significant modulatory effect on ECM gene expression was observed following 
48 hour stimulation of primary NP cultures with IL-16, CCL2, CCL3, CCL7 or 
CXCL8.  The effect of IL-16 stimulation on ECM gene expression has not been 
investigated previously in any cell type.  However, for the chemokines investigated 
here, several reports of modulation have been made in articular chondrocytes.   
The modulatory potential of CCL2 and CCL3 stimulation on proteoglycan synthesis 
has been investigated previously in primary human articular chondrocytes (Yuan et 
al., 2001).  This study demonstrated down-regulation of proteoglycan synthesis 
measured by incorporation of 
35
S into newly synthesised proteoglycan molecules 
(Yuan et al., 2001).  Here, the effects of CCL2 and CCL3 stimulation on 
transcription of the IVD proteoglycan, aggrecan, was investigated in either 
monolayer or alginate experimental systems.  Data generated indicates that CCL2 
and CCL3 do not elicit modulatory effects on aggrecan transcription in primary NP 
cultures.  However, since the investigations by Yuan et al. (2001) did not 
investigate modulatory effects of CCL2 and CCL3 stimulation on proteoglycan 
transcription, it is unknown whether the down-regulation of proteoglycan synthesis 
in articular chondrocytes is a transcriptional modulation or a translational 
modulation.  Hence, potentially CCL2 and CCL3 may modulate proteoglycan 
synthesis by NP cells if their modulatory effect is translational.   
The modulatory potential of CCL2 and CXCL8 stimulation on ECM degrading 
enzyme production has been investigated previously in primary articular 
chondrocytes (Borzi et al., 2000; Yuan et al., 2001).  These studies demonstrate 
that CCL2 stimulation up-regulates MMP-3 transcription (Yuan et al., 2001) and 
that CCL2 and CXCL8 stimulation up-regulate the release of MMP-3 from 
chondrocyte cultures (Borzi et al., 2000; Yuan et al., 2001).  Here, the effects of 
CCL2 and CXCL8 stimulation were investigated in monolayer cultures.  Data 
generated indicates that CCL2 and CXCL8 do not elicit modulatory effects on 
MMP-3 transcription in primary NP cultures.  However, since protein level 
investigations were not performed here these chemokines may modulate release of 
ECM degrading enzymes. 
The data presented here indicates clearly that IL-1β exerts significant 
transcriptional modulatory potential over cytokines, chemokines, ECM constituents 
and ECM degrading enzymes in NP cells.  However, gene expression alterations 
may not be an accurate reflection of modulatory effects occurring at the protein 
level.  Hence, whilst other cytokines and chemokines (IL-16, CCL2, CCL3, CCL7 
and CXCL8) did not demonstrate transcriptional modulatory potential it is possible 
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that they may still exert translational modulatory potential that could affect protein 
expression.   
6.3.3 Selection of Treatments for Protein Expression Studies 
Cell culture supernatants collected from alginate cultures subjected to IL-1β 
stimulation were selected for further cytokine and chemokine protein expression 
analysis.  These samples were selected on the basis of the modulatory potential of 
IL-1β on other cytokines and chemokines displayed at the level of gene expression 
described in this chapter.   
6.3.4 Summary 
Data presented in this chapter confirms the transcriptional modulatory potential of 
IL-1β on cytokines, chemokines, ECM components and ECM degrading enzymes 
in NP cells.  Further, it demonstrated that for certain targets, particularly the ECM 
degrading enzymes, this modulation by IL-1β is dependent on NP cell phenotype.  
This investigation also demonstrates that IL-16, CCL2, CCL3, CCL7 and CXCL8 do 
not modulate cytokine, chemokine, ECM component or ECM degrading enzyme 
expression at the level of transcription in NP cells.   
 254 
 
7 The Effect of Interleukin-1β 
Stimulation on Cytokine and 
Chemokine Release from Primary 
Human Nucleus Pulposus Cells In 
Vitro 
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7.1 Introduction 
This chapter describes investigations into the modulatory effect of IL-1β on cytokine 
and chemokine release from primary NP alginate cultures.  Multiplex bead 
immunoassays were used to simultaneously quantify 20 cytokines and chemokines 
in conditioned media from cultures under basal conditions and following stimulation 
with IL-1β.   
7.1.1 Methods 
Full details of methods used in this study are given in Chapter 2, sections; 
• 2.4 Cell culture 
• 2.6 Luminex Multiplex Bead Immunoassay 
7.1.2 Specific Objective 
This chapter aims to address the hypothesis that: 
Regulatory inter-relationships exist between IL-1β and the cytokines and 
chemokines of the IVD. 
The specific objective is: 
• To determine the regulatory potential of IL-1β on cytokine and chemokine 
release from primary NP alginate cultures       
7.2 Results  
Expression of all cytokines and chemokines investigated was detected in 
conditioned media from alginate NP cultures under basal conditions (Figure 7-1).  
The cytokine expression profile was dominated by IL-6 (>100pg/mL), followed by 
CSF2 and TNF-α (>10pg/mL), IL-4 (~10pg/mL) and IL-1β (~5pg/mL).  Low 
concentrations of IFN-γ, IL-10, IL-2 and IL-5 (<1pg/mL) were also detected.  The 
chemokine expression profile was dominated by CXCL8 (>9,000pg/mL) and CCL2 
(>2,000pg/mL), followed by CCL7 (~15pg/mL), CCL3, CXCL1 and CXCL9 
(~7pg/mL), CCL4 (~4pg/mL), CCL5 (~2pg/mL) and CCL8 (~1pg/mL).  Low 
concentrations of CCL11 and CXCL10 (<1pg/mL) were also detectable.   
7.2.1 Cytokine Release Following IL-1β Stimulation 
7.2.1.1 IL-1β Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of IL-1β into culture media (Figure 7-2A).  Increased release of IL-1β was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).  
Stimulation ≥10pg/mL resulted in significant increase in IL-1β release from alginate 
cultures compared to basal levels (P<0.05). 
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7.2.1.2 IL-2 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of IL-2 into culture media (Figure 7-2B).  Increased release of IL-2 was 
observed separately in cells derived from 4 IVDs, standard curve generation failure 
prevented IL-2 investigation in cells derived from a fifth IVD (data not shown).  
Although a trend of increasing IL-2 release following stimulation was observed, this 
was only significant following 100ng/mL treatment (P=0.002).   
7.2.1.3 IL-4 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of IL-4 into culture media (Figure 7-2C).  Increased release of IL-4 was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).  
Significant increase in IL-4 release occurred following stimulation with ≥10pg/mL 
(P<0.05).   
7.2.1.4 IL-5 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of IL-5 into culture media (Figure 7-2D).  Increased release of IL-5 was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).  
Significant increase in IL-5 release occurred following stimulation with ≥10pg/mL 
(P<0.05). 
7.2.1.5 IL-6 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of IL-6 into culture media (Figure 7-2E).  Increased release of IL-6 was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).  
Significant increase in IL-6 release occurred following stimulation with ≥1pg/mL 
(P<0.05).   
7.2.1.6 IL-10 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of IL-10 into culture media (Figure 7-2F).  Increased release of IL-10 was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).  
Significant increase in IL-10 release occurred following stimulation with ≥10pg/mL 
(P<0.05).       
7.2.1.7 TNF-α Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of TNF-α into culture media (Figure 7-3A).  Increased release of TNF-α was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).  
Significant increase in TNF-α release occurred following stimulation with ≥10pg/mL 
(P<0.05).     
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7.2.1.8 IFN-γ Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of IFN-γ into culture media (Figure 7-3B).  Increased release of IFN-γ was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).  
Significant increase in IFN-γ release occurred following stimulation with ≥1pg/mL 
(P<0.05). 
7.2.1.9 CSF2 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CSF2 into culture media (Figure 7-3C).  Increased release of CSF2 was 
observed separately in cells derived from 4 IVDs, standard curve generation failure 
prevented investigation in cells derived from a fifth IVD (data not shown).  
Significant increase in CSF2 release occurred following ≥10pg/mL (P<0.05).     
7.2.2 Chemokine Release Following IL-1β Stimulation 
7.2.2.1 CCL2 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CCL2 into culture media (Figure 7-4A).  Increased release of CCL2 was 
observed separately in cells derived from all 5 IVDs investigated (data not shown). 
Significant increase in CCL2 release occurred following stimulation with ≥1pg/mL 
(P<0.05). 
7.2.2.2 CCL3 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CCL3 into culture media (Figure 7-4B).  Increased release of CCL3 was 
observed separately in cells derived from 4 IVDs, standard curve generation failure 
prevented investigation in cells derived from a fifth IVD (data not shown).  
Significant increase in CCL3 release occurred following stimulation with ≥10pg/mL 
(P<0.05).   
7.2.2.3 CCL4 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CCL4 into culture media (Figure 7-4C).  Increased release of CCL4 was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).  
Significant increase in CCL4 release occurred following stimulation with 100pg/mL 
(P<0.05).  
7.2.2.4 CCL5 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CCL5 into culture media (Figure 7-4D).  Increased release of CCL5 was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).   
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Figure 7-2  Interleukin Release from Alginate Nucleus Pulposus Cultures Following IL-1β 
Stimulation  
Alginate cultured NP cells were subjected to 48 hour treatment with 0pg/mL, 1pg/mL, 
10pg/mL, 100pg/mL, 1ng/mL, 10ng/mL or 100ng/mL IL-1β.  Each treatment was 
performed in triplicate on cultures derived from five NP tissue samples, with the exception 
of IL-2 that was performed in triplicate on cultures derived from four NP tissue samples.  
Graphical data represents mean detection level ± SEM.  * indicates P<0.05. 
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Figure 7-3  TNF-α, IFN-γ and CSF2 Release from Alginate Nucleus Pulposus Cultures 
Following IL-1β Stimulation  
Alginate cultured NP cells were subjected to 48 hour treatment with 0pg/mL, 1pg/mL, 
10pg/mL, 100pg/mL, 1ng/mL, 10ng/mL or 100ng/mL IL-1β.  Each treatment was 
performed in triplicate on cultures derived from five NP tissue samples, with the exception 
of CSF2 that was performed in triplicate on cultures derived from four NP tissue samples.  
Graphical data represents mean detection level ± SEM.  * indicates P<0.05. 
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Figure 7-4  C-C Chemokine Release from Alginate Nucleus Pulposus Cultures Following IL-
1β Stimulation    
Alginate cultured NP cells were subjected to 48 hour treatment with 0pg/mL, 1pg/mL, 
10pg/mL, 100pg/mL, 1ng/mL, 10ng/mL or 100ng/mL IL-1β. Each treatment was performed 
in triplicate on cultures derived from five NP tissue samples, with the exceptions of CCL3 
and CCL8 that were performed in triplicate on cultures derived from four NP tissue 
samples.  Graphical data represents mean detection level ± SEM.  * indicates P<0.05. 
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Significant increase in CCL5 release occurred following stimulation with ≥100pg/mL 
(P<0.05).    
7.2.2.5 CCL7 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CCL7 into culture media (Figure 7-4E).  Increased release of CCL7 was 
observed separately in cells derived from all 5 IVDs investigated (data not shown).  
Significant increase in CCL7 release occurred following stimulation with ≥10pg/mL 
(P<0.05).     
7.2.2.6 CCL8 Release 
IL-1β treatment did not affect CCL8 expression in alginate cultured NP cells.  No 
effect of treatment was observed in cells derived from 4 IVDs, standard curve 
generation failure prevented investigation in cells derived from a fifth IVD (data not 
shown).   
7.2.2.7 CCL11 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CCL11 into culture media (Figure 7-4F).  Increased release of CCL11 
was observed separately in cells derived from all 5 IVDs investigated (data not 
shown).  Significant increase in CCL11 release occurred following stimulation with 
≥10ng/mL (P<0.05).   
7.2.2.8 CXCL1 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CXCL1 into culture media (Figure 7-5A).  Increased release of CXCL1 
was observed separately in cells derived from all 5 IVDs investigated (data not 
shown).  Significant increase in CXCL1 release occurred following stimulation with 
≥1pg/mL (P<0.05).      
7.2.2.9 CXCL8 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CXCL8 into culture media (Figure 7-5B).  Increased release of CXCL8 
was observed separately in cells derived from all 5 IVDs investigated (data not 
shown).  Significant increase in CXCL8 release occurred following stimulation with 
≥1pg/mL (P<0.05).   
7.2.2.10 CXCL9 Release  
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CXCL9 into culture media (Figure 7-5C).  Increased release of CXCL9 
was observed separately in cells derived from 2 IVDs, standard curve generation 
failure prevented investigation in cells derived from three other IVDs (data not 
shown).  Although a trend of CXCL9 up-regulation was observed, this was only
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Figure 7-5  C-X-C Chemokine Release from Alginate NP Cultures Following IL-1β 
Stimulation  
Alginate cultured NP cells were subjected to 48 hour treatment with 0pg/mL, 1pg/mL, 
10pg/mL, 100pg/mL, 1ng/mL, 10ng/mL or 100ng/mL IL-1β.  Each treatment was 
performed in triplicate on cultures derived from five NP tissue samples, with the 
exceptions of CXCL9 that was performed in triplicate on cultures derived from two NP 
tissue samples and CXCL10 that was performed in triplicate on cultures derived from four 
NP samples.  Graphical data represents mean detection level ± SEM.  * indicates P<0.05. 
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significant following 100pg/mL and 100ng/mL treatment (P=0.0225 and P=0.0151 
respectively).   
7.2.2.11 CXCL10 Release 
Alginate cultured NP cells responded to 48 hour IL-1β treatment by increasing 
release of CXCL10 into culture media (Figure 7-5D).  Increased release of CXCL10 
was observed separately in cells derived from 4 IVDs, standard curve generation 
failure prevented investigation in cells derived from a fifth IVD (data not shown).  
Although a trend of increasing CXCL10 release following stimulation was observed, 
this was only significant following 100ng/mL treatment (P=0.0072).  
7.2.3 Summary of Results 
The results presented in this chapter are summarised in Table 7-1. 
Target IL-1β treatment effect Target IL-1β treatment effect 
Cytokines Chemokines 
IL-1β ↑* CCL2 ↑* 
IL-2 ↑* CCL3 ↑* 
IL-4 ↑* CCL4 ↑* 
IL-5 ↑* CCL5 ↑* 
IL-6 ↑* CCL7 ↑* 
IL-10 ↑* CCL8 No effect 
TNF-α ↑* CCL11 ↑* 
IFN-γ ↑* CXCL1 ↑* 
CSF2 ↑* CXCL8 ↑* 
  
CXCL9 ↑* 
  
CXCL10 ↑* 
Table 7-1  Summary of IL-1β Stimulation Effects on Cytokine and Chemokine Release 
from Alginate Cultured Nucleus Pulposus Cells 
↑, increased release into culture media following IL-1β stimulation; *, significant increase 
in protein release compared to basal levels (P<0.05) 
7.3 Discussion 
The objective of this investigation was to determine the effects of IL-1β stimulation 
on modulation of cytokine and chemokine production by primary alginate NP 
cultures.  It is worth noting at this point that the parameter measured in these 
investigations is cytokine and chemokine release into culture media.  The 
quantifications made do not account for cytokines or chemokines synthesised but 
not released or those sequestered through GAG interactions with either the cell 
surface or ECM laid down within the alginate beads (Proudfoot, 2006).   
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Luminex multiplex bead immunoassays were used to interrogate conditioned media 
recovered from primary alginate NP cultures, by this method the presence and 
concentration of target analytes was determined.  All cytokine targets investigated 
were detected in conditioned media from alginate cultures under basal conditions, 
indicating a diverse cytokine release profile is a feature of primary NP cells.  Data 
generated indicates the cytokine expression profile is dominated by IL-6 
(>100pg/mL), CSF2 (>10pg/mL) and TNF-α (>10pg/mL), all of which were detected 
previously at the mRNA level in our gene expression studies (see Chapter 3, 
section 3.2 and Chapter 4, section 4.2).  The chemokine expression profile was 
dominated by CCL2 (>2,000pg/mL) and CXCL8 (>9,000pg/mL), both of which were 
detected previously at the mRNA level in our gene expression studies on NP cells 
isolated directly from NP tissue (see Chapter 3, section 3.2 and Chapter 4, section 
4.2).  NP cell protein production was also identified previously in tissue sections, 
(Chapter 5, section 5.2).  CCL2 and CXCL8 gene expression was investigated in 
our previous study using alginate NP cultures, where constitutive expression under 
basal conditions was identified (see Chapter 6, section 6.2).    
With the exception of CCL8, IL-1β stimulation significantly increased release of all 
cytokines and chemokines investigated from alginate NP cultures.  Several different 
modulatory patterns were observed and these appeared to be IL-1β concentration 
dependent.   
The targets that dominated the cytokine and chemokine protein expression profile 
under basal conditions; IL-6, CCL2 and CXCL8, were particularly sensitive to IL-1β 
stimulation.  Significant increases in protein release occurred for IL-6 (32-fold), 
CCL2 (3-fold) and CXCL8 (2-fold) following stimulation with only 1pg/mL IL-1β.  
Other targets sensitive to this level of IL-1β stimulation were IFN-γ and CXCL1, 
where 3-fold and 13-fold increases in protein release were observed.  Considering 
these five targets, three different modulatory responses were observed.  For 
CXCL8 and IFN-γ, the increase in protein release following 1pg/mL stimulation was 
maximal - no further significant increase in expression was observed with 
increasing dose stimulation.  For IL-6 and CCL2, a further significant increase in 
protein release, on top of that observed following 1pg/mL stimulation, was observed 
following stimulation with 10pg/mL, before maximal release was achieved.  CXCL1 
release increased in a dose dependent manner with significant increases between 
stimulation concentrations up to 1ng/mL prior to reaching maximal.   
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Increasing IL-1β stimulation to 10pg/mL was seen to modulate other cytokines and 
chemokines.  Significant auto-induction of IL-1β (4.5-fold) occurred, alongside 
increases in protein release for IL-4 (2.5-fold), IL-5 (5.5-fold), IL-10 (10-fold), TNF-α 
(3-fold), CSF2 (3-fold) and CCL7 (2-fold).  Considering these seven targets, three 
different modulatory responses were observed.  For IL-1β and CSF2, the increase 
in protein release following 10pg/mL stimulation was maintained following 
stimulation with 100pg/mL however, protein release increased significantly again 
following stimulation with 1, 10 and 100ng/mL.  For TNF-α, the protein release 
stimulated by 10pg/mL IL-1β was maintained following stimulation with 100pg/mL 
and 1ng/mL however, 10 and 100ng/mL stimulation resulted in further increases in 
protein release.  For IL-4, IL-5, IL-10 and CCL7 the increase in protein release 
following 10pg/mL IL-1β stimulation was maximal – no further significant increase 
in expression was observed with increasing dose stimulation.  
Increasing IL-1β stimulation to 100pg/mL extended the modulatory effect to other 
chemokines.  Significant increases in protein release following 100pg/mL 
stimulation were detected for CCL3 (8.5-fold), CCL4 (5.5-fold) and CCL5 (4-fold).  
For CCL3, protein release was further significantly increased following 1ng/mL 
treatment before maximal levels were reached.  For CCL4 and CCL5 the protein 
release stimulated by 100pg/mL IL-1β was maximal.   
The four remaining targets; IL-2, CCL11, CXCL9 and CXCL10, were less sensitive 
to modulation by IL-1β.  Stimulation with 10ng/mL was required before release of 
CCL11 was significantly increased compared to basal levels and stimulation with 
100ng/mL was required to significantly increase release of IL-2 and CXCL10.  As a 
result of standard curve generation failure CXCL9 release was only quantified in 
alginate cultures derived from two IVD samples.  Data generated indicates a trend 
of increasing CXCL9 release following IL-1β stimulation although release was only 
significantly increased following 100pg/mL and 100ng/mL stimulation.    
IL-1β stimulated release of IL-6, CCL2, CXCL8 and TNF-α from primary NP 
cultures has been investigated previously (Yoshida et al., 2002; Huang et al., 2008; 
Studer et al., 2011).  The effect of IL-1β stimulation on IL-6 release from primary 
NP cultures has been investigated in monolayer and alginate experimental systems 
(Huang et al., 2008; Studer et al., 2011).  Monolayer cultured primary human NP 
cells derived from prolapsed IVDs responded to 24 hour, 30ng/mL IL-1β stimulation 
with an ~8.1 fold increase in IL-6 release into culture media measured by ELISA 
(Huang et al., 2008).  Alginate cultured primary human NP cells derived from 
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degenerate IVDs responded to 24 hour 0.5ng/mL IL-1β stimulation a ~611 fold 
increase in IL-6 release into culture media measured by ELISA (Studer et al., 
2011).  Data generated in this investigation confirms these previous reports of IL-1β 
stimulated release of IL-6 from primary NP cultures and further, demonstrates that 
IL-6 release is not a dose dependent response to IL-1β stimulation.   
The effect of IL-1β stimulation on CCL2 release from primary NP cultures has been 
investigated previously (Yoshida et al., 2002; Huang et al., 2008).  These studies 
demonstrate CCL2 release from monolayer cultured primary human NP cells is 
increased ~3.2 fold following 24 hour 30ng/mL IL-1β stimulation (Huang et al., 
2008), here maximal CCL2 release (~10 fold) occurred following 10pg/mL IL-1β 
stimulation.  The increased fold-release observed here may represent a differential 
response to IL-1β stimulation between monolayer and alginate cultured NP cells.  
Dose-dependence of CCL2 release following IL-1β stimulation has been 
investigated previously in monolayer cultured rabbit NP cells (Yoshida et al., 2002).  
Treatment concentrations between 0.01 and 100ng/mL IL-1β were applied for 24 
hours prior to quantification of CCL2 in culture media.  Stimulation with 0.1ng/mL 
IL-1β was required to significantly increase CCL2 release (Yoshida et al., 2002).  
Data generated here confirms previous reports of CCL2 release from NP cultures 
following IL-1β stimulation (Yoshida et al., 2002; Huang et al., 2008).   
The effect of IL-1β stimulation on CXCL8 and TNF-α release from primary NP 
cultures has been investigated previously (Huang et al., 2008).  These studies 
demonstrate monolayer cultured primary human NP cells derived from prolapsed 
IVDs respond to 24 hour, 30ng/mL IL-1β stimulation by increasing release of 
CXCL8 (~2.3 fold) and TNF-α (~3 fold) into culture media, measured by ELISA 
(Huang et al., 2008).  The fold change in CXCL8 release reported in monolayer 
cultures (Huang et al., 2008) is similar to the maximal 2-fold increase seen here in 
alginate NP cultures although we report a greater increase in TNF-α release (~10 
fold), which may be related to a differential response between monolayer and 
alginate cultures.      
IL-1β stimulated release of other cytokines and chemokines has not been 
investigated previously in NP cultures although some targets have been 
investigated in articular chondrocyte cultures or cartilage explants (Recklies & 
Golds, 1992; Villiger et al., 1992; Pulsatelli et al., 1999; Moos et al., 2001).  These 
studies demonstrate IL-1β stimulated release of CCL2 (Villiger et al., 1992; 
Pulsatelli et al., 1999), CCL3 (Pulsatelli et al., 1999), CCL5 (Pulsatelli et al., 1999), 
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CXCL1 (Recklies & Golds, 1992) and CXCL8 (Recklies & Golds, 1992; Pulsatelli et 
al., 1999) from primary human articular chondrocytes derived from OA, RA and 
normal tissue donor cartilage samples.  Stimulation of OA cartilage explant cultures 
also demonstrates the modulatory effect of IL-1β on chondrocyte production of IL-4 
and IL-10, where an increase in the percentage of immune-positive cells is 
observed following IL-1β stimulation (Moo et al., 2001).   
7.3.1 Summary  
Data generated in this investigation confirms the production of cytokines and 
chemokines by primary NP cells, and their release into the extracellular 
environment.  The finding that produced cytokines and chemokines are secreted by 
NP cells confirms their potential to act as intercellular signals in paracrine signalling 
mechanisms or as autologus regulators in autocrine signalling mechanisms.   
This investigation confirms the modulatory potential of IL-1β on cytokine and 
chemokine production at the protein level, as observed previously in gene 
expression studies (Chapter 6).  Although it remains unclear from this investigation 
whether IL-1β stimulation affects protein synthesis or modulates the release of pre-
formed intracellular protein stores.   
The modulatory effects of IL-1β stimulation appeared to be dose-dependent with 
respect to the different cytokine and chemokine targets.  Increasing the dose 
stimulation was seen to extend the modulatory influence of IL-1β to further cytokine 
and chemokine targets unresponsive to lower dose stimulation.  This may indicate 
that IL-1β modulates cytokine and chemokine release by several different 
mechanisms, and that these mechanisms are induced in a concentration 
dependent manner.  The observed patterns of cytokine or chemokine release may 
represent groups of cytokine and chemokine targets that are modulated by the 
same mechanism.       
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8 General Discussion  
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The overall aim of studies described in this thesis was to investigate the hypothesis 
that cytokines and chemokines are integral to the pathogenesis of IVD 
degeneration and prolapse, both of which may lead to the generation of LBP.   
The first specific objective of these studies was to identify cytokines and 
chemokines produced within the NP of normal, degenerate and prolapsed IVDs, 
and the second, to identify the ‘target cells’ of these cytokines and chemokines 
based on receptor expression.  These two objectives were addressed by the 
studies described in Chapters 3, 4 and 5 of this thesis, where human NP tissue was 
utilised to identify cytokines and chemokines produced by cells present within NP 
tissue samples, to identify the cellular source of this production, and to relate 
production to characteristic features of the pathology of IVD degeneration.   
Previous studies have identified that cytokine and chemokine expression is 
increased in degenerate and prolapsed IVD tissue compared to that obtained from 
normal tissue donors (Burke et al., 2002; Le Maitre et al., 2005; Bachmeier et al., 
2007; Le Maitre et al., 2007d).  Based on these findings, it would appear that there 
is a direct association between cytokine and chemokine expression and IVD 
pathology, although whether this is cause or effect remains unknown.   
The progression of IVD degeneration is known to proceed by the altered behaviour 
of native cells (Urban et al., 2000), the pathological changes this causes to IVD 
tissue structures is known to increase the susceptibility of IVDs to prolapse injury 
(Adams & Hutton, 1985).  Due to the association between pathology and cytokine 
expression a number of studies have attempted to understand the role that 
cytokines may play in the disruption of native cell behaviour.  These studies have 
identified that the cytokines, IL-1 and TNF-α, can dysregulate ECM turnover (Le 
Maitre et al., 2005; Le Maitre et al., 2007d; Hoyland et al., 2008; Millward-Sadler et 
al., 2009; Studer et al., 2011), by down-regulating rates of anabolic metabolism and 
up-regulating rates of catabolic.   
With the exception of IL-1 and TNF-α, studies investigating the production of 
cytokines and chemokines within the IVD are limited.  Initial observations of 
cytokine and chemokine expression in the IVD by Ahn et al. (2002) and Kawaguchi 
et al. (2002) identified a further 11 cytokine and chemokine targets however, to 
date detailed investigations into the expression or potential roles of these targets 
within the IVD have only been performed for IL-6 and IFN-γ (Shamji et al., 2010; 
Gabr et al., 2011; Studer et al., 2011).   
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Chapters 3 and 4 of this thesis describe our initial investigations to determine the 
cytokine and chemokine gene expression profile of cells isolated directly from NP 
tissue.  In total, 25 cytokine and 18 chemokine targets were investigated, alongside 
associated receptors and where relevant, activating enzymes and signalling 
accessory proteins.  Of the 43 cytokine and chemokine targets investigated, gene 
expression of 35 was confirmed, 17 of which are novel findings to the IVD.  Further, 
in 34 of the 35 cases, corresponding signalling receptor expression was also 
detected, indicating that the cytokines and chemokines produced in the IVD may 
function within it, as intercellular signalling molecules.   
Chapter 4 describes a more detailed investigation into the gene expression profile 
of cells isolated directly from NP tissue samples.  This study not only confirms gene 
expression of cytokines, chemokines and signalling receptors within the IVD, but 
identifies targets with differential expression profiles based on the pathology of 
tissue samples from which they were derived.  The differential expression profile 
observed for certain targets indicates an association between target and pathology, 
although these investigations are not sufficient to indicate whether the relationship 
may be cause or effect.   
An important observation was made during the course of studies described in 
Chapters 3 and 4, and this has implications both for the interpretation of data 
generated here, and for the design of future investigations into IVD pathology.  That 
is, degenerative changes were not consistent throughout tissue samples, but rather 
present as ‘degenerative lesions’ surrounded by histologically normal tissue.  The 
implications of this observation on data generated in these studies is that, it is 
impossible to know what percentage of cells isolated from any tissue sample are 
derived from a degenerate lesion or a histologically normal tissue region.   
To overcome this limitation in future studies, it may be better to use the method of 
Laser Capture Microdissection (LCM) to isolate NP cells, rather than enzymatic 
digestion of ECM for cell isolation as used here.  LCM uses sections of fixed tissue 
that are examined microscopically and cells ‘captured’ from their native position 
within the tissue section by laser dissection (Simone et al., 1998).  By this method, 
it would even be possible to perform a spatial comparison of target expression, if 
cells were collected separately from degenerate lesions and tissue appearing 
histologically normal within the same sample.   
Studies using the method of LCM would address a further limitation of the 
investigations described in Chapters 3 and 4.  That is, that the isolation of cells 
from tissue samples by enzymatic digestion of ECM constitutes an in vitro 
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manipulation, which may affect the cytokine and chemokine gene expression profile 
of isolated cells.  Practically, because of the acellularity of NP tissue, cell isolation 
prior to RNA extraction is required to concentrate sufficient cell numbers into an 
appropriate reaction volume.  However, mRNA expression, particularly of inducible 
targets, is often transient and stability is low, for example IL-16 mRNA half-life is 
only 2 hours (Cruikshank et al., 2000).  Hence, the time frame of enzymatic 
digestion (4 – 18 hours) is sufficient for mRNA expression profile alterations to 
occur.   
Gene expression profiling generates large data sets that can be ‘mined’ to elucidate 
information related to specific parameters of interest.  Data generated in Chapters 3 
and 4 was interrogated in respect of relative levels of mRNA expression and the 
frequency at which detection was made, within particular study groups.  It may be 
useful to subject this data to further analysis, related to the co-expression of targets 
investigated.  In OA, two distinct cytokine phenotypes have been described; TNF-
α
High
 characterised by TNF-α and IL-6 expression, and TNF-α
Low
 characterised by 
IL-1β, transforming growth factor-β, IL-4 and IL-10 expression (Moos et al., 2000; 
Moos et al., 2001).  These distinct phenotypes are thought to arise from 
polymorphisms affecting the expression of IL-1β or IL-1Ra, and therefore link 
cytokine expression with a genetic predisposition in OA (Moos et al., 2000).  
Further, co-expression can be an indication of molecules that share regulatory 
pathways, are modulated by the same stimuli, or exert modulatory potential over 
each other.  It may be the case that cytokine co-expression patterns are 
characteristic of IVD pathology, and principle component analysis or multivariate 
analysis of data generated in these investigations may be sufficient to provide initial 
indications as to cytokine and chemokine co-expression patterns within the IVD.   
Chapter 5 describes investigations by IHC into protein production and localisation 
of cytokines, chemokines and receptors.  These studies were necessary in order to 
confirm that observed gene expression was translated into protein production within 
the IVD.  For all targets investigated, protein expression by native NP cells was 
confirmed.  Analysis of the expression patterns of these produced proteins allowed 
for the identification of differential expression profiles based on the pathology of the 
IVD.  However, the differential protein expression profiles observed did not in all 
cases agree with the previously obtained gene expression profiles for the same 
targets across the same study groups.   
Differences between mRNA and protein expression profiles arise primarily through 
two mechanisms, either mRNA production is transient, and produced transcripts 
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unstable, whilst the proteins produced have greater stability and increased half-life, 
remaining detectable over a longer time period (Villiger et al., 1992), or translational 
modifications exert effects on rates of protein production that are not related to or 
detectable at, the level of mRNA transcription.  Either scenario may account for the 
differences observed in these investigations, although since production is a 
prerequisite for activity, the protein expression profile is a better indication of factors 
likely to be active within the IVD.   
The findings reported in Chapters 3, 4 and 5 of this thesis suggest that cytokine 
and chemokine expression is increased in the IVD in line with increasing severity of 
pathological tissue changes.  Together, these studies add further evidence to the 
association between cytokine and chemokine expression and IVD pathology. 
The third specific objective was to determine the inter-relationships that exist 
between the cytokines and chemokines of the IVD.  This objective was addressed 
by studies described in Chapters 6 and 7 of this thesis, where in vitro manipulations 
of primary NP cultures were performed to determine the effect of cytokine or 
chemokine stimulation on NP cell behaviour.  
Chapter 6 describes investigations to determine the modulatory effects of selected 
cytokines and chemokines on mRNA expression of target cytokines and 
chemokines.  In total, the effects of stimulation with 6 different cytokines and 
chemokines were investigated, although only IL-1β was seen to modulate 
transcription of other cytokines and chemokines under the experimental conditions 
investigated.   
Whilst no significant effects were observed for the other 5 cytokines and 
chemokines, this lack of modulatory potential cannot be considered conclusive.  In 
a previous study by Villiger et al. (1992), the modulatory potential of IL-1β and LIF 
on mRNA expression of CCL2 was investigated.  This study demonstrated that 
whilst both cytokines up-regulate CCL2 mRNA transcription, the kinetics of the 
response to IL-1β and LIF are different.  Time course investigations indicated that 
LIF stimulation induced a rapid increase in CCL2 transcription that was maximal 2 
hours post stimulation, and returned to basal levels by 5 hours post stimulation.  
The initial response to IL-1β stimulation was slower, taking 8 hours to reach 
maximal however, the effect was longer lasting (>11 hours).  Both cytokines were 
seen to up-regulate levels of CCL2 detectable in conditioned media collected 24 
hours post stimulation (Villiger et al., 1992), and so modulate protein expression in 
a similar manner, but through different transcriptional modulatory mechanisms.     
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These investigations by Villiger et al. (1992) demonstrate that the kinetics of 
transcriptional response to cytokine stimulation is different depending on the 
cytokine applied.  A limitation therefore, of investigations described in Chapter 6 of 
this thesis is that all stimulations were performed for 48 hours, the time point 
previously identified as optimal for detection of IL-1β stimulated responses (Le 
Maitre, 2003).  As such, in order to confirm the transcriptional modulatory potential 
of the other cytokines and chemokines investigated, further time course 
investigations are required.    
Chapter 7 describes investigations by immunoassay into production and secretion 
of cytokines and chemokines by alginate NP cultures following IL-1β stimulation.  
These studies were necessary in order to confirm that the transcriptional 
modulatory potential of IL-1β extended to the level of protein expression.  In total, 
the effect of IL-1β stimulation on secretion of 20 cytokines and chemokines was 
investigated.  For 19 of these targets, it was confirmed that IL-1β up-regulates 
secretion, although it is difficult to interpret the data relating to up-regulation of IL-
1β since exogenous IL-1β was supplemented to the cultures.     
The final objective of this thesis was to understand how the different cytokine and 
chemokine expression profiles and inter-relationships may contribute to the 
disruption of catabolic and anabolic cellular metabolism.  This objective was 
addressed by studies described in Chapters 6 and 7, whereby the effects of 
cytokine stimulation on anabolic and catabolic metabolism were investigated 
alongside the quantification of cytokine and chemokine production by primary NP 
cultures, with and without IL-1β stimulation. 
In a recent study by Liebscher et al. (2011) that investigated the cell population of 
the IVD, the young adult human lumbar NP was determined to contain ~2,600 
cells/mm
3
.  This physiological value described by Leibscher et al. (2011) is slightly 
increased compared to the cell density used in investigations described in Chapters 
6 and 7, where cell density equivalent to 2,000 cells/mm
3
 was used.  Accounting for 
the increased cell numbers in vivo the concentration of cytokines and chemokines 
within the IVD can be calculated, assuming that the culture model used accurately 
represents the in vivo scenario.   
On account of this, basal IL-1β expression would be ~8.5pg/mL within the IVD.  
Considering the modulatory potential of IL-1β stimulation, as determined in Chapter 
6, this concentration would stimulate ECM remodelling.  Although the effect may 
not be detrimental, since gene expression of aggrecan was observed to be up-
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regulated alongside the down-regulation of type II collagen, up-regulation of MMP-3 
(stromelysin) and -13 (collagenase), whilst aggrecanolytic ADAMTS-4 transcription 
was not significantly affected.  The net effect of this modulatory pattern may result 
in beneficial changes, promoting a more gelatinous and less collagenous ECM.  
This would indicate that the low level detection of IL-1β, identified previously in the 
normal IVD (Le Maitre et al., 2005; Le Maitre et al., 2007d) may be beneficial to IVD 
structural integrity.   
There has been some success in indentifying environmental conditions that can 
lead to IL-1 production within the IVD, such as excessive loading stresses (Wang et 
al., 2007).  The findings presented in this thesis suggest that this production of IL-1 
in response to changing environmental conditions may be an appropriate response 
to trigger adaptive tissue remodelling.  However, our findings also support the 
previously reported detrimental effects of excessive or increased IL-1β production 
on ECM structural integrity (Le Maitre et al., 2005; Hoyland et al., 2008; Millward-
Sadler et al., 2009; Studer et al., 2011).        
The findings reported in Chapters 6 and 7 of this thesis indicate that IL-1 is a key 
regulator of NP cell behaviour.  IL-1β exerts significant modulatory potential on the 
production of other cytokines and chemokines by NP cells in vitro, and on 
transcription of genes related to ECM remodelling.     
The context in which we sought to identify the cytokine and chemokine expression 
profile of the IVD was in so far as it related to the progression of IVD pathology, and 
to the effects that it may elicit on attempted biological therapies targeted at 
impeding progression of, or even reversing this pathology.  In respect of IVD 
degeneration, pathological changes associated with altered cellular behaviour are 
related to proliferation (Johnson & Roberts, 2003), differentiation (Gruber et al., 
2005; Roberts et al., 2006), dysregulated metabolism (Antoniou et al., 1996a; 
Weiler et al., 2002) and cell death (Park et al., 2001a).  It seems reasonable to 
assume that, if the cytokines and chemokines identified here do form part of the 
pathological mechanism of IVD degeneration and prolapse, their effects would be 
related to the adverse alterations in cell behaviour observed in that pathology.   
Aside of the investigations described previously, the effects of cytokines and 
chemokines on NP cell behaviour have not been comprehensively studied, 
although their effects in other cell types have been described.  Chondrocytes 
exhibit morphological and biochemical similarity to NP cells, and so the effects of 
cytokines and chemokines on chondrocyte behaviour may be relevant to that of NP 
cells.  In chondrocytes, effects of cytokine and chemokine stimulation have been 
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described in relation to all of the common features of altered NP cell behaviour as 
seen in IVD degeneration.  These include increased rates of proliferation (Mazzetti 
et al., 2004), hypertrophic differentiation (Merz et al., 2003; Wei et al., 2010), 
increased catabolic metabolism (Carroll et al., 1995; Alaaeddine et al., 2001; Yuan 
et al., 2001; Mazzetti et al., 2004), decreased anabolic metabolism (Alaaeddine et 
al., 2001; Yuan et al., 2001), and induced cell death (Borzi et al., 2002; Wei et al., 
2006).  The precedents set in these investigations indicate that further investigative 
work into the role of cytokines and chemokines within the IVD is warranted.    
Elucidation of the pathology of IVD degeneration is required for the successful 
development of treatment strategies.  IVD degeneration increases the risk of LBP 
development (Luoma et al., 2000) and 40% of LBP cases are linked directly to IVD 
degeneration (Schwarzer et al., 1995).  Successful treatment of IVD degeneration 
therefore represents a mechanism by which the incidence of LBP within the 
population may be decreased.   
Currently, several research initiatives are investigating the regenerative potential of 
stem cell therapy within the IVD to enhance the degenerate cell population (Steck 
et al., 2005; Le Maitre et al., 2009; Collin et al., 2011; Yang et al., 2011).  
Application of the soluble factor, TGF-β, elicits well described effects on 
mesenchymal and adipose-derived stem cell differentiation, indeed its application in 
vitro is required to stimulate differentiation towards a NP phenotype (Steck et al., 
2005; Yang et al., 2011).  The survival and differentiation characteristics of stem 
cells injected into NP explant cultures, under conditions modelling the environment 
of the ‘normal’ IVD have been confirmed (Le Maitre et al., 2009).  However, the 
findings presented in this thesis suggest that cells implanted into the degenerate 
IVD would encounter a diverse and altered range of soluble factors, including 
cytokine and chemokine signalling molecules.  The effects of these on stem cell 
behaviour have not been investigated, and clearly the response of implanted cells 
to their surrounding environment will have considerable influence over the success 
of stem cell therapy to the IVD.  To this end, the studies described in this thesis 
provide insight into the conditions of the 'degenerate niche' and may form the basis 
of further investigations to determine the effects this environment may elicit on stem 
cell behaviour.   
8.1 Future Work 
Accumulating evidence supports a direct association between cytokine and 
chemokine expression and IVD pathology.  The investigations described in this 
thesis have identified NP cells as a source of numerous cytokines and chemokines, 
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although the effects that these elicit in and around the IVD are largely unknown.  
Further investigation, to determine whether these factors affect NP cell behaviour in 
respect of proliferation, differentiation and cell death is warranted since this may 
link expression with pathology.   
Although preliminary investigations into the effects of cytokines and chemokines in 
dysregulated NP cell metabolism were described in this thesis, the studies were by 
no means conclusive.  Further work in this area, including; time course 
investigations into the effects of cytokine and chemokine stimulation on 
transcription of ECM components and ECM degrading enzymes, and investigations 
at the protein level into synthesis of ECM components and ECM degrading 
enzymes would help to clarify the regulatory role of cytokines and chemokines in 
tissue remodelling.   
Whilst we have identified the production of chemokines and chemokine receptors 
within the IVD, the studies described here are not sufficient to confirm their 
biological activity.  Biological activity of secreted chemokines is controlled at the 
levels of interaction with ECM GAGs (Proudfoot, 2006), and proteolytic processing 
(Wolf et al., 2008).  The conserved chemokine N-terminal domain can be exposed 
or protected by ECM GAG interaction following sequestration within the ECM, once 
exposed this domain becomes susceptible to proteolytic cleavage.  Chemokine 
proteases included members of the MMP and ADAM families that are often present 
in the ECM milieu, proteolytic cleavage of chemokines can serve to activate, 
enhance, dampen or inactivate biologic activity and modulate the affinity of a 
chemokine to a specific receptor (Wolf et al., 2008).     
The activity of chemokine receptors is also subject to multiple levels of regulation.  
Functional activity requires receptors to be presented on the cell surface in a 
conformation compatible with ligand binding and coupling to a heterotrimeric G 
protein (Bennett et al., 2011).  Post-translational modifications including sulphation 
and glycosylation are known to influence receptor conformation and therefore 
compatibility with ligand binding (Farzan et al., 1999; Sloane et al., 2005), and 
phosphorylation affects receptor presentation or internalization modulating a cells 
capacity to respond to chemokine signalling (Horuk, 2001).  Investigating the 
biological activity of chemokines and chemokine receptors in the IVD would provide 
knowledge as to the conditions under which they are active.   
In respect of LBP, the finding that NP cells secrete cytokines and chemokines 
confers the potential for these to function as biochemical stimuli on local 
nociceptive nerve fibres.  This may be particularly relevant to pain arising from IVD 
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prolapse since elevated cytokine and chemokine levels are found in the 
cerebrospinal fluid of IVD prolapse patients (Brisby et al., 2002) and a recent 
investigation using an animal model of IVD prolapse indicates that pain intensity is 
associated with NP derived CXCL8 production (Kim et al., 2011).  Therefore, 
investigations into the effects of NP derived cytokines and chemokines on nerve 
cells may provide insight into the mechanisms by which LBP is generated.    
8.2 Conclusions   
The studies described in this thesis investigated in detail the expression of 
cytokines and chemokines by the NP cell population of the IVD.  Evidence 
presented has shown that expression of certain cytokines and chemokines is up-
regulated in NP cells from the degenerate IVD compared to those from the normal 
counterpart, and that expression correlates with pathological tissue changes 
characteristic of degeneration.  Co-expression of receptors for these molecules was 
also identified, indicating that these factors may form part of an intercellular 
cytokine and chemokine communication network within the IVD.   
In vitro, NP cells were shown to secrete a diverse range of cytokines and 
chemokines, and IL-1 was demonstrated to be a modulator of this activity.  Indeed, 
data presented is further evidence to suggest IL-1 is a key modulator of NP cell 
behaviour.  Here, IL-1 exerted modulatory potential over expression of other 
cytokines and chemokines, and modulated anabolic and catabolic metabolism.  In 
vitro stimulations with other cytokines and chemokines were less conclusive as to 
the effects these may elicit on NP cell behaviour however, together the data 
presented implicates that cytokines and chemokines are integral to the 
pathogenesis of IVD degeneration and prolapse.         
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Appendix 3  Automated Tissue Processing Schedule 
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Appendix 5 Chemokine Systematic Nomenclature, Synonyms & 
Acronyms 
Systematic 
Name 
Other Names 
CCL2 MCP-1 (Monocyte Chemoattractant Protein-1) 
CCL3 MIP-1α (Macrophage Inflammatory Protein-1α) 
CCL4 MIP-1β (Macrophage Inflammatory Protein-1β) 
CCL5 RANTES (Regulated on Secretion Normal T-cell Expressed and Secreted) 
CCL7 MCP-3 (Monocyte Chemoattractant Protein-3) 
CCL8 MCP-2 (Monocyte Chemoattractant Protein-2) 
CCL13 MCP-4 (Monocyte Chemoattractant Protein-4) 
CCL19 ELC (Epstein-Barr Virus-Induced Receptor Ligand Chemokine) 
CCL20 
LARC/MIP-3α (Liver and Activation-Related Chemokine/Macrophage 
Inflammatory Protein-3α) 
CXCL1 Gro-α (Growth Related Oncogene-α) 
CXCL2 Gro-β (Growth Related Oncogene-β) 
CXCL3 Gro-γ (Growth Related Oncogene-γ) 
CXCL5 
ENA-78 (Epithelial Cell-Derived Neutrophil-Activating Factor, 78 Amino 
Acids) 
CXCL6 GCP-2 (Granulocyte Chemoattractant Protein-2)  
CXCL8 IL-8 (Interleukin-8) 
CXCL9 Mig (Monokine Induced by γ-Interferon) 
CXCL10 γIP-10 (γ-Interferon-Inducible Protein-10) 
CX3CL1 Fractalkine 
CCR1 C-C Chemokine Receptor 1 
CCR2 C-C Chemokine Receptor 2 
CCR3 C-C Chemokine Receptor 3 
CCR5 C-C Chemokine Receptor 5 
CCR6 C-C Chemokine Receptor 7 
CCR7 C-C Chemokine Receptor 8 
CCR8 C-C Chemokine Receptor 8 
CXCR1 C-X-C Chemokine Receptor 1 
CXCR2 C-X-C Chemokine Receptor 2 
CXCR3 C-X-C Chemokine Receptor 3 
CX3CR1 C-X3-C Chemokine Receptor 1 
Duffy Duffy Blood Group Chemokine Receptor 
D6 Chemokine Binding Protein 2 
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Appendix 6  Suppliers Details 
Abcam Cambridge, UK 
Ambion Paisley, UK 
Applied Biosystems Warrington, UK 
Beckton Dickinson Oxford, UK 
Bioline London, UK 
Fisher Scientific Loughborough, UK 
Gibco Paisley, UK 
GraphPad Software Inc. San Diego, USA 
Invitrogen  Paisley, UK 
JeioTech Supplied by Jencons 
Jencons East Grinstead, UK 
Leica Milton Keynes, UK 
Luminex Corporation Austin, USA 
MediaCybernetics Marlow, UK 
Nunc Supplied by Fisher Scientific 
Olympus Corporation Tokyo, Japan 
Peprotech London, UK 
Qiagen Crawley, UK 
Sanyo Electric Co. Ltd. Osaka, Japan 
Shandon Elliott Supplied by Jencons 
Sigma Dorset, UK 
StatsDirect Ltd. Altrincham, UK  
Vector Laboratories Peterborough, UK 
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